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Increased globalization in business competition makes the ability to innovate and to redefine 
strategy crucial to a company. An interesting question however is if a management team can control 
innovation and strategic renewal of the company at all; or do such changes emerge, driven by 
external events or by bottom-up processes in the organization? The present research project 
addresses some of these issues through the overall research question “How does innovation strategy 
evolve?” 
The research question is examined in a specific empirical context. Since 2001, I have worked as an 
internal innovation consultant at Novo Nordisk A/S; a pharmaceutical firm founded in 1923 
operating in a well established industry (insulin for diabetes treatment), characterized by intensive 
investments in Research and Development.  I took advantage of this unique access to the internal life 
of an organization and consequently set up my research project as a longitudinal in-depth case study 
of the medical device innovation activities at Novo Nordisk A/S covering the period 1980-2008. The 
study specifically analyzes the relationship between the classic core product of the firm (insulin) and 
complementary products (medical devices, such as insulin ‘pens’), which hold the potential to either 
enhance the value of the core product, or to become a distinct business of its own. 
Burgelman’s evolutionary theory of strategy making, especially his ‘internal ecology model’ 
(Burgelman 1991, 2002), has been chosen as the basic theoretical framework for the project. Some 
expansions of this framework, however, were needed. First, the present study puts greater emphasis 
on analyzing the external environment and its influence on internal strategy processes. Second, the 
analysis includes the role of management cognition, especially the notion of the corporate dominant 
logic (Prahalad & Bettis, 1986; Bettis & Prahalad, 1995), understood as an enduring top management 
worldview or mindset based on reinforcement of experiences from the past.  
With regard to results, the present study identifies a more entrepreneurial role of the top 
management driven induced strategy process than traditionally described in evolutionary theory. In 
this case study, strategic variation and trial-and-error learning is not restricted to the autonomous 
initiatives in the ‘internal ecology’; on the contrary, top management cognition creates strategic 
visions or hypotheses, which are enacted as experiments in the market, for example in the form of 
new product categories. External feedback determines the destiny of these strategic experiments. 
Thereby innovation strategy (in case, for medical devices) serves as a strategic laboratory at 
corporate level, so to speak. 
The device-based strategic experiments face the challenge of escaping the gravity of the dominant 
logic, which repeatedly pulls the strategy back towards the well-known success formula, centered on 
the drug itself (i.e. the insulin). Thus, the induced strategy process mediates core assets 
(pharmaceutical drugs) and complementary assets (medical devices), by swinging the pendulum 
between cycles of innovation strategy which define the devices as core or complementary 
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respectively. Hence, the balance between what is defined as core and what is defined as 
complementary in the corporate innovation strategy seems to be dynamic and negotiable.  
As a consequence of the cycles of strategic experimentation, the corporate induced strategy process 
acts as a force of strategic entrepreneurship, seen over extended time.  
The implications for research point towards a new paradigm of strategic research in the ‘middle 
ground’ between rational choice theory and evolutionary theory, as proposed by Gavetti & Levinthal 
(2004).  The present research project suggests that a firm’s ability for strategic adaptation depends 
both on strategic context determination of autonomous initiatives in the ‘internal ecology’ and on 
ability to enact induced strategic experiments with alternating innovation strategies in the market. 
This theory of ‘inbound’ and ‘outbound’ strategic search establishes a dynamic understanding of the 
corporate induced strategy process. In this understanding, innovation strategies act as hypotheses, 
which create strategic dissonance between vision and reality and thereby drive strategic learning.  
The implications for management practice are first recognition of how fortunate it has been for 
Novo Nordisk to sustain the core business strategy, protected by the dominant logic. This fact relates 
to a background where the core market proved to hold immense growth potential, and the industry 
was relatively stable compared to for instance the IT industry. On the other hand, Novo Nordisk’s 
success is partly due to cycles of strategic experiments with complementary assets for innovation, in 
case medical devices. Top management initiated these explorative experiments and the learning was 
utilized for expansion of the position within the core business. Hence, one can conclude that a 
company should explore and utilize the value of complementary assets, since these are perfect tools 




I den stigende globale konkurrence har virksomheders evne til innovation og til at redefinere deres 
forretning fået livsvigtig betydning. Men kan man som ledelse overhovedet styre innovation og 
strategisk fornyelse, eller opstår fornyelsen organisk, så at sige af sig selv, drevet af ydre 
omstændigheder eller nedefra i organisationen? Dette forskningsprojekt indkredser en del af denne 
problematik gennem den overordnede problemformulering “Hvordan udvikler innovationsstrategi 
sig?”  
Problemstillingen undersøges empirisk i en specifik kontekst. Siden 2001 har jeg arbejdet som 
intern innovationskonsulent i Novo Nordisk A/S; et firma etableret i 1923, som opererer i den 
forskningstunge farmaceutiske industri med insulin til diabetesbehandling som sit hovedprodukt. Jeg 
har valgt at udnytte min unikke tilgang til organisationens indre liv ved at udforme forsknings-
projektet som et dybdegående langtids-casestudie i konteksten udvikling af medicinske devices (dvs. 
insulinpenne og lignende udstyr) hos Novo Nordisk A/S i perioden 1980-2008. Specielt analyseres 
relationen mellem devices som komplementære produkter i forhold til virksomhedens klassiske 
kerneprodukt (insulin): Understøtter devices salget af kerneproduktet, eller udnyttes devices til 
selvstændig forretningsudvikling? 
Som teoretisk ramme er primært valgt Robert A. Burgelmans evolutionære teori om strategi-
udvikling kaldet strategiudviklingens interne økologi (Burgelman 1991, 2002). Desuden er inddraget 
nogle supplerende perspektiver, som Burgelmans teori gør mindre ud af: For det første er der lagt 
større vægt på omverdenens indflydelse på organisationens strategiudvikling; for det andet inddrages 
ledelseskognition i analysen, herunder begrebet dominerende logik (Prahalad & Bettis, 1986; Bettis & 
Prahalad, 1995), der betegner et relativt statisk ledelsessyn på virksomhedens succesfaktorer, som 
er opbygget gennem erfaring.  
Som resultat påviser casestudiet en mere innovativ rolle for den topstyrede, inducerede strategi-
proces, end man normalt ser beskrevet i evolutionær ledelsesteori.  I mit studie er strategisk 
fornyelse og prøven-sig-frem ikke begrænset til de såkaldte autonome initiativer i den interne 
økologi; tværtimod fører topledelsens kognition til eksperimenter med strategiske visioner eller 
hypoteser, der prøves af i markedet f.eks. med introduktion af nye produktkategorier. Reaktionen fra 
omverdenen bestemmer disse eksperimenters skæbne. Innovationsstrategien kan altså siges at være 
en slags strategisk laboratorium for virksomheden som helhed.  
De strategiske eksperimenter med devices har desuden den konstante udfordring, at den 
dominerende logik trækker strategien tilbage imod den velkendte formel, baseret på selve insulinen 
som forretningens basis. Således balancerer strategiudviklingen mellem kerneprodukter (i dette 
tilfælde insulin) og komplementære produkter (devices), som på skift danner basis for vekslende 
innovationsstrategier. Dermed synes grænsen mellem kerne og komplementær at være dynamisk 
eller m.a.o. til konstant forhandling.  
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Som konsekvens af eksperimenterne med innovationsstrategien fremmer den inducerede strategi-
proces virksomhedens strategiske fornyelseskraft set over et længere tidsperspektiv. 
Det forskningsmæssige perspektiv af nærværende projekt peger frem mod et nyt paradigme i 
strategiforskning midt imellem rationelle og evolutionære standpunkter, som foreslået af Gavetti & 
Rivkin (2004). Min forskning påviser, at strategisk fornyelse afhænger såvel af evnen til at udnytte de 
interne, autonome initiativer som af evnen til at udnytte topstyrede eksperimenter med alternative 
innovationsstrategier i markedet. Denne teori om strategisk prøven-sig-frem indadtil som udadtil 
etablerer en dynamisk forståelse af den inducerede strategiproces. I denne forståelse optræder 
innovationsstrategier som hypoteser, der etablerer et spændingsfelt mellem vision og virkelighed og 
dermed driver strategisk læring.  
De ledelsespraktiske perspektiver er først anerkendelse af, hvor værdifuldt det har været for Novo 
Nordisk at fastholde kernestrategien båret af den dominerende logik. Dette skal ses på baggrund af et 
kernemarked, der viste sig at indeholde et enormt vækstpotentiale, og hvor omverdenen var relativt 
stabil sammenlignet f.eks. med IT-branchen. Omvendt kan en væsentlig del af Novo Nordisks succes 
tilskrives, at topledelsen har åbnet for en række strategiske eksperimenter med komplementære 
produkter, dvs. devices så som insulinpenne, og forstået at udnytte læringen fra disse eksperimenter 
til at udbygge positionen på kerneområdet. Man kan derfor konkludere, at man bør udforske og 
udnytte de komplementære produkters værdi, da disse er perfekte redskaber til strategiske 
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Initial puzzles 
Bubbles burst. When the Internet or dotcom bubble burst in 2001, I lost my job as a business 
developer at Ericsson Denmark. To my fortune, the Danish pharmaceutical company Novo Nordisk 
A/S had just established a new R&D unit for medical devices, called Protein Delivery Systems (PDS). 
Novo Nordisk’s main business is in diabetes care, and PDS was formed out of a vision called ‘closed 
loop’; this referred to medical device systems, which were able to mimic the function of the human 
pancreas by continuously monitoring the blood sugar level and, at the same time, continuously infuse 
the needed amount of insulin. The healthy human body automatically registers the blood sugar level;  
if this gets too high, the pancreas releases insulin, which in effect lowers the blood sugar level by 
igniting the glucose metabolism – and if the blood sugar gets too low, the liver will release sugar from 
its depots. This fine-tuned mechanism is disturbed at diabetes patients, and hence they must monitor 
the blood sugar level manually and eventually infuse insulin with a syringe, if the blood sugar is too 
high, or take in extra carbohydrates, if the blood sugar is too low. The idea of ‘closed loop’ was to 
develop a feedback system of devices, which could both automatically monitor the blood sugar level 
and, if needed, infuse insulin, without the patient having to worry about it. Such ‘closed loop’ system 
was regarded as the holy grail of diabetes treatment, and being able to develop such system would 
mark the beginning of a new era, which also was foreseen to boost the sales of Novo Nordisk. So it 
was a very optimistic and entrepreneurial organization, in which I began working by yearend 2001 
as an internal consultant in innovation processes. 
Already in 2004, one of the two legs of the ‘closed loop’ vision was cut off, namely the project for 
developing continuous blood sugar monitoring. And in 2005, the bubble burst: PDS was terminated; 
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the vision had died. – Why? Didn’t top management know what they were doing when they launched 
PDS? As employees, we got no real explanation for the turbulence in innovation strategy. I didn’t 
expect such turbulence, since Novo Nordisk was a very mature company (founded 1923), acting in a 
relatively stable industry (product lifecycles of typically 20 years), based on a tradition of science and 
intensive R&D investments – not the kind of company, from which you expect impulsive fluctuations 
in the innovation strategy. 
Furthermore, when I began examining the history of Novo Nordisk, I discovered that this was 
actually the second time that such visionary innovation strategy had bloomed and withered. At a 
much earlier stage in 1988, a division was established for medical devices, called Medical Systems 
Division (MSD), on a similar vision of full circle homecare for the patient, based on medical devices 
including devices for blood sugar monitoring. In 1988, the technologies were not mature for 
envisioning an automatic ‘closed loop’ system – the patient would still have to do everything 
manually. But the mere vision of providing the patient with all the drugs and devices, he/she needed 
for taking care of the disease at home (not at the hospital) was very progressive. However, MSD also 
had a lifetime of only four years, followed by a strategic turnaround in 1992: focus now should solely 
be on injection devices, in order to support the pharmaceutical drugs.   
During my research, I’ve talked with many veteran colleagues about the evolution of the medical 
device activities at Novo Nordisk, and it was a great eye-opener for me, when a manager from the 
device area, who had been part of this venture for two decades, first described the development and 
then concluded: “It’s really funny to see how we started in MSD by diverging – then we converged again 
– then came PDS, where we went off at countless tangents – we even included our inhalable insulin 
project, that was really extreme – and now we have narrowed down again and have become focused 
again; our area must secure that the next generation prefilled [insulin pen] simply gets launched. That 
is our key function within Novo Nordisk today. It’s quite funny – it has all happened within 20 years” 
(interviewed in 2008). First, I should explain the use of the words ‘divergent’ and ‘convergent’: in this 
context, these concepts refer to the latitude of the device innovation activities. By “diverging” the 
manager means expanding the scope of the activities through adding new areas; by “converging” he 
means contracting the scope of activities to fewer areas. The point, however, is that this manager 
sees the MSD period from 1988 to 1992 as similar to the PDS period from 2001 to 2005: both periods 
were “divergent”. In contrast, the period between MSD and PDS (1992-2001) is likened with the 
period after 2005: in these periods the activities “converged”.  
When I dug more into the history of the medical device activities at Novo Nordisk, it struck me that 
the fluctuations in strategy, as outlined in the quotation above, contrasted the actual development in 
the market. Until 1985, insulin was sold in vials, to be injected with traditional syringes. Novo 
Nordisk introduced the first injection device, the NovoPen®, in 1985. The NovoPen® was well 
received by the market and was followed by the introduction of several other ‘insulin pens’, as these 
devices were called (because they imitated the look of a fountain pen). The insulin pens contained 
the insulin in a customized insulin cartridge, and therefore the market penetration of the devices can 
be measured by the volume of insulin sold in these cartridges compared to the total volume of insulin 
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sold. Since 1985, insulin sold in cartridges customized for devices has steadily increased market 
share, compared to insulin sold in traditional vials, and today (2012) accounts for nearly two thirds 
of all insulin sold globally (source: internal Novo Nordisk statistics). This development has been 
initiated and driven by Novo Nordisk. In other words, the introduction of insulin devices (‘insulin 
pens’) has gradually changed the market towards the new systems, displaying a steady growth. 
Metaphorically, the market impact of the new insulin devices since 1985 has slowly increased like a 
train, which mile for mile crosses the landscape, following the laid down track. In contrast to this 
steady increase in market impact, the explicit innovation strategy of Novo Nordisk has unfolded two 
very “divergent” waves, as described in the above quotation from a veteran device manager. The two 
epochs which he labeled “divergent” (Medical Systems Division, MSD, 1988-92; Protein Delivery 
Systems, PDS, 2001-05), held ambitious visions about how Novo Nordisk could create large revenue 
streams based on medical device systems, beyond the revenue from the insulin itself; in other words 
making medical devices a business of its own. Outside these two ‘waves’ were periods, in which the 
explicit strategy defined the insulin drug as the sole revenue generator, and the role of the medical 
devices was seen more or less as “advanced packaging” for the drug (as it was called by several 
informants from the device area). One can say that there have been two waves of visionary ideas 
about revolutionizing diabetes care through the means of medical devices – and in between, the role 
of medical devices in the explicit strategies has been almost understated, if we consider the actual 
market success. Metaphorically spoken, the strategy twice has attempted to lift off from the laid 
down track in a helicopter. 
 
As a consequence of the above observations and reflections, I asked myself about the reasons for 
these fluctuations in explicit innovation strategy, which seemed to contrast the actual development 
in market impact. To what extent were the fluctuations planned and deliberate or, alternatively, 
emerging ‘by themselves’, either driven by external trends and events or by bottom-up 
organizational processes? “How does innovation strategy evolve?” became the overall research 
question, which guided my longitudinal case study of the medical device innovation activities at Novo 
Nordisk. First, I mapped and analyzed each transformation of innovation strategy, which had 
occurred. From the concrete understanding of each transformation, the next level of reflection arose: 
Is there a pattern in the changes of innovation strategy? Can we, in other words, extract a generalized 
understanding, i.e. a theory?  





The topic of this research project is the evolution of innovation strategy, stated in the overarching 
question “How does innovation strategy evolve?” 
For examining the topic, evolutionary theory on strategy-making forms a theoretical basis (see next 
section, and Chapter 2, about the theoretical framework), especially Robert A. Burgelman’s (1991; 
2002) theory on the ‘internal ecology’ of induced and autonomous strategies. Consequently, the topic 
is addressed with a general research question based on the ‘internal ecology’ model: 
 What is the role of induced and autonomous strategy processes for the evolution of 
innovation strategy? 
Specific questions 
To study the general questions empirically, I focus on the evolution of the innovation strategy for a 
specific area in a specific organization; namely, the medical device innovation activities at the 
pharmaceutical company Novo Nordisk A/S in the period 1980-2008. Following a logic of lifecycles 
(see Definitions below) the evolution of innovation strategy can be split into sub-questions about the 
creation, the growth and the eventual change of a strategy. Consequently, the following specific 
research questions are stated: 
1. How did the innovation strategy for medical devices at Novo Nordisk come into being? 
2. Through which processes was the device innovation strategy substantiated or 
retained, once established? 
3. Through which processes was the device innovation strategy altered or reconfigured? 
a. Phase by phase, transformation by transformation 
b. Patterns of change across the individual phases and transformations. 
Inspired by literature (see next section and Chapter 2) some underlying themes will be examined. 
One important theme is the role of management cognition for the evolution of innovation strategy. An 
element hereof is the perception of the medical devices as either core assets for innovation, i.e. seen 
as means of creating a business of its own – or as complementary assets for innovation, i.e. seen as 
enhancers of the sales of pharmaceutical drugs. Another theme is the already mentioned relationship 
between induced and autonomous strategy-making processes, which overlaps with the question of 
deliberateness versus emergence in the evolution of strategy. And a third theme is the interplay 




The following definitions of the concepts used in the research questions are applied (mentioned in 
alphabetic order): 
Autonomous and induced strategies:  Burgelman (1991) contrasts two sorts of strategy making 
processes: “The induced process concerns initiatives that are within the scope of the organization’s 
current strategy and build on existing organizational learning; the autonomous process concerns 
initiatives that emerge outside of it and provide the potential for new organizational learning” (p. 241). 
This definition, as can be seen, links to the content or scope of the strategy process and resembles the 
two modes of organizational learning described by March (1991): exploitation and exploration. 
However, Burgelman (1991) also links the concepts to the organizational hierarchies: in the normal 
case, he claims that autonomous strategies work their way up from beneath the organization, 
whereas induced strategies are exactly ‘induced’ from the top. And further, Burgelman analyzes the 
process: Does the strategy develop out of local experiments, i.e. vision ‘ex post’, or does it develop out 
of cognition, i.e. vision ‘ex ante’? The normal distribution of these three parameters in Burgelman 
(1991, 2002) is shown in Table I-1.   
 
 Autonomous strategy Induced strategy 
Content (per definition) Explores opportunities outside 
current strategy 
Expands within current strategy 
Actor Lower or middle managers Top management 
Process Action-based: learning from 
experiments (vision ex post) 
Cognition-based: plan before 
action (vision ex ante) 
 
Table I-1. The normal distribution of parameters in Burgelman (1991, 2002) for characterizing respectively 
autonomous and induced strategy. 
 
Cognition: thinking. “The mental action or process of acquiring knowledge and understanding through 
thought, experience, and the senses”1. In the context of this research, cognition is seen as part of the 
mental aspect of strategy making, e.g. formulation of visions and strategies in words and models, as 
opposed to the physical aspect, e.g. trial-and-error experiments or other action in the ‘real world’. 
Core and complementary assets: builds on Teece (1986), who describes innovation as comprising 
core technical knowledge, needed for the invention itself, and complementary assets, needed for the 
successful commercialization of the invention. Teece mentions processes such as marketing, 






1 http://oxforddictionaries.com/definition/cognition, accessed 2011-07-16 
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manufacturing and after-sales support as examples of complementary assets. For this research 
project, however, it is essential that he also mentions: “when the innovation is systemic, the 
complementary assets may be other parts of the system. For instance; computer hardware typically 
requires specialized software” (ibid, p. 288). In this understanding, the medical devices may be seen as 
complementary assets, being part of the pharmaceutical product offering as a whole – but also 
potentially being seen as core technical knowledge, needed for innovation on par with the other 
components, such as knowledge about the insulin.  
Evolution: “the gradual development of something”2. The term is here used to label changes of an 
organization (or its environment) over time, unfolding as cycles of variation-selection-retention. Van 
de Ven (2007) defines evolution by stating: “An evolutionary model explains change as a recurrent, 
cumulative, and probabilistic progression of variation, selection, and retention among entities in a 
designated population” (p. 204). The present research project studies only at one entity, namely Novo 
Nordisk – however, such organization can in itself be seen as a population or an ecosystem of 
initiatives (as in Burgelman, 1991) or of multiple cognitive frames (as in Kaplan, 2008).  
Innovation: the invention and market introduction of new products. Hence, compared to literature 
on management of innovation in general (example: “Innovation is about knowledge – creating new 
possibilities through combining different knowledge sets”, in the textbook by Tidd, Bessant & Pavitt 
2005), the definition of innovation is here narrowed down to product innovation only, since that is 
the focus of the present study.  
Innovation strategy: the strategy for the individual innovation activities with the objective to create 
product or business innovations (strategy understood as a plan for the future or a storyline of the 
past). 
Life cycles: “the series of changes in the life of an organism including reproduction”3; i.e. the sequence 
of birth, growth and decline which an organization, a technology or a new product follows. In this 
context meaning that also strategies are born (i.e. formulated), grow (i.e. are implemented and 
substantiated) and decline (i.e. lose momentum and eventually are formally cancelled, to be replaced 
by new strategies). However, social phenomena like strategies do not evolve in predefined phases, as 
we often observe in nature; ‘evolution’ in social science is not deterministic.  
Strategy: the pattern of activities of a company over time, before action (strategy as plan) or after 
action (strategy as pattern). This definition builds on Mintzberg (2007), who identifies the two 
meanings of the word, the forward-looking plan or commitment to action, or the backward-looking 






2 http://oxforddictionaries.com/definition/evolution, meaning 2, accessed 2011-07-16 
3 http://oxforddictionaries.com/definition/life+cycle, accessed 2011-07-16 
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“pattern in a stream of decisions” (p. 2). In general, whenever the word ‘strategy’ in this thesis is not 
attached to ‘innovation’, the word refers to business strategy; i.e. it is the corporate storyline about 
the company’s product-markets – it’s customers, offerings, value proposition, profit model etc. 
Theoretical framework 
The present research project belongs to the research field of strategic management and explores the 
topic of ‘strategy making’. Concepts from the field of management of innovation have been included 
as well, because of the specific focus on innovation strategy. As the overall research question is “How 
does innovation strategy evolve?”, we need a basic understanding of what strategies are, how they 
come into existence and how they evolve. This basic understanding is taken from general strategic 
management literature, from research on strategy making and, since strategies both exist in 
observable reality and in managers’ minds, from literature on strategic cognition.   
The literature on strategic management unfolds several schools of thought (see for example Gavetti & 
Levinthal, 2004, for a review). In broad terms, these can be placed in a continuum between rational 
choice theory and behavioral decision theory:   
a) Rational choice theory builds on a premise of the organization or the management team as 
a rational agent, where the actor is supposed to make informed and deliberate decisions 
based on analysis of the consequences of alternative options. This rational premise is 
consistent with mainstream (neo-classic) economics. Examples within strategic management 
comprise both the early, operational approach to strategy as for instance in Ansoff (1965), as 
well as the later positioning school with Porter (1980) as the principal representative.  
b) In opposition to the rational premise in economic and management theory, a paradigm of 
behavioral decision theory evolved based on the research of H. Simon (e.g. 1955), who 
analyzed the limitations of rationality in actual decision behavior. These limitations became 
known as ‘bounded rationality’. Bounded rationality implies that even if managers are 
“intendedly” rational, they don’t have full access to information and they only have limited 
resources and capabilities for processing information. In alignment with the notion of 
bounded rationality, several schools of thought developed. These schools of thought shared 
their focus on actual organizational behavior, in contrast to the ideal of rational choice. One 
such school is the stream of research in management cognition (see Walsh, 1995, and Kaplan, 
2011, for reviews), which provides evidence for the constraints and biases of the cognitive 
representations used in decision making. Another school consists of evolutionary economic 
theory (Nelson & Winter, 1982), which analyzes how knowledge and experience become 
embedded in enduring organizational routines. Within strategic management theory, models 
of emergent strategy and evolutionary strategy making were developed by researchers such 
as Mintzberg (1994) and Burgelman (1991).  
If we turn towards the topic ‘evolution of strategy’, one should notice that the rational choice 
models, such as the positioning school, mainly are concerned with explaining the causes of superior 
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business performance as reflected in the competitive landscape (the outcome of strategy), and less 
with analyzing the underlying process of strategy formation. The main question for rational choice 
theory on strategy can be stated as: ‘what kind of strategy should we build?’  
Conversely, the evolutionary theories are more focused on the actual behavior in the process of 
strategy making. The main question of such theories could be stated as: ‘where do strategies come 
from?’ Thus, Gavetti & Rivkin (2007) summarize the two research strands as “the content-oriented 
rational-choice class and the process-centered learning class” (p. 422). For the present research 
project, behavioral theories (or learning models) of strategy-making provide the best foundation for 
understanding the evolution of innovation strategy.  
The theoretical framework will be analyzed in detail in Chapter 2. However, some core elements 
should be presented here.  
First, the word strategy (see Definitions) has two meanings or two dimensions: Strategy can be a 
forward-looking plan or vision or it can be a backward-looking “pattern in a stream of decisions” 
(Mintzberg, 2007). This dualism comprises a time-bound dimension: strategy as perceived before or 
after action. 
Furthermore, strategies exist as concepts or theories in the minds of managers (in the form of 
forward-looking visions and plans; or backward-looking rationalization of experience) and they also 
manifest as patterns in actual organizational behavior or practice. This dualism comprises a space-
bound dimension spanning the two realms, in which strategies exists: the mental and the physical 
(Gavetti & Rivkin, 2007).  
These two basic dualisms (time-bound: before/after action and space-bound: mental/physical 
realms) can be synthesized into a simple model of a learning cycle, see figure I-1, inspired by similar 
learning cycles in literature on strategic search and managerial cognition (Burgelman, 1988, Figure 
2; Gavetti & Levinthal, 2000, Figure 1; Walsh, 1995, Figure 1; Prahalad & Bettis, 1986,  Figure 1). The 
model shows how strategy making unfolds in a learning cycle of theory application into practice, 
from which experiences fuel further theorizing. This basic learning cycle synthesizes the dualism 
between the mental and the physical realms in the vertical axis (between Theory and Practice) and 
the dualism between the forward-looking and backward-looking search processes in the horizontal 
axis. Going from theory to practice is normally associated with forward-looking and deliberate 
strategy making, because it springs out of a strategic intent or vision. Going from practical experience 
to theory is normally seen as the basis of backward-looking and emergent strategy making, because 
the strategy is formed via trial-and-error, where the understanding develops en route (Mintzberg, 
1994), or even backwards, as rationalization of experience (Burgelman, 1988). 





Figure I-1. Strategy making shown as a learning cycle between theory and practice, inspired by similar 
learning cycles in literature on strategic search and managerial cognition – see Chapter 2. Even the learning 
cycle is here depicted as one loop, the learning process of course is recursive and in principle endless; loop 
after loop unfolds. 
 
The interplay between deliberate or theory-driven strategy making on the one side and emergent or 
experience-based strategy making on the other has been very thoroughly analyzed in Burgelman’s 
evolutionary theory on the ‘internal ecology of strategy making’ (Burgelman 1991, 2002). He basically 
models how long-term adaptation of the corporate, induced strategy is achieved via continuous 
integration of local, autonomous initiatives from the ‘internal ecology’ of the organization.  
The learning cycle in figure I-1 integrates the mental and the physical aspects of strategies in the 
Theory-Practice dimension. The ‘theory’ part includes strategy formulation, visioning and reasoning 
in general. Research on managerial cognition informs about the pervasive influence of cognitive 
representations (or, mental models) of reality. For the present research project, I especially apply the 
concept of dominant logic (Prahalad & Bettis, 1986; Bettis & Prahalad, 1995), which terms a set of 
mental models, which have settled as a top management worldview or mindset, created via 
reinforcement of experiences from the past. Such dominant logic, once established, is difficult to 


























Since the present research project addresses the evolution of innovation strategy, we need a basic 
characterization of this concept as compared to ‘strategy’ in general.  
First, what is innovation? – “The word innovation derives from the Latin word innovatus, which is the 
noun form of innovare "to renew or change," stemming from in—"into" + novus—"new". ”4. In a 
business context, “newness can refer to anything that affects customers, manufacturing, sales or 
service” (Foster & Kaplan, 2001, p. 24). Literature on innovation distinguishes innovation from 
invention: “Invention is the first occurrence of an idea for a new product or process, while innovation is 
the first attempt to carry it out into practice” (Fagerberg et al, 2005, p. 4); “Innovation is invention that 
has produced economic value. Without economic value there can be no innovation. Invention precedes 
innovation” (Foster & Kaplan, 2001, p. 24). For the present research project, the concept of 
innovation is narrowed down to the introduction of new products (and the concurrent new 
business).  
What is then innovation strategy? – Strategies in general are seen as overall patterns in a company’s 
activities, either in form of forward-looking plans or backward-looking storylines. Corporate strategy 
as a forward-looking plan may (but must not) envision the creation of new product-markets. In such 
case, the corporate strategy comprises a strategy for innovation. However, innovation can be 
organized as a distinct set of activities within a company. Thus, Christensen (2002) defines: 
“Management of innovation signifies the management and organization of the individual innovation 
processes with the objective to produce product or process innovations” (p. 1318). Accordingly, I define 
innovation strategy as such:  
 Innovation strategy is the strategy for the individual innovation activities with the objective to 
create product or business innovations (strategy understood as a plan for the future or a 
storyline of the past). 
Clearly, the innovation strategy may be overlapping with the general business strategy – often, the 
overarching corporate strategy comprises an underlying specific innovation strategy. In large 
organizations, where innovation is organized as a distinct set of activities, the strategy levels will be 
equal to organizational levels; the innovation strategy will be the responsibility of the organizational 
unit for product innovation. 






4 http://en.wikipedia.org/wiki/Innovation, accessed 26-05-2012 
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Research design  
For understanding the evolution of innovation strategy we need a process research model rather 
than a variance research model (Van de Ven, 2007): “In general terms, a variance model explains 
change in terms of relationships among independent variables and dependent variables, while a process 
model explains how a sequence of event leads to some outcome” (p. 148; my emphasis). The 
fundamental difference between the two approaches is shown in figure I-2. The process study 
approach does not exclude the search of causality; but the way to causality goes through “a narrative 
describing how things develop and change” (ibid, p. 148). 
To establish such narrative, I chose the format of a longitudinal case study of the medical device area 
at the pharmaceutical company Novo Nordisk A/S, analyzing the medical device innovation activities 
since the beginning of these activities around 1980 to year-end 2008. The study also includes a 
combined qualitative and quantitative tracking of the portfolio of product innovation projects within 
the studied timeframe. Such case study design opens for a ‘thick description’ of the events, contexts 
and interpretations (Stake, 2000, p. 437). The ‘thickness’ is achieved both via in-depth interviews and 
studies of archival data resulting in: 
• Analysis at multiple levels: external industry dynamics; corporate events and top 
management cognition; local device level events (cognition, strategy and structure); and 
concrete innovation activities (innovation projects and product launches). 




Figure I-2. “Two approaches to explaining strategic change” - from Van de Ven, 2007 (p. 149). 
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What can we learn from a case study of Novo Nordisk? 
When scholars study how strategies evolve, they often select empirical contexts which amplify the 
change processes, since these contexts provide clearer input for analysis of the drivers and processes 
of strategic transformations. Thus, periods of ‘ferment’ (Anderson & Tushman, 1990), displaying 
technological discontinuities, have been popular research contexts (examples include Barr et al, 
1992; Christensen & Bower, 1996;  Noda & Bower, 1996; Tripsas & Gavetti, 2000; Tripsas, 2009). 
Also, young companies or immature industries, characterized by highly dynamic environments, have 
served as ‘test tubes’ of strategy making (examples include Burgelman, 1988 ,1991; Gavetti & Rivkin, 
2007; Kaplan, 2008).  These research contexts are well suited for analyzing strategy evolution, 
because discontinuities and high industry velocity make the change processes more visible (for the 
researcher) and more challenging (for the firm). However, the challenges of strategic renewal reach 
beyond these dynamic environments. In fact, strategic change is often more challenging either for 
mature companies, due to settled routines and capabilities, or in relatively stable industries, where 
the signals from the environment are more subtle and hence more difficult to make sense of. Where 
‘radical innovation’ may seem natural for a young company or in the case of technological 
discontinuities, then the management of such innovation implies complex challenges to mature 
organizations (Leifer et al, 2000). Yet, in terms of research of strategic change, large and mature 
companies comprise complex organizational structures and often very dim decision processes.  Novo 
Nordisk A/S was founded 1923, employs 32,800 employees (March 2012) and is, as these lines are 
written, the most valuable company at the Scandinavian stock markets (spring 2012). Moreover, the 
company has been in the same main business (insulin for diabetes treatment) throughout the 
company’s entire lifetime. To get an inside research perspective on the strategy evolution of this 
company is a unique opportunity for examining whether the strategy evolvement in such context 
resembles the mechanisms described in the studies of more dynamic contexts. Perhaps the mature 
and stable empirical context will provide other results, which again can feed back to the existing 
theories on strategy evolution?  
Selection of one main theoretical model 
In the beginning of my research, many theoretical perspectives were examined and often applied for 
analyzing the empirical case story. These perspectives include (in chronological order):  
 Organizational learning models, going back to Argyris & Schön (1978)  
 Abernathy & Clark’s (1985) theory about architectural innovation  
 Strategy-structure incongruities (Chandler, 1990, 1992; Christensen, 2002 a & b)  
 Weick’s (1993) concept of sensemaking  
 Nonaka’s (1994) theory on organizational knowledge creation  
 Dynamic capabilities (Teece, Pisano & Shuen, 1997; Teece, 2007; Eisenhardt & Martin, 2000)  
 Theories on ambidexterity (O’Reilly III & Tushman, 2004, 2008; O’Reilly, C. J. et al, 2009)  
 Mintzberg’s (2007) taxonomy of organizational archetypes  
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 Discovery vs. creation of entrepreneurial action (Alvarez & Barney, 2007).  
All of these theoretical perspectives opened interesting views of the empirical case. However, my 
attempt has been to build a coherent storyline in the case analysis; this is best achieved using one (or 
two) overarching theoretical models. My choice ended by Burgelman’s evolutionary model on 
strategy making, complemented with a perspective on management cognition, for two reasons: 
1. Burgelman’s model is the most direct answer to my research question, “How does innovation 
strategy evolve?”, apart from the focus on broader business strategy rather than specific 
innovation strategy. Burgelman (1991, 2002) goes deeply into the transformation processes 
of strategy and the evolution from an emergent state to an institutionalized state of strategy 
making. 
2. This framework had the best resonance with the story I was creating in the case narrative 
(see also Chapter 3 on research method), about two modes of innovation strategy: these 
modes resembled Burgelman’s concept of autonomous and induced strategy (measured by 
the content of the strategies). 
 
Contribution  
The present case study’s in-depth analysis of innovation strategy at multiple levels of one 
corporation over a period of 30 years is in itself seldom.  
The case study identifies a more entrepreneurial role of the top management driven induced strategy 
process than traditionally described in evolutionary theory. In the present case study, strategic 
variation and trial-and-error learning is not restricted to the autonomous initiatives in the ‘internal 
ecology’; top management enacts induced strategic experiments in the market, for example in the 
form of new product categories. External feedback determines the destiny of these strategic 
experiments. Thereby, the innovation strategy (in case, for medical devices) serves as a ‘strategic 
laboratory’ at corporate level and, in effect, the induced strategy process acts as a force of strategic 
entrepreneurship. 
A specific finding in the present case study is that the induced process mediates innovation logics of 
core assets (pharmaceutical drugs) versus complementary assets (medical devices), by swinging the 
pendulum between cycles of innovation strategy. Thus, the balance between what is defined as core 
and what is defined as complementary in the corporate innovation strategy seems to be dynamic and 
negotiable.  
 
Structure of the thesis 
Chapter 2 describes the theoretical framework of the thesis in more detail, comprising literature on 
strategy making as well as literature on strategic cognition. Further, the theoretical framework is 
synthesized by applying the model of strategic learning shown in figure I-1. Chapter 3 outlines the 
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overall research design and the concrete research methods. Chapter 4 holds the in-depth case study, 
including the empirical evidence and analysis of the strategic transformations, phase by phase. 
Chapter 5 analyzes the pattern of evolution across the entire period (the “whole story”). Further, 
Chapter 5 also discusses the theoretical framework in the light of the case study and builds theory. 
Chapter 6 summarizes the conclusions.  
Appendix A provides a detailed description of the research method for the management cognition 
analysis, which were conducted at the device area of Novo Nordisk in 2007 and again 2010 (the 
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Introduction 
This research project seeks to understand how an innovation strategy comes into being, how it is 
retained and how it eventually is changed or substituted by another innovation strategy. 
Evolutionary literature on strategy making is concerned exactly with these questions, just regarding 
business strategies in general, and therefore these theories are applied as the main theoretical 
instrument for the present case study.  It will then be examined if the specific context of innovation 
strategy opens for new perspectives of the evolutionary theories on strategy making.  
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The presentation of the theoretical framework is laid out as follows: 
First, a basic understanding of the nature of business strategies and of the paradigms underlying 
general strategic management research is established.  Based on this foundation, selected 
evolutionary models of strategy making are presented. Thereafter, specific literature on strategic 
cognition is analyzed, because this literature holds important keys for understanding strategic 
evolution. Furthermore, some theoretical perspectives from the field management of innovation are 
presented.  A specific topic from this literature concerns integration of complementary assets for 
innovation, which is an underlying theme in my whole case study of medical device innovation at the 
pharmaceutical company Novo Nordisk.  
Following the presentation of the theoretical framework, the concepts are synthesized into a model 
of strategic learning. 
29 
 
Understanding strategy – and dimensions of strategy 
research 
As described in Chapter 1, research on strategic management can be seen in a continuum between 
rational choice theory and behavioral decision theory. In a rational choice perspective, the 
organization or the management team acts as a rational agent, who makes deliberate decisions based 
on analysis of alternatives. This rational premise is underlying all mainstream neo-classic economic 
theory, and was adopted in management research. The term “rational”, however, has two meanings, 
as described by Kahneman (2011). In everyday language, it is associated with calculation and 
reasoning. In economic theory, “rational” means internally consistent: “The only test of rationality is 
not whether a person’s beliefs and preferences are reasonable, but whether they are internally 
consistent. A rational person can believe in ghosts so long as all her other beliefs are consistent with the 
existence of ghosts…Rationality is logical coherence – reasonable or not” (p. 411 – my emphasis). In 
the strategic management literature applied in the current project, the term “rational” seems rather 
to be used in the everyday meaning, associated with reasoning (e.g. Nelson, 2008, p. 78), and hence 
the term “rational” is here used as “based on reasoning”.  
The rational versus the behavioral paradigm  
The premise of rationality was underlying the early instrumental or ‘engineering’ approaches to 
strategic management, e.g. in Ansoff (1965), which aimed for solving the problem of how to design a 
corporate strategy. One element in the rational choice paradigm is the presumption that the actor is 
free to choose the best alternative and implement this option. Such premise to a large extent also 
underlies the positioning school of strategic management (Porter, 1980). Consequently, the 
positioning school has been criticized by the behavioral oriented schools, because of the path 
dependent bonds that in reality limit the available options. This debate and the standpoint of the 
positioning school are illustrated in the following quotations from Porter (1991): “Firms inherit 
positions that constrain and shape their choices, but do not determine them. They have considerable 
latitude in reconfiguring the value chain with which they compete, expanding or contracting their 
competitive scope, and influencing important dimensions of their industry environment” (p. 104). “The 
cross-sectional frameworks address the choice of strategy given whatever array of capabilities the firm 
and its rivals possess at a point in time and can feasibly develop in the future” (ibid, p. 105). “The firm 
cannot be seen only as optimizing within tight constraints, but as having the ability to shift the 
constraints through creative strategic choices, other innovative activity, and the assembly of skills and 
other needed capabilities. There are alternative strategies open” (ibid, p. 110). 
The belief in free rational decisions was criticized with Herbert Simon’s analysis of the limitations of 
rationality, which later has been noted in the concept of bounded rationality. Thus, Simon (1955) 
identified the constraints evolving from path dependency as well as the limitations of available 
information, resources and analytical capabilities, which are presumed to be unlimited in an ideal or 
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‘global’ rationality. “Broadly stated, the task is to replace the global rationality of economic man with a 
kind of rational behavior that is compatible with the access to information and the computational 
capacities that are actually possessed by organisms, including man, in the kinds of environments in 
which such organisms exist” and “we are interested in models of “limited” rationality rather than 
models of relatively “global” rationality” (Simon 1955, p. 99 and 113). Simon called his theory a 
‘behavioral model’ and several schools of research in strategic management subscribed to the 
behavior oriented paradigm erected by the Carnegie School, which besides Herbert Simon included 
researchers such as R. Cyert and J. March.  Their interest in actual decision behavior as opposed to 
the ideal or ‘global’ rationality also opened for studying strategic management in a process theory 
perspective (Van de Ven, 2007 – see Introduction), where the interest moved from studying 
conditions and variables behind different strategic outcomes to studying the processes leading to the 
formation and change of a strategy.  
Basic dualities of strategy  
One of the researchers to build on Herbert Simon and the Carnegie School was Henry Mintzberg, who 
has researched within the field of strategy making since the 1960’s (e.g. “The Science of Strategy-
Making”, in Sloan Management Review 1967). Mintzberg noted that Simon saw the concept of 
strategy as a “pattern: consistency in behavior over time” (Mintzberg, 2007, p. 1). This led Mintzberg 
to pursue the question: “because there is a pattern, must there necessarily be a plan? In other words, 
must strategies always be deliberate? Or can they emerge: that is, can patterns just form out of 
individual actions?” (Mintzberg, 2007, p. 4 – the emphasized words are italics in the original). 
Mintzberg’s strong orientation towards a behavioral or learning oriented model is clearly expressed 
in the following statement: “If deliberate strategy is about control, then emergent strategy is about 
learning. It suggests that anyone, so-called formulators and implementers alike, can learn their way into 
strategies – action by action, perhaps also decision by decision. Indeed, strategies can form without 
people even realizing it, although they may recognize these strategies once they have formed” 
(Mintzberg, 2007, p. 5). This quotation perfectly contrasts the rational choice theory, and Mintzberg’s 
concept of ‘emergent strategy’ opens for new perspectives on strategy making, which has been 
further explored by other researchers, such as Burgelman (1991).  
The dualism between deliberate and emergent strategy is one aspect of strategy making. Another 
aspect – where Mintzberg’s work similarly can illuminate the understanding – is the dualism 
between the mental and the physical realms of strategy making.  Corporate strategies can be seen as 
managers’ way of making sense of the world and conceptualizing a storyline about the organization 
in the form of a perceived pattern in the activities over time – looking backward, as a rationalization 
of past behavior, or forward, as a plan or vision. Strategies are top managers’ tools for understanding 
the corporate situation – they give language to complex matters, such as dynamics in the internal and 
external environment. In this sense, strategies belong to the mental realm of perception, reasoning, 
theory and cognition. This mental aspect of strategies has been well expressed by Mintzberg (1994): 
“No one has ever seen or touched a strategy. Strategies, in other words, do not exist as tangible entities. 
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They are abstract concepts, in the minds of people. And the best of them seem to be gestalt in nature, 
tightly integrated, whether intended strategies as synthesized patterns of preferences prior to the 
taking of actions or realized strategies as synthesized patterns already formed among actions. Thus, 
serious change in strategy generally means shift in gestalt – the conception of a new worldview, 
generally based on a permanent change in conditions, or at least the perception of such a change”  
(p. 240 – the emphasized words are italics in the original).  
Aligned with the above thinking, Burgelman (1983) states: “the concept of corporate strategy 
represents the more or less explicit articulation of the firm's theory about its past concrete 
achievements. This theory defines the identity of the firm at any moment in time. It provides a basis for 
the maintenance of this identity and for the continuity in strategic activity. It induces further strategic 
initiative in line with it” (p. 66). Thus, the emphasis in the understanding is here on strategy as a 
‘theory’; and this theory is both backward-looking (building on past achievements) and forward-
looking (inducing further initiatives).  
However, even if strategies are abstract concepts in the minds of people, or theories, they also often 
manifest in action – for example launch of new products in new markets etc. Thus, strategies have a 
dual nature, both belonging to the intangible sphere of thinking and to the physical and observable 
sphere of behavior or action.  
Identification of a theoretical ‘middle ground’  
Gavetti & Levinthal (2004) analyze the first nearly 50 years of research on business strategy. They 
map the strands of research according to two dimensions: a) the view on choice processes (rational 
choice models versus behavioral models) and b) the level of analysis. This second dimension in their 
map concerns whether researchers describe context and situation specific events, or rather seek for 
general and more permanent structural factors.  When applying this map, Gavetti & Levinthal (2004) 
place the positioning school (e.g. Porter, 1980) in a so-called ‘structure-conduct-performance’ 
paradigm, which is characterized as being both highly rational and structural. Researchers like Henry 
Mintzberg and Robert Burgelman are placed in a cluster of ‘emergent views’ on strategy, which are 
behavioral rather than rational and situational rather than structural: “These authors argued that a 
firm’s articulated strategy was often an ex post construction, occurring subsequent to the emergence of 
patterns of behavior that had, de facto, already configured the firm’s strategy” (Gavetti & Levinthal, 
2004, p. 1312).  
Gavetti & Levinthal (2004) propose a ‘middle ground’ between rational and behavioral views and 
between situational and structural levels of analysis. They suggest the new paradigm ‘in the middle’ 
to build on evolutionary economics, going back to Nelson & Winter (1982). However, they identify 
some limitations in the evolutionary theory which should be overcome in order to serve as a broader 
paradigm. One such basic limitation is the evolutionary theory’s focus on organizational routines as 
the holder of the “DNA” of the company: “…our general term for all regular and predictable behavioral 
patterns of firms is “routine”…In our evolutionary theory, these routines play the role that genes play in 
biological evolutionary theory. They are a persistent feature of the organism and determine its possible 
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behavior” (Nelson & Winter, 1982, p. 14).  Such premise nearly excludes elements of deliberation and 
reasoning. Thus, the evolutionary theory is mostly behavioral: organizations learn through their 
activities, and this learning becomes imbedded in the organizational routines, displaying large degree 
of tacit knowledge. If a new ‘middle ground paradigm’ should be able to embrace the rational 
perspective, then “the current challenge is to identify other genetic traits [than organizational 
routines], as well as search mechanisms operating on those traits, consistent with more deliberate 
forms of thinking” (Gavetti & Levinthal, 2004, p. 1314). The dilemma is between remaining faithful to 
the evolutionary logic, implying that “the property of firm-level behavioral continuity must be 
maintained” (ibid, p. 1314, my emphasis), and at the same time embracing deliberation and 
reasoning. “The question then arises as to what extent the evolutionary framework can incorporate 
elements of deliberation and cognition” (ibid, p. 1314). As an example of ‘middle ground’ research, 
they mention amongst others Tripsas & Gavetti’s (2000) case study of Polaroid, because it “illustrates 
the power of cognitive representations as carriers of behavioral continuity, thus giving them a similar 
status as routines as part of the organization’s genetic material” (Gavetti & Levinthal, 2004, p. 1314). 
In accordance herewith, research on strategic cognition has been included in the theoretical 
framework of the current research (see later section).  
Besides the focus on organizational routines as the holder of the ‘corporate DNA’, traditional 
evolutionary theory also is biased towards seeing the routines and capabilities as developing “from 
below” in the organization, and Gavetti & Levinthal (2004) therefore suggest to “pay more attention 
to the linkages across actors within the organizational hierarchy” (ibid, p. 1315). This perspective is 
salient in the research of Robert A. Burgelman, which I shall present in the next sections.  
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Where do strategies come from?  
Mintzberg (1994) defines three sources of strategy: 
 Intended strategies, which are plans formulated ahead of time (some of which are never 
realized) 
 Deliberate strategies, which are intended strategies realized via use of formal control 
systems 
 Emerging strategies, which are formed (not formulated) ‘en route’, as adaptation to the real 
world: “where a realized pattern was not expressly intended” (p. 25). 
Together, these sources result in the realized strategy. See figure II-1, which shows two strategy 
processes, respectively Deliberate and Emergent Strategy Process (taken from Mintzberg, 2007). 
 
Figure II-1.The sources of strategy, as described by Mintzberg (1994, 2007) (here from Mintzberg, 2007, p. 6). 
 
Strategy making as social learning 
Burgelman’s (1988) case study on Internal Corporate Venture units in large firms analyzes the 
emergent strategy process in detail. Burgelman (1988) describes strategy making as a social learning 
process of interplay between an action realm (in the form of entrepreneurial activities) and a 
cognitive realm (in the form of strategy formulation). Strategic renewal is seen as a result of gradual 
development, where each step depends on emerging activities in previous phases. Burgelman 
suggests that in the beginning of a new business, action and strategy are narrowly based and grow 
together (learning by doing). Gradually, a strategic (cognitive) framework can be abstracted. In the 
end, strategy can be separated from action – as it becomes institutionalized. Burgelman (1988) 
describes this institutionalizing of a strategy as a shift from ‘doing well is basis for planning well’, to 
‘planning is basis for doing’ (p. 81). Thus, Burgelman differentiates the two phases, respectively 
before and after the institutionalization (ibid, p. 83): 




 The steady state: A strategy is distilled from experiences to induce further strategic 
activities through a planning process. 
What starts as “opportunistic search in the stream of ongoing work” at operational level, manifested in 
local experiments, can – in case of success – gradually gain impact at yet higher management levels, 
ultimately to be recognized at corporate management level and thereby change the firm’s ‘concept of 
strategy’. Hereafter, the institutionalization of the new strategy begins.  
Figure II-2 synthesizes Burgelman’s (1988) theory of interplay between the two aspects of strategy 
making: the physical aspect (experiments and implementation in the ‘realm of action’) and the 
mental aspect (strategy formulation in the ‘realm of cognition’).  
 
 
Figure II-2. Strategy making as a social learning process, based on Burgelman (1988). The process is here 
depicted as a ‘sound wave’ swinging in the polarity between the realms of cognition and action, gradually 
gaining resonance at yet higher organizational levels.  
 
Forward-looking cognitive search and backward-looking experiential learning 
Similarly to Burgelman (1988), Gavetti & Levinthal (2000) analyze how organizational search 
processes can either be forward-looking, based on cognition, or backward-looking, based on 
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about the linkage between the choice of actions and the subsequent impact of those actions on 
outcomes. Such beliefs derive from the actor's mental model of the world (Holland et al., 1986)” (p. 
113).  “In contrast, experiential wisdom accumulates as a result of positive and negative reinforcement 
of prior choices (Levitt and March, 1988). Choices that have led to what are encoded as positive 
outcomes are reinforced, while the propensity to engage in actions that have led to negative outcomes is 
diminished. In this sense, experiential learning offers a form of backward-looking wisdom” (ibid, p. 
114). They summarize this understanding in a learning or reinforcement cycle – see figure II-3.  
 
 
Figure II-3. Gavetti & Levinthal’s (2000) model of “intelligence of action” as a learning or reinforcement cycle 
comprising forward-looking cognitive search and backward-looking experiential search.  
 
Gavetti & Levinthal (2000) state that the forward- and backward-looking search processes are 
complementary, because experience-based search is limited to the number of experiments you can 
actually engage in, and cognitive search is constrained by the incompleteness of the mental models in 
use. Their theory is not focused on strategic search; however, their theory can be directly applied to 
strategy making.  
Cognitive and experience-based search in a perspective of organizational 
maturation  
In a more recent study, Gavetti & Rivkin (2007) develop a time-bound theory on action and cognition 
in strategy making. Their research question is: “Where do strategies come from?”, and the title of the 
paper addresses the dualism between the mental and the physical aspect of strategy: “On the Origin 
of Strategy: Action and Cognition over Time”. They conduct a longitudinal case study of the Internet 
portal company Lycos and its search for strategies. For building their theory, they contrast two 
strategy models:  “The positioning model portrays strategic search as cerebral and top-down; the core 
search mechanism is deductive application of economic logic to a firm’s activities—the central elements 
that are searched. It assumes firms are highly plastic, conforming readily to the shape desired by the 
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management team. The evolutionary model posits that managers are intendedly but boundedly 
rational (Simon 1957a, p. xxiv). As a result of cognitive bounds, much behavior in organizations is based 
on semiautomatic rules and routines (Nelson and Winter 1982). The core search mechanism is local 
search: Actors seek solutions that entail incremental change to existing routines—the key elements 
searched—often through trial and error (Cyert and March 1963) and with limited deliberation. 
Managers rely on local search because they are cognitively limited and know their firms are not fully 
plastic” (p. 421, my emphasis). 
Based on their longitudinal case study, Gavetti & Rivkin (2007) suggest that positioning and 
evolution models have different plausibility or likelihood depending on the maturity of both the 
company and the industry: For young companies in immature industries, local search and 
experiments is most plausible. This corresponds to the evolution model; action comes before 
cognition. Conversely, rationality gains plausibility especially as the industry matures. This 
corresponds to the positioning model; cognition and planning comes before action. Gavetti & Rivkin 
(2007) conclude: “The world of action, the world of cognition, and their interplay are sensitive to time, 
and our models need to incorporate this sensitivity” (p. 436). They summarize their contribution such: 
 “Over time, the cognitive and physical elements that make up a strategy become less plastic, 
while mechanisms to search rationally for a strategy become more available. This generates a 
fundamental tension in the origin of strategy: Managers struggle to understand their 
environment well enough to search rationally for an effective strategy before their firms lose 
the plasticity [plasticity: see quotation above] necessary to exploit that understanding. A focus 
on time allows us to synthesize and extend the evolutionary and positioning models of strategic 
search” (ibid, p. 420). 
Gavetti & Rivkin (2007) thus propose that the plasticity (“conforming readily to the shape desired by 
the management team”, p. 421) of the firm decreases as result of the maturation of the company – the 
organization settles in its competencies, routines etc. By contrast, the possibilities for rationality in 
strategic search increase with the maturation of the industry. This theory integrates the evolutionary 
and positioning models of strategy as depending on the stage of maturation of the company and its 
industry. 
Conclusion on origin of strategies 
Based on the presented research, there seems to be strong evidence showing that the strategy 
processes evolve in phases. Just as we all learn our ways through the childhood via endless trial-and-
error processes, so does strategy making seem to begin with local experimentation leading to 
retroactive rationalizing, based on which top management can  induce further strategic activities 
through a planning process (Burgelman, 1988). Similarly, strategic search in a young organization 
seems more likely to be based on action or behavior (the evolutionary model), where cognition and 
rationality (the positioning model) increases likelihood as the organization and especially its 
industry matures (Gavetti & Rivkin, 2007). Put differently: 
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 In the emergent state (a strategy before institutionalization; or an immature organization) 
strategy making is dominated by experience-based learning (trial-and-error practice and 
backward-looking search). 
 In the steady state (a strategy after institutionalization; or a mature organization) strategy 
making is dominated by cognition-based planning (beliefs and forward-looking search). 
From the understanding of strategy making as a learning process, I build on previous approaches in 
literature on strategic search and managerial cognition to model strategy making as a learning or 
reinforcement cycle. Burgelman (1998) does so in his Figure 2, p. 84. Gavetti & Levinthal (2000) do it 
in their Figure 1 (shown above as Figure II-3). Prahalad & Bettis (1986) similarly show the dominant 
logic as being created in a reinforcement cycle in their Figure 1 (shown below as Figure II-9). Walsh 
(1995) summarizes the body of literature on managerial cognition in a recursive learning cycle in his 
Figure 1 (p. 282), displaying respectively the development and the use of knowledge structures. 
‘Knowledge structures’ are cognitive representations of the information environment, built up from 
past experience (“mental templates” for interpretation of the environment; ibid p. 281 – i.e. theories 
about the world).  The use of the cognitive representations leads to consequences in practice; which 
again feed back to further development of the mental templates (the theories).  Applying this 
thinking, my Figure I-1, shown again here as figure II-4, synthesizes theory-based and experience-
based processes of strategy making into a basic, recursive learning cycle. The conclusion from this 
section is that the two processes (respectively the right and the left side of the learning cycle) have 





Figure II-4. The basic learning cycle of strategy making, repeated from figure I-1, inspired from Walsh (1995) 
and others. The experience-based process seems dominant before strategic institutionalization; while the 
theory-based process gains importance after institutionalization of strategy.  
 
How strategies evolve 
The internal ecology of strategy making 
The basic idea that strategy processes are not all planned by top management, but also emerge from 
lower levels in the organization, is central in the theoretical framework developed by R.A. Burgelman 
(1991, 1996, 2002). Central here are the concepts of induced and autonomous strategy. “Induced 
strategy exploits initiatives that are within the scope of a company’s current strategy and that extend it 
further in its current product-market environment. Autonomous strategy exploits initiatives that 
emerge through exploration outside of the scope of the current strategy and that provide the basis for 
entering into new product-market environments” (Burgelman, 2002 - p. 327). This definition clearly 
reflects the two modes of organizational learning proposed by March (1991), exploitation and 
exploration: induced strategy as exploitation of existing capabilities and positions; autonomous 
strategy as exploration outside existing capabilities and positions.   
According to Burgelman (2002), induced and autonomous strategy should be balanced, since 


























other words: the strategic renewal (variation) comes from emerging autonomous strategies, whereas 
selection and retention are obtained via the induced strategy. This interplay between induced and 
autonomous strategy is framed as the ‘internal ecology of strategy making’.  
Burgelman’s theory is depicted in a simplified form in figure II-5. 
 
 
Figure II-5. A simplified image of Burgelman’s model of ‘internal ecology of strategy making’ (based on 
Burgelman, 2002). The concept ‘strategic context determination’ is the process by which corporate 
management recognizes a legitimate role of an autonomous initiative in the induced strategy. 
 
Burgelman’s theory comprises in-depth analysis of the evolution of strategy and provides many keys 
to answering my research questions, although the theory concerns business strategy in general – 
therefore we shall go into more detail with this framework.  
Burgelman (1991) builds his theory on a longitudinal case study of Intel Corporation. He notes that 
when Intel in 1985 made the strategic decision to exit the DRAM (memory) business and devote its 
main activities to the microprocessor business, this seemingly dramatic decision was a formal 
articulation of a de facto development in Intel’s activities over more than 10 years. In fact, at the time 
of decision, the memory business accounted for less than 25% of Intel’s revenue, whereas the 
microprocessor business had gradually climbed to app. 75%. How can such development take place, 
even though Intel’s formal strategy still saw Intel as a “memory company”? 
To explain the development, Burgelman (1991) contrasts the two sorts of strategy making processes 
within an evolutionary framework of variation-selection-retention: 
The induced strategy process is driven by top management’s intent within the established domain. 
Even if this might result in planned variation (Burgelman 1991, p. 246), the induced process 
generally has “a variation-reduction effect on the set of strategic initiatives” (ibid, p. 245). Variation 
(i.e. alternative and novel opportunities) in the induced process implies that top management, based 
on its ex ante vision, proposes initiatives (projects) and then seeks resources for establishing them. 
The main parts of the induced process, however, concern the selection and retention. For the 
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the place of new initiatives within the organizational structure (so-called structural context 
determination). The potential fit to the organizational structure must be defined for any new project, 
in order to allocate resources. In the retention part, a process of organizational learning identifies the 
basis of success, the distinctive competencies and the field of activities of the organization, and 
integrates these elements into the top management vision.  
In the autonomous strategy process, however, variation is created by operational-level managers’ 
local experiments, “seeking to use their skills in new combinations with [the] organization’s distinctive 
competencies” (Burgelman 1991, p. 254). The survival of such initiatives depends on the ability of the 
lower-level managers to mobilize top management for a so-called strategic context determination 
process – that is, identifying the strategic value of the various experiments in order to assess their 
business potential for the corporation. This selection process requires that top management makes 
sense of the experiments and defines a strategic space for the new initiatives within the overall 
corporate strategy. Hereby top management must be able to rationalize and justify the new 
initiatives based on a corporate strategic intent. Eventually top management will “recognize that a 
major change in strategy is necessary and feasible”, which again will “lead to a new, ex post vision” 
(ibid, p. 254). In other words: based on the interpretation of the autonomous experiments, top 
management concludes a new strategic intent. “Once formally ratified, [the] new vision becomes part 
of the basis for the induced process” – that is the retention part of the autonomous process (ibid, p. 
254).  
Linked to the induced and autonomous strategy processes, Burgelman (1991) defines four modes of 
organizational adaptation, three of which are linked to the induced strategy process: 
1. Relative inertia, which is characterized “reluctance to change organizational strategy” (ibid, 
p. 254) 
2. Adjustments, which are characterized by “relatively minor changes to strategy” (ibid) 
3. Reorientation, which is characterized by “major changes in strategy as response to major 
environmental change” (ibid) 
4. Strategic renewal, characterized by “major changes in organizational strategy preceded by 
internal experimentation” (ibid). 
The ‘strategic renewal’ is, as the only of these, linked to the autonomous strategy process. Since the 
present research project identifies strategic transformations linked to the induced strategy process, 
it is worthwhile to look closer at Burgelman’s (1991, p. 253) description of the most radical induced 
adaptation, which is here quoted in its entirety (my emphasis, except for the word ‘reorientation’):  
 “Reorientation. Major changes in the strategy seem likely to upset the induced strategic 
process in fundamental ways. The necessity for a major strategic change suggests that selective 
pressures from environmental variations have made the organization's capacity for 
relatively modest adjustments largely irrelevant. At first, threat-rigidity (Staw, Sandelands and 
Dutton 1981) may lead top management to reaffirm familiar approaches. For instance, Cooper 
and Schendel (1976) found that established firms, confronted with the threat of radically new 
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technologies, were likely to increase their efforts to improve the existing technology rather than 
switch to the new technology, even after the latter had passed the threshold of viability. 
Eventually, however, confronted with chronic low performance, top management is more 
likely to take major risks (March 1981b, Singh 1986) by making extreme and vacillating 
changes in the strategy, potentially involving a complete change of domain (Hambrick and 
D'Aveni 1988). When an organization finds itself in a precarious situation, reorientation 
may be perceived by top management as necessary to maintain or regain viability (Miles 
and Cameron 1982), and may be better than doing nothing. However, as March (1981b) has 
observed, organizations facing bad times, and therefore following riskier and riskier 
strategies, may simultaneously increase their chances of survival through the present crisis, 
but also reduce their life expectancy: "for those organizations that do not survive, efforts to 
survive will have speeded the process of failure." (1981b, p. 567)”. 
From this description, as well as the overall characterization “major changes in strategy as response 
to major environmental change” (ibid, p. 254), I understand ‘reorientation’ as a reactive or even 
defensive response to external pressure or internal crisis (the well-known ‘burning platform’). Such 
reorientations took place twice at Novo Nordisk, as can be seen in the case story. Burgelman’s (1991) 
model lacks an induced process for major strategic changes, driven by proactive visions about future 
possibilities. ‘Strategic renewal’ solely belongs to the autonomous process. This limitation has made 
it necessary to expand the model for the present research project.  
Burgelman (1991) calls his framework the “intraorganizational ecology of strategy making”, and this 
evolutionary model is used to explain how the microprocessor business at Intel grew autonomously 
from the bottom until, ex post, to be recognized as the new corporate strategy for Intel.  
In a later paper, Burgelman (2002) continues the longitudinal case study of Intel. He describes how 
CEO Andy Grove, after reformulation of the corporate strategy in 1985, focused the activities around 
the highly successful core business of microprocessors to a degree where nearly everything else was 
abandoned. “Grove began to consider non-core business development as a distraction. …strategic 
planning was almost exclusively focused on the core business… Resource allocation favored the core 
business” (ibid, p. 351). Burgelman (2002) terms such kind of strategic inertia ‘co-evolutionary lock-
in’.  He explains the phenomenon by comparing his evolutionary model of strategy making with the 
rational actor model: “Intel’s strategy making before Grove became CEO resembled an internal-ecology 
model in which induced (memory-related) and autonomous (microprocessor-related) initiatives 
competed for the company’s scarce resources based on their success in the external competitive 
environment. This paper documents how Grove’s successful strategy vector created a highly focused 
induced-strategy process, which moved Intel’s strategy making away from the internal-ecology model 
and closer to the rational-actor model” (ibid, p. 327). 
Burgelman (2002) further comments that the backside of the success of the microprocessor strategy 
was a blockage of the strategic context determination process described above. “In spite of Grove’s 
efforts to vectorize everybody in the same direction, numerous autonomous strategic initiatives 
continued to emerge, indicating continued attempts at exploration. The decrease in Intel’s capacity to 
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activate strategic context determination processes, however, prevented the company from 
exploiting the more viable autonomous initiatives” (ibid, p. 355 – my emphasis). Thereby the so-
called ‘co-evolutionary lock-in’ destroyed what Burgelman considers a sound balance between 
autonomous and induced strategy processes. “The capacity to activate and successfully complete such 
processes [autonomous initiatives and strategic context determination] can be viewed as a measure of 
the intelligence of the company’s internal selection environment and may be at the very heart of 
strategy making as an adaptive organizational capability” (ibid, p. 355). 
One should notice that Burgelman (1991) does not restrict the validity of the ‘internal ecology’ model 
to the case of Intel. On the contrary, he states that “The perspective [internal ecology model] serves to 
illuminate data from a field study of the evolution of Intel Corporation’s corporate strategy. The data, in 
turn, are used to refine and deepen the conceptual framework” (ibid, p. 239) and he makes generalized 
proposals such as “consistently successful organizations are characterized by top managements who 
spend efforts on building the induced and autonomous strategic processes” (ibid, Abstract). Thus, 
Burgelman’s (1991) model is not an intrinsic case study (Stake, 2000), but a generalized theory. 
The theory on internal ecology of strategy making (Burgelman 1991; 2002) is shown graphically in 
figure II-6.  
 
Figure II-6. A model of the theory on internal ecology of strategy making in Burgelman (1991; 2002). Only 
some of the many autonomous initiatives succeed in mobilizing top management for the strategic context 
determination process, eventually leading to strategic renewal. Reinforcement in the induced process may 
result in co-evolutionary lock-in, which again may impede strategic renewal. The external environment 
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Conclusions on strategy evolution 
The evolutionary theories of strategy-making subscribe to the behavioral paradigm within strategic 
literature. These theories are centered on emergent, experience- or learning-based strategy 
processes. Burgelman’s theory remains one of the most comprehensive evolutionary models of 
strategy making, and Burgelman thoroughly analyses how business strategies evolve. The essence of 
Burgelman’s theory is that long term renewal of induced strategy is mediated by autonomous 
initiatives.  
However, related to the present empirical case study, some gaps remain: 
 It remains open, whether the theory can explain the evolution of innovation strategy, 
defined as ‘the strategy for the individual innovation activities with the objective to create 
product or business innovations’. In the Intel case study, the autonomous microprocessor 
strategy obviously built on previous innovation activities, but Burgelman (1991) does not as 
such analyze the emergence of this innovation strategy, i.e. before the establishment of 
microprocessors as a business. Rather, he analyses how the microprocessor business 
gradually (over a period of nearly 15 years) takes over as the main business and as the 
official corporate strategy; at the time of the formal change in strategy (1985), the 
microprocessors already accounted for 75% of Intel’s turnover (Burgelman, 1991). This 
internal competition between the induced memory business strategy and the autonomous 
microprocessor business strategy is different than an (earlier) competition about which new 
product categories to develop and launch – microprocessors and memory products both 
existed in the market at the period, which Burgelman (1991) analyses.  
 Burgelman’s ‘internal ecology model’ to large extent disregards the influence of external 
dynamics (e.g. competitor moves): an intra-organizational perspective is deliberately chosen 
in order to arrive at new understanding of strategy processes (Burgelman 1991, p. 240). 
 According to Burgelman (2002), induced strategy reduces variation, whereas autonomous 
strategy increases variation (p. 354). Strategic renewal is described as tied to the 
autonomous process only; major strategic changes in the induced process are termed 
‘reorientation’, and these are described as reactive or defensive responses to a ‘burning 
platform’. A vision-based or proactive major change of strategy within the induced process is 
not described in the model.  
 Managerial cognition is mentioned, but has no central role in the internal ecology model. 
In conclusion, Burgelman’s ‘internal ecology model’ seems the most direct theoretical response to my 
research question “How does innovation strategy evolve?”; however, it is interesting to examine the 
significance of the different research contexts: business strategy in general versus innovation 
strategy, and a relatively young company in a dynamic industry (Intel) versus a mature company in a 




The role of management cognition for strategy  
Departing amongst others from Herbert Simon’s analysis of the limited rationality in actual decision 
making (e.g. Simon, 1955), a large stream of research on management cognition evolved – see Walsh 
(1995) and Kaplan (2011) for reviews. Walsh (1995) summarizes the general landscape of this 
research as such: “The basic idea is that individuals can approach information processing in two 
dominant ways. They can use a "top-down" (Abelson and Black 1986) or "theory-driven" (Nisbett and 
Ross 1980) approach, whereby their past experiences in similar circumstances guide present 
information processing, or they can let the current information context guide information processing in 
a "bottom-up" or "data driven" approach. In the former case, the cognitive structures generated from 
experience affect individuals' abilities to attend to, encode, and make inferences about new information; 
in the latter case, the information itself shapes individuals' response to it” (p. 281). This understanding 
is the basis of the model of strategy making as a learning cycle between theory and practice (figure II-
4).  
A part of the research on management cognition focuses specifically on strategic cognition – see 
Narayanan et al (2011) for a review. This literature (according to Narayanan et al, 2011) analyzes the 
strong influence of the cognitive structures on decision making, hereunder ‘strategy frames’, which 
filter the information and direct managers’ attention via a sort of ‘cognitive template’ for how to 
understand the environment. The literature also identifies how such strategy frames “often lag 
behind changes in the internal or external environment, making strategic change problematic” (ibid, p. 
336); in other words: cognitive inertia may result in strategic inertia.  
We shall now look into the concepts of strategy frames, cognitive inertia, dominant logic and framing 
contests, since these concepts haven proven to be valuable for analyzing the empirical case.  
The impact of the initial ‘framing’ of the business – and of identity  
Noda & Bower (1996) conduct a dual case study of the strategic development of respectively 
BellSouth and US West (two regional US telecom operators established by the breakup of the Bell 
system in 1984), during the period of breakthrough for cellular/mobile telephony (1983-1994). The 
case study clearly illustrates the importance of how top management defines the business and 
phrases the strategic direction: 
 BellSouth defined itself as a telecommunication company (ibid, p. 173) and saw the new 
cellular business as complementary; as a growth vehicle (ibid, p. 174). Consequently, top 
management set modest goals for profit and cash flow from the new business and invested 
for the long term profitability. The modest expectations were met; the new business had 
gradual success, and therefore top management invested more – a positive reinforcement 
cycle, which ended with a strong, official corporate commitment to the cellular business 
(ibid, p. 176, 177, 186). 
 US West saw itself as a diversified firm in the “information industry” (ibid, p. 173); they even 
started up real estate investments and financial service business. Top management expected 
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cellular business to be profitable on a short term basis, since they perceived it on equal terms 
with the many other businesses (ibid, p. 174). This led them to a ‘cream-skimming’ strategy 
with less emphasis on long term investments. Their high, short term expectations could not 
be met and hence a negative self-fulfilling prophecy cycle was started (ibid, p. 176, 177, 179, 
186). This led top management to reduce its investments even further (ibid, p. 176) and they 
missed the opportunity of the cellular business.  
In conclusion, this case study clearly states how the initial framing of corporate strategy (or 
‘phrasing’, see ibid p. 188) sets the stage for the activities and for evaluation of the results. Via the 
learning from the early experiences, a dominant logic (see later part) about the new business was 
built, which became self-reinforcing and difficult to change. In other words, there’s a direct link 
between initial strategic framing and the later performance.  
Tripsas (2009) studies the concept of an organization’s identity and how it might hinder a company 
from adopting new technologies, in the case where these technologies do not fit to the internal 
identity of the firm. She defines internal identity as “a shared understanding by organizational 
members regarding what is central, distinctive, and enduring about an organization” (ibid, p. 441). She 
conducts a longitudinal case study of a disguised digital photography company on the effect of 
‘identity threats’ from new technologies. She finds that “First, identity serves as a lens that filters a 
firm’s technical choices…Second, the self-reinforcing dynamics among identity, organizational action, 
and the industry and technological context create a strong impediment to change” (ibid, p. 454). In this 
analysis, the concept of identity in many ways resembles Prahalad & Bettis’ (1986) and Bettis & 
Prahalad’s (1995) analysis of the dominant logic of a firm as a filter mechanism, built up via 
reinforcement cycles, which result in strategic inertia (see the section on dominant logic). The two 
concepts are closely related – dominant logic, even if not being explicit, consists of cognitive models 
and is therefore closer to the sphere of deliberate cognition, where identity seems more emotional, 
based on tacit experience. Both concepts label shared mental structures within an organization, 
which have an enduring function with regards to the worldview of the management team and in 
effect on the corporate strategy. Thus, Tripsas (2009) states: “When faced with uncertainty or a 
challenging issue, managers view the issue through the lens of the firm’s internal identity, which guides 
interpretation and action” (p. 441). Metaphorically, the identity of a firm can perhaps be compared to 
the internalized value systems of the parents, which guide a child or a young person through his/her 
life. Staying in the metaphor, the dominant logic would then be cognitive schemas for problem 
solving, which are created through the person’s own successful problem solving experiences.  
To conclude this part on framing and identity: The initial framing of a strategy has a long lasting 
effect, because the framing process scopes the subsequent learning or reinforcement cycles and 
defines the metrics of success. Similarly, the internal identity of a company provides enduring 
guidance for the decision making in the organization, and thereby offers an alternative to 
organizational routines as part of the ‘corporate DNA’ (Gavetti & Rivkin, 2007). 
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Cognitive and strategic inertia  
Barr, Stimpert & Huff (1992) analyze longitudinal data from a matched pair of U.S. railroad 
companies during the decades after World War II, in which the entire U.S. railroad industry was 
undergoing a significant decline – private cars, and trucks for transportation of goods, were taking 
over the transportation market. These external dynamics of course hit both companies, which 
displayed a number of similarities from the outset, such as geographical area, size of company etc. 
Still, the two companies responded very differently to the changes in the external environment, and 
their different courses of action led them to different destinies – the one (Rock Island) sought 
bankruptcy in the mid 1970s and ceased to exist. The other (C&NW) was viable as the article was 
published in 1992. Based on archival data (annual reports) the authors thoroughly identify and 
analyze the mental models of the top management of the two corporations. They link the different 
courses of action to differences in the development of top management’s mental models: “…the 
leaders of the C&NW not only recognize changes in their environment, they also gradually change their 
mental models…” -  “At the Rock Island, in contrast, changes in beliefs and action are not undertaken 
until the railroad is near bankruptcy.” In other words, C&NW successfully adapted their mental 
models to changes in the market conditions, whereas this learning did not take place at Rock Island, 
which therefore ended with having a business understanding out of sync with market reality. Using 
vector symbols, this analysis is illustrated in figure II-7.  
 
 
Figure II-7. A graphical model of the railroad case by Barr, Stimpert & Huff (1992).  
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Tripsas & Gavetti’s (2000) case study of Polaroid’s struggle with the challenges of digital 
photography similarly deals with the problem of adapting the top management cognition to changes 
in the external environment – in case, the new technology of digital imaging. The new technology per 
se was not a challenge for Polaroid – their digital cameras got top scores in comparative product 
evaluations. Polaroid’s challenge mimicked the one of Rock Island – they did not realize that the 
changes in external reality required them to rethink their business. Polaroid had built their success 
on a business model, which they themselves compared to Gillette’s razor-blade model: They sold high 
quality cameras at relative low prize to retain the profits from the consumer goods needed for 
making pictures (i.e. the films). They wrongly believed that digital cameras would not change the 
consumers’ wish for paper prints of the images; so top management stuck to the same business 
model, which had paved the way for Polaroid’s historical success. This cognitive inertia led to the 
decline of Polaroid.   
Another example of cognitive inertia and resulting strategic inertia is found in Christensen & Bower’s 
(1996) study of the disk-drive industry, which presents the dilemma of incumbent firms between 
serving existing customers with sustaining innovation versus addressing new markets associated 
with innovations based on disruptive technologies. Disruptive technologies are defined as: 
“Technologies which disrupt an established trajectory of performance improvement, or redefine what 
performance means” (ibid, page 202). These technologies tend to be valued more in remote or 
emerging markets than in established markets (ibid, p. 203). Thus, the managerial challenge is 
caused by external factors (new technologies) – however, I am here more interested in the internal 
dimension of the challenge. The dilemma lies in the resource allocation for innovation – in the end, 
the well-known existing customers will be prioritized over the uncertain emerging new customers 
segments, resulting in lack of ability to change the innovation strategy. Interestingly, Christensen & 
Bower (1996) describe how the incumbent firms often experiment with the disruptive technologies 
internally in the form of technical prototypes etc., but top management disregards these projects in 
their selection for the innovation strategy, because the existing customers respond negatively to the 
prototypes. In Burgelman’s (2002) wording, the strategic context determination is blocked by a co-
evolutionary lock-in, which makes the companies unable to exploit the potential of the autonomous 
initiatives. Christensen & Bower (1996) state that when the incumbent firms later are forced to take 
the disruptive technologies up again for product development, it is often too late – consequently, 
entrant firms are more successful in building businesses based on the disruptive technologies. 
Christensen & Bower’s theory is modeled in figure II-8. The model shows how the cognitive inertia of 
top management, by bonds to the existing customer needs, hinders the exploitation of the new 
technologies. First when entrant companies have success in establishing product-markets based on 
the new technologies, this external change will force a shift in the cognition at top management level, 





Figure II-8. A model of Christensen & Bower’s (1996) theory on incumbent firms’ failure with regards to 
integrating disruptive technologies in their innovation strategies. 
 
Dominant logic 
Prahalad & Bettis (1986) analyze the mechanisms which lock top management in their thinking, as 
illustrated in the previous case studies. They describe how managers develop a dominant general 
management logic based on experiences from the main business of the firm. “A dominant general 
management logic is defined as the way in which managers conceptualize the business and make 
critical resource allocation decisions” (ibid, p. 490). “Dominant logic, as we have defined it here, is a 
mind set or a world view or conceptualization of the business and the administrative tools to accomplish 
goals and make decisions in that business” (ibid, p. 491). This ‘dominant logic’ summarizes the 
‘success formula’ of the dominant management coalition and causes managers to perceive problems 
and solutions as framed by past experiences. Prahalad & Bettis (1986) refer to the concept of operant 
conditioning; meaning that behavior, which is reinforced, will occur more frequently in the future. 
Thus, the dominant logic evolves in a positive cycle of reinforcement of ‘doing the right things’ in the 
past. “This reinforcement results in their [managers’] focusing effort on behaviors that led to success” 
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Figure II-9, from Prahalad & Bettis (1986), p. 491, showing the learning cycle behind the establishment of the 
dominant logic of a firm.  
 
Bettis and Prahalad (1995) elaborate the concept of dominant logic. “We have come to view the 
dominant logic as an information filter…Organizational attention is focused on data deemed relevant 
by the dominant logic. Other data are largely ignored” (p. 7). The direction of organizational attention 
towards certain issues (deselecting other) is a central element in a behavioral analysis of strategy, cf. 
Ocasio (1997). Thus, Bettis & Prahalad (1995) place the dominant logic “as a fundamental aspect of 
organizational intelligence” (p. 7). Their key point is that dominant logic is crucial for an 
organization’s adaptability. “Interestingly, it [dominant logic] provides a set of heuristics that simplify 
and speed decision making. This inherently results in ‘adaptive ability’, so long as changes in the 
underlying logic are not necessary” (ibid, p. 11, my emphasis). As indicated by the previous studies, 
the bond to past experiences has a ‘toxic side effect’, if the management team wrongly applies the 
established dominant logic to situations, where changes in the environment have made the learned 
behaviors inappropriate.  
Since the dominant logic is shaped via positive reinforcement of successful actions, it can be difficult 
to alter or unlearn the logic, once established: “Interestingly, the more successful organizations have 
been, the more difficult unlearning becomes” (Prahalad & Bettis, 1986, p. 498). Therefore, the 
dominant logic can cement as a ‘deep structure’ (Gersick, 1991), like the scientific paradigm in 
Kuhn’s (1964) analysis of scientific revolutions. This understanding of the role of dominant logic is 
reflected in Bettis & Prahalad (1995). They describe the dominant logic as a ‘local optimum’ or 
equilibrium, which it requires substantial efforts to escape (Bettis & Prahalad, 1995, p. 12-13). Small 
fluctuations from the dominant logic will end by returning to the original equilibrium – it takes a far 





Figure II-10 – taken from Bettis & Prahalad, 1995. It takes a far move to escape the established equilibrium of 
the current dominant logic. Hence, dominant logic may hinder strategic renewal.  
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Burgelman (1983, 1988) uses the term ‘concept of strategy’ in a way that resembles the concept of 
dominant logic (Burgelman 1983, p. 68 – my emphasis):  
 “The concept of strategy provides a more or less explicit, and more or less shared, frame of 
reference or "paradigm" (Duncan & Weiss, 1979; Jelinek, 1979) concerning the bases of the 
firm's past success. Not unlike the sociological notion of a paradigm (Kuhn, 1970; Masterman, 
1970), it provides guidance for further strategic action in line with it. At the same time, it 
crystallizes the attitudinal and social factors that were selected together with the 
cognitive, substantive factors underlying the past success. As such, it also is likely to 
prescribe, often implicitly and tacitly, attitudes and managerial styles and an ideology 
deemed necessary for the prolongation of the firm's success. Autonomous strategic behavior, 
identified here as the major source of strategic renewal, thus is likely to encounter nonrational 
obstacles in its efforts to convince top management that changes in corporate strategy are 
necessary”. 
As can be seen, the overlap to the concept of ‘dominant logic’ is huge, and even the ‘gravity’ (Figure II-
10) is described. If I should point to differences, then the dominant logic is a purely cognitive 
phenomenon; an information filter for making sense of the whole environment of the business; 
whereas Burgelman’s ‘concept of strategy’ is more closely linked to the strategy. Furthermore, in 
Burgelman (1988) the change in a firm’s ‘concept of strategy’ is the result of the initial strategy 
making process, concluding the emergent state. The establishment of a dominant logic would require 
longer reinforcement cycles within the induced strategy process, perhaps even linked to the eventual 
stage of ‘co-evolutionary lock-in’ of the strategy (Burgelman, 2002).  
I have here chosen to apply the concept of dominant logic, both because of the opening towards the 
literature on management cognition, and because it not always is crystal clear, when Burgelman’s 
(1983, 1988) ‘concept of strategy’ refers to a deep cognitive structure underlying the firm’s strategy 
making (the ‘paradigm’) or to the ‘strategy concept’ (the strategy as the individual theory or plan, 
building on the underlying paradigm). The concept of ‘dominant logic’ is here easier to decode; it 
always terms the underlying ‘mental models’, the ‘paradigm’ beneath the strategy making. 
 
How the dominant logic might be loosened up 
Based on a recent case study, Kaplan (2008) links cognitive frames and strategy making under 
conditions of uncertainty into a theory of ‘framing contests’. Kaplan (2008) defines frames as “the 
means by which managers make sense of ambiguous information from their environments” (p. 729). 
She describes strategy making as a ‘framing contest’ between different groups within the 
organization, each promoting their cognitive frame “to make their frame resonate and mobilize action 
in their favor” (ibid, p. 730). In her ethnographic case study of a single company (a disguised 
manufacturer of communication technologies), she observed such ‘framing practices’: “By 
attempting to establish the legitimacy of a frame or of themselves as claimsmakers or by realigning the 
frames in play, actors sought to push the strategic choice in the direction of their own frames and 
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interests... If framing practices were successful, this process produced a predominant frame” (ibid, p. 
736). By proposing this concept of framing contests, the view on management cognition is lifted 
above the perspective of cognitive inertia – the contest between different cognitive frames becomes a 
driver of strategic renewal. “I find that frames influence strategic choices, not in a deterministic 
fashion, but rather in one mediated by organizational framing contests. This model opens up the black 
boxes of politics in cognitive models and of cognition in political models of strategy making by showing 
that frames are both constraints and resources for actors acting purposefully to shape strategic 
choices” (ibid, p. 745, my emphasis). Kaplan (2008) herself makes the link to Prahalad & Bettis 
(1986) by stating “The framing contests model sheds light on the organizational processes by which 
dominant logics emerge and change” (p. 746).  
To conclude: where dominant logic is formed through reinforcement cycles, starting from the initial 
framing of strategy, the dominant logic may change as result of framing contests between managers – 
at least, under conditions of uncertainty.  
Conclusions on management cognition and strategy  
In conclusion, some key findings from the theories on management cognition could be:  
 The link between top management’s cognitive structures and strategic inertia is well 
documented. However, most of the underlying case studies are on technological 
discontinuities and environmental changes not controlled by the focal firm, setting top 
management in a reactive role (Barr, Stimpert & Huff, 1992; Christensen & Bower, 1996; 
Tripsas & Gavetti, 2000). The entrepreneurial role of top management cognition is 
underresearched. 
 The initial identity and framing of strategy form the basis of organizational learning cycles, 
which have an enduring effect via establishment of the dominant logic. One study analyzed 
how the dominant logic might undergo change processes: Kaplan (2008) analyses ‘framing 
contests’ as an ecosystem of cognitive frames, which compete for becoming dominant. This 
theory therefore points towards a more dynamic model of managerial cognition.  
 
Integrative competencies 
The evolution of innovation strategy at Novo Nordisk to large extent is a case of integration of 
complementary products (medical devices) in a drug-based, pharmaceutical company. Some 
theoretical concepts could facilitate the understanding of this perspective.  
In a context of Open Innovation, Christensen (2006) describes two trends in today’s business 
environment:   
 Growing technological complexity, which makes deep technical competencies less important 
than so-called ‘background competencies’ for utilizing emerging areas of knowledge  
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 Increasing vertical disintegration of the industries, where nobody can have full control and 
ownership of the entire value chain of their business.  
These trends force large companies into a role as system integrators or ‘innovation architects’, and 
this role again requires integrative competencies for synthesizing various knowledge resources into 
applications.  
The foundation of integrative competencies are the complementary assets (Teece, 1986), which 
typically characterize larger, established companies as compared to technology-specialized startup 
companies. Complementary assets include customer linkages, established distribution channels, 
production know-how for economies of scale etc. The role of complementary assets is to amplify the 
value of the core assets. Teece (1986) describes the core of an innovation as the “technical knowledge 
about how to do things better than the existing state of the art” (p. 288). Around the core technological 
know-how, a range of complementary assets are needed for commercializing the basic technical 
invention. Interestingly, Teece states: “In some cases, as when the innovation is systemic, the 
complementary assets may be other parts of the system. For instance; computer hardware typically 
requires specialized software, both for the operating system, as well as for the applications”(ibid, p. 
288). 
Going back to Christensen (2006): integrative competencies, which utilize complementary assets, 
enable large firms to orchestrate a portfolio of technologies and transform these into product 
offerings.  
This whole perspective of complementary assets and system integration is very relevant for the case 
study of the medical device activities at Novo Nordisk, where the medical devices most of the time 
have been perceived as complementary products compared to the pharmaceutical drugs in the 
product innovation strategy. Still, in the present form, the theories lack the longitudinal perspective 
of the dynamics between core and complementary assets for innovation strategy in a single company 
– i.e. what happens with the balance between core and complementary over time?   
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A synthesized model of strategy evolution 
This section provides a synthesized theoretical model of how a strategy comes into being, is 
sustained and eventually changed, based on the research presented earlier in this chapter. 
Mintzberg (2007) describes combined deliberate and emergent processes of strategy formation: “If 
deliberate strategy is about control, then emergent strategy is about learning …almost every sensible 
real-life strategy process combines emergent learning with deliberate control” (p. 5; my 
emphasis). This quotation underpins that the conceptual dichotomy between deliberate and 
emergent strategy is exactly conceptual; in real life, these processes are closely interrelated. 
Mintzberg’s graphical model (see figure II-1) may therefore be misleading, since it shows the 
deliberate and emergent processes as two separate sources of strategy. In reality they develop 
together, as analyzed in Burgelman (1988). In fact, the dichotomy may simply consist of different 
hierarchical standpoints: what is deliberate seen from one hierarchical level is emergent seen from 
the next level (cf. figure II-2).  
However, there is empirical evidence for varying levels of significance of respectively emergent and 
deliberate processes: 
 In Burgelman’s case studies of internal corporate venture units (1988) and of Intel (1991) – 
and in Gavetti & Rivkin’s (2007) case study of the internet portal Lycos – the emergent 
(experience-based) learning seems to dominate the strategy making when it comes to 
strategic renewal. 
 However, in Noda & Bower’s (1996) case study of two telecom operators’ different 
approaches to the upcoming mobile telephony, the initial strategic framing (deliberate 
strategy formulation) seemed to determine both the scope and the outcome of succeeding 
experiences in the market. 
Based on the above reflections on the conceptual dichotomy, the learning or reinforcement cycle 
(figure II-4) has been applied as the basic model of strategy formation over Mintzberg’s two separate 
streams (figure II-1); because the interrelatedness of deliberate and emergent processes is visible. 
Still, it should be noted that the two sides of the learning cycle might have shifting emphasis in 
different stages of development. In the following, different evolutions of strategy are applied by 
applying the generic model of strategic learning (figure II-4), laid out in four scenarios:  
1) the emergent state; 2) strategic lock-in; 3) induced strategic adaptation; 4) induced strategic 
reconfiguration.  
Scenario 1: the emergent state 
In the emergent state, the ‘theory’ is most often established via retroactive rationalization of 
emergent experiments (Burgelman 1988). Figure II-11 models this initial formation of a strategy – 




Figure II-11. The initial formation of strategy as a learning cycle between deliberate (forward-looking) and 
emergent (backward-looking) processes. The depicted learning cycle represents strategy making before 
institutionalization; i.e. in the emergent state (cf. Burgelman 1988). In this phase, the experience-based 
learning seems to dominate, according to the presented literature. As an empirical example, Burgelman 
(1988) builds his theory on an investigation of strategy making in internal corporate venture units.  
 
When a strategy first has been institutionalized, the strategy making changes character and becomes 
an induced process: planning before action (Burgelman, 1988). However, strategic learning still takes 
place. In that sense, Mintzberg’s (2007) statement “If deliberate strategy is about control, then 
emergent strategy is about learning” is unfortunate; it’s not an either-or between deliberate strategy 
and learning. Burgelman & Grove (1996) state: “The fact is, corporate strategy is realized by 
performing a series of such strategic actions, and not via strategic planning. Strategic plans are 
abstract, far away, and give managers a lot of chances to reconsider as they go along” (p. 21). This 
implies that when the induced strategy is implemented, practical experiences provide feedback to 
the strategy making process in the form of positive or negative reinforcement.  
Scenario 2: strategic lock-in 
Let’s look at the scenario of positive reinforcement. This occurs, when the central strategic actions are 
successful. Consequently, the core of the strategy is sustained, although it will continuously be 
adjusted based on feedback from practice. Such feedback includes the perceived distinctive 
competencies (Burgelman, 1991) and the perceived critical tasks for success (Prahalad & Bettis, 
1986). Following Prahalad & Bettis (1986), repetitive positive reinforcement can eventually result in 
the establishment of a dominant logic, which becomes hard to change. The dominant logic is the 
cognitive aspect of ‘co-evolutionary lock-in’ of strategy, using Burgelman’s (2002) terminology. In 
case of lock-in, strategic renewal is suppressed, and the strategic activities are focused on 
exploitation of established capabilities and positions. The dominant logic retains the lock-in by 
directing management attention narrowly towards the core business – everything else is perceived 
























described in Burgelman’s (2002) analysis of Intel Corporation after the institutionalization of the 
microprocessor strategy in 1985. 
 
 
Figure II-12. Strategic learning after institutionalization of strategy, i.e. in the ‘steady state’ (Burgelman, 
1988), displaying the scenario of positive reinforcement. Continuous positive reinforcement of the initial 
theory (strategy) may lead the induced strategy process towards a strategic lock-in, supported by a dominant 
logic, which impedes strategic renewal and focuses the activities on exploitation. The case study of Intel after 
1985 in Burgelman (2002) provides an empirical example of this scenario. 
 
Scenario 3: induced strategic adaptation 
Let’s now look at the case of negative reinforcement of the induced strategy. After the 
institutionalization of a strategy, the starting signal for strategic change could be negative 
reinforcement of the current strategy in the form of negative results (Prahalad & Bettis, 1986) or so-
called strategic dissonance (Burgelman & Grove, 1996). The latter refers to misalignment between 
the strategic intent and the reality of action – the primary example is Intel, where the de facto 
strategy had changed years before the explicit strategy was reformulated in 1985. Burgelman & 
Grove (1996) propose the concept of a “strategic inflection point”: a moment, where industry 
changes, technological developments or de facto changes in strategic actions require reformulation of 
the corporate strategy. As result of such negative reinforcement, an explorative search process seeks 
for alternative strategic options, in theory and practice. The most successful theories (strategy 
frames) and strategic initiatives (emergent practices) are selected, as they gain resonance within the 
corporate management team. Thereafter, new cycles of induced strategy making processes begin. In 
the case of Intel Corporation in the 1980’s (cf. Burgelman, 1991), the negative reinforcement came 
from the fact that Japanese companies were taking over the DRAM (memory) business. The emerging 
business of microprocessors won the framing contest as the most convincing alternative strategy, 
due to successful results. Hence, the microprocessor business became institutionalized as the new 
induced strategy in 1985. See figure II-13. Burgelman (1991) reversely focuses on the emergence of 


































can either analyze the transition as autonomous ‘renewal’ or as a ‘reorientation’ of strategy in 




Figure II-13. Strategic learning after the initial institutionalization of strategy, displaying the scenario of 
negative reinforcement. The starting point is negative reinforcement of the existing strategy, which triggers 
search for strategic alternatives. Emergent practice unfolds a variety of experiments; and framing contests 
offer interpretations of reality, formulated as alternative strategies (Kaplan, 2008). Via selection a process, a 
new induced strategy is chosen, which is then continuously refined via new induced learning cycles. An 
empirical example of this scenario is the Intel Corporation in the 1980’s (Burgelman, 1991), where the 
memory business declined and the microprocessor business emerged and eventually was institutionalized in 
1985 as the new corporate strategy.  
 
Scenario 4: induced strategic reconfiguration 
When posing a dichotomy such as autonomous and induced strategy (or emergent and deliberate 
strategy), the induced strategy process will tend to be perceived as a ‘conservative’ force as opposed 
to the ‘creative’ autonomous strategy. However, we should not forget that strategy per definition is a 
conservative aspect of organizational life: it’s the enduring pattern of an organization’s activity. As 
stated by Michael Porter (1991): “Strategy, in modern language, is a solution to the agency problem 
that arises because senior management cannot participate in or monitor all decisions and directly 
ensure the consistency of the myriad of individual actions and choices that make up a firm’s ongoing 
activities” – “Strategy is seen as a way of integrating the activities” – “An explicit and mutually 
reinforcing set of goals and functional policies is needed to counter the centrifugal forces” (p. 96). 
Porter is here of course colored by the rational choice paradigm, seeing strategy as a deliberate and 
explicit construct. However, the analysis of strategy as an aligning force, which creates consistency, is 
valid also in an evolutionary perspective. Furthermore, Porter (1991) states, “Strategy is the act of 
aligning a company and its environment. That environment, as well as the firm’s own capabilities, are 
subject to change. Thus, the task of strategy is to maintain a dynamic, not a static balance” (p. 97 – 











































result in a deterministic view on the induced strategy process as purely static; where strategic 
renewal is seen as only coming from emergent processes.  
Even though the deliberate (induced) strategy process is constrained by ‘bounded rationality’, there 
still is rationality (reasoning) in place – and a lot can be learned and changed based on reasoning. 
The coin called ‘bounded rationality’ has two sides: the constraints of cognition make the one side; 
the ability to learn and adapt makes the other. This point was made in the analysis of bounded 
rationality by Nelson (2008): “I use the term “bounded rationality” to connote the reasoning and 
learning abilities of an actor who has a goal to achieve and, on the one hand, an at least partially 
formed theory about how to achieve it (this is the “rationality” part of the concept), and on the other 
hand, that the actor’s theory is likely somewhat crude and perhaps even a bad guide for action, and that 
success is far from assured (this is the meaning of the “bounded” qualification to rationality)” (p. 78). 
Further, Nelson analyzes how learning can take place, departing from the (imperfect) theory: “at any 
time search for a satisfactory or a better way of doing something is strongly oriented, but also limited, 
by a theory held by the actor at that time. Empirical exploration of alternatives at any time is treated as 
like going down a path, which current theory suggests is promising, finding out where it in fact leads, 
and then perhaps trying another path. However, the actor is not locked into his present theory. As a 
result of what is learned in exploration, theory may be revised…my approach here puts special emphasis 
on the role of trial and error learning in potentially leading to improvements in the theory held 
by the actor” (ibid p. 79 – my emphasis). In terms of strategy making: the starting point is an ‘ex ante’ 
vision or strategy; from here, explorative search unfolds trial-and-error; this process eventually leads 
to improvement or change of the strategy. – Since this cyclic process is based on ‘ex ante’ vision or 
theory, such strategic change takes place within the induced strategy process.  
Based on the above understanding, negative reinforcement is not the only scenario of strategic 
change within the induced strategy process. We need a model of theory-driven strategic change – see 
figure II-14. The initial vision (or, ‘crude’ theory; Nelson, 2008) drives an explorative search, which 
via trial-and-error and interpretation of experiences results in improvement or revision of the 
‘theory’, i.e. reconfiguration of the strategy, which again drives further strategic learning. Thus, such 
scenario (based on Nelson, 2008) implies strategic change initiated out of positive vision rather than 
negative reinforcement. An empirical example of this scenario could be the case of BellSouth 
exploring the mobile telephony, as analyzed in Noda & Bower (1996). However, the present case 
study provides further empirical evidence.  
To distinguish the two scenarios of strategic change in the ‘steady state’ (Burgelman, 1988), the 
change process starting with negative reinforcement is here labeled ‘induced strategic adaptation’ 
(since it adapts the strategy based on negative feedback); whereas the vision-driven process is 
labeled ‘induced strategic reconfiguration’ (or ‘strategic renewal’), since it changes the strategy going 
out from a positive vision.  
It is here necessary to point to the differences in my terminology compared to Burgelman’s (1991) 
terminology. Burgelman (1991) links the induced and autonomous strategy processes to four modes 
of organizational adaptation (inertia; adjustment; reorientation; renewal). ‘Reorientation’ in his 
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terminology is an induced process response to negative reinforcement. ‘Renewal’ labels the 
autonomous process, which creates novel opportunities based on positive reinforcement of previous 
experiments – described in my Scenario 1 of the initial strategy formation. The case of theory-based 
strategic renewal within the induced process is not present in Burgelman’s (1991) four modes of 
organizational adaptability.  
 
 
Figure II-14. Strategic learning in the ‘steady state’, displaying the scenario of ‘theory’-based strategic 
change, based on Nelson (2008). The induced strategy process defines a ‘crude theory’ or vision, which via 
trial-and-error and interpretation ‘en route’ results in a revised theory, i.e. a reconfigured strategy. An 
empirical example of this scenario is found in Noda & Bower’s (1996) analysis of BellSouth’s exploration of 
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Overall research design  
Process study 
The present research projects aims for understanding the processes of change in innovation strategy. 
This calls for a process research study rather than a variance research study (Van de Ven, 2007): 
“Variance and process models are used to empirically examine two different types of research questions 
that are often asked about an issue being studied: 
 What are the antecedents or consequences of the issue? 
 How does the issue emerge, develop, grow, or terminate over time?” (p. 145). 
Important is that both models can lead to understanding causality; the process model just takes 
another road: 
“From a variance perspective, events represent changes in variables, and these changes are the building 
blocks of process in an input-process-output model. But since a process question is not whether, but 
how, a change occurred, we first need a story that narrates the sequence of events that unfolded as the 
innovation emerged from concept to implementation. Once the sequence or pattern of events in a 
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developmental process is found, then one can turn to the ‘what’ questions about the causes or 
consequences of the event sequence” (Van de Ven, 2007, p. 146). 
To follow a process study model has implications for data collection and analysis. Concerning the 
data needed: “Process questions of how things change and develop over time require longitudinal data 
that can be obtained either from historical archival files or from a real-time field study of a change 
process” (Van de Ven, 2007, p. 195). Concerning the data analysis: “Analysis of process data requires 
methods that (1) can identify and test temporal linkages between events and also overall temporal 
patterns (Poole et al, 2000); and (2) can cope with the multiple time scales that often occur in processes 
(where some events extend for years, other events embedded in them run for shorter periods, and others 
embedded within these run for even shorter periods) (Langley 1999)” (Van de Ven, 2007, p. 159). 
With regards to data collection, the case study at hand builds both on archival data and a five-year 
real-time field study. With regards to the data analysis, I thoroughly mapped events and overall 
trends at several levels of analysis, from the trends in the industry over corporate management 
events all the way to concrete innovation projects of the case organization. I here had great benefit 
from utilizing the method for data analysis prescribed by Mintzberg (2007), because it describes 
concrete techniques for working at multiple levels of analysis and multiple timeframes – see the 
section on the methods of the historical case study.  
Qualitative case study 
This research project aims for an in-depth understanding of the processes of change in the 
innovation strategy at a particular context. Again, this points not towards a quantitative, cross-
sample study of variables and their interdependencies. I have chosen an inductive approach to 
qualitative research, going deep into the events in one organization. This empirical research has the 
format of a longitudinal case study of the medical device area at the pharmaceutical company Novo 
Nordisk A/S, describing the medical device innovation activities since the beginning of these 
activities around 1980 to year-end 2010. Such case study design opens for a thick description of the 
events, contexts and interpretations (Stake, 2000, p. 437). According to Stake (2000), case studies 
can be either intrinsic, where the interest is on the idiosyncratic case itself – or instrumental, where 
the case “facilitates our understanding of something else” (ibid, p. 437), often at more generalized 
level. The present case study holds an intrinsic part, driven by the curiosity of understanding the 
fluctuations in strategy at the organization where I worked, presented in Chapter 4. However, the 
present case study also holds an instrumental part, driven by my theoretical studies, presented in 
Chapter 5. The inclusion of both intrinsic and instrumental dimensions is consistent with the 
methodological framework in Mintzberg (2007): his prescribed method of analysis works from 
understanding concrete events up to synthesizing overall patterns, thereby building theory in the 
form of more generalized explanations – see the part on data analysis for the historical case study. 
The case study also includes a combined qualitative and quantitative tracking of the portfolio of 
product innovation projects at the case organization within the studied timeframe. Furthermore, I 
made two rounds of interviews in respectively 2007 and 2010 with managers at the device R&D 
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organization of Novo Nordisk, in order to analyze the local management cognition. Together, there 
are thus three empirical investigations and three data sets: 1) the historical development of the 
medical devices activities 1980-2010, which forms the overarching narrative; 2) the development in 
device innovation project portfolio 1980-2010; 3) the two interview rounds 2007 and 2010 amongst 
device R&D managers. The specific research methods for each of these investigations are described 
in separate sections below. 
Special research setting 
Since I am myself employed at the case organization, the research method includes participant 
observation and can be characterized as ‘self-ethnography’ (Alveson, 2003) and ‘engaged 
scholarship’ (Van de Ven, 2007). ‘Self-ethnography’ is defined by Alveson (2003) as “a study and a 
text in which the researcher-author describes a cultural setting to which s/he has a ‘natural access’, is 
an active participant, more or less on equal terms with other participants” (p. 174).  Where a 
conventional researcher has the challenge to ‘break in’ to experience the focal organization from the 
inside, in self-ethnography the challenge is the opposite; the researcher “struggles in order to create 
sufficient distance in order to get perspective on lived reality” (ibid, p. 176). In the present case, the 
struggle especially was about seeing the corporate perspective of the history. In the beginning, I 
found myself again and again taking a standpoint from a pure device area perspective. The corporate 
perspective and the understanding of the external environment were then built up gradually.  
Limitations due to business confidentiality 
As a consequence of the specific research setting, Novo Nordisk A/S had to approve the case study 
before publication, in order to avoid disclosure of confidential information. As result, all information 
about the years 2009 and 2010 has been left out from the findings.  
A further consequence of the confidentiality issue is that names and roles of individual managers are 
not disclosed – apart from some of the early founders. For the same reason, the names of external 
consultants are not disclosed. Similarly, the names of specific organizational departments are not 
disclosed – since these names often label the concrete projects, which the departments host.  
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1. Research method for the longitudinal case study  
This research project takes a historical perspective to gain insight into the evolution of the strategy, 
and has the overall format of a longitudinal case study.  
Qualitative data were used to identify and describe the strategic phases which the Novo Nordisk 
medical device innovation activities undertook from the start around 1980 until yearend 2010. 
Quantitative data were then included for analyzing the evolution in product innovation activities, 
described in the next section. Data collection, data analysis and conceptualization have interacted in 
an iterative process of interviewing, mapping data along a time axis, comparing with archival 
documents, categorizing and analyzing data, describing the historical phases and the development of 
the product innovation portfolio, addressing open questions in conversations with managers 
(informal interviews), new formal interviews to validate the findings, adapting the analysis etc.  A 
retrospective graph of the overall research process is shown in figure III-1.  
 
 
Figure III-1. Diagram of the overall research process. 
Data collection  
The data consist of public annual reports; a design case study published in 1993 (Freeze, 1993); 
internal documents especially on strategy; internal project portfolio lists and project documentation; 
a comprehensive internal report of the entire history of the Novo Nordisk device activities, made by a 
former device production manager in 2006; 43 semi-structured, recorded interviews with current 
and previous managers from the device area as well as at corporate level; and hundreds of informal 
day-to-day conversations with current managers and employees with historical experience from the 
device area. This daily access to data was enabled by the fact that the author since yearend 2001 has 
been employed at the case organization, serving as an internal consultant within innovation 
management and innovation processes.  
The prioritization of data has been, in order of significance: interviews – internal documents – public 
documents. The interviews were semi-structured and lasted from 10 to 123 minutes each (mean 58 















 Device area evolution 
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min.). They were conducted in Danish language from June 2007 through August 2011. All interviews 
but one were recorded and 26 were transcribed. Detailed notes were taken in all cases but two. See a 
list of the interviews in table III-1.  
Date Position Duration Recorded Notes Transcribed Interview used for: 
2007.06.28 Department manager 2:03 Yes Yes Yes Mindset analysis 2007 + 
historical case study 
2007.06.29 Department manager 1:36 Yes Yes Yes Mindset analysis 2007 + 
historical case study 
2007.07.02 Department manager 1:19 Yes Yes Yes Mindset analysis 2007 + 
historical case study 
2007.07.03 Device VP 1:21 Yes Yes Yes Mindset analysis 2007 + 
historical case study 
2007.07.04 Device VP 0:54 Yes Yes Yes Mindset analysis 2007 + 
historical case study 
2007.07.05 Senior project manager 0:49 Yes Yes Yes Mindset analysis 2007 + 
historical case study 
2007.07.11 Department manager 1:15 Yes Yes Yes Mindset analysis 2007 + 
historical case study 
2007.07.12 Department manager 0:52 Yes Yes Yes Mindset analysis 2007 + 
historical case study 
2007.07.16 Project director 1:08 Yes Yes Yes Mindset analysis 2007 + 
historical case study 
2007.08.08 Device SVP 0:59 Yes Yes Yes Mindset analysis 2007 + 
historical case study 
2008.04.15 Strategy manager 1:00 No Yes No Historical case study 
2008.05.05 Former device manager 1:13 Yes Yes No Historical case study 
2008.05.09 Device VP 1:06 Yes Yes Yes Historical case study 
2008.05.26 Device manager 1:13 Yes Yes No Historical case study 
2008.06.23 Project director 1:01 Yes Yes No Historical case study 
2008.07.01 Device VP 1:16 Yes No No Historical case study 
2008.08.11 Production manager 1:02 Yes Yes Yes Historical case study 
2008.08.26 Department manager 0:42 Yes Yes No Historical case study 
2009.01.23 Device manager 0:45 Yes No No Historical case study 
2009.01.27 Quality manager 1:01 Yes Yes Yes Historical case study 
2009.03.23 Device SVP 0:32 Partly Yes Yes Historical case study 
2009.03.30 Device VP  0:10 No Yes Only notes Historical case study 
2009.08.14 Quality engineer 0:53 Yes Yes No Historical case study 
2009.09.18 Development engineer 1:12 Yes Yes No Historical case study 
2009.10.22 Strategy manager 0:46 Yes Yes No Historical case study 
2009.11.18 Former executive 0:51 Yes Yes No Historical case study 
2009.12.03 CSO 0:35 Yes Yes No Historical case study 
2009.12.08 Former device manager 1:34 Yes Yes No Historical case study 
2009.12.17 Former device manager 1:37 Yes Yes No Historical case study 
2010.06.30 Strategy manager 0:27 Yes Yes No Historical case study 
2010.07.07 Strategy manager  0:34 Yes Yes No Historical case study 
2010.08.06 Device VP 0:57 Yes Yes Yes Mindset analysis 2010 
2010.09.09 Department manager 0:48 Yes Yes Yes Mindset analysis 2010 
2010.08.11  Device VP  0:46 Yes Yes Yes Mindset analysis 2010 
2010.08.12  Department manager 0:55 Yes Yes Yes Mindset analysis 2010 
2010.08.20 Department manager 0:45 Yes Yes Yes Mindset analysis 2010 
2010.08.23 Department manager 0:46 Yes Yes Yes Mindset analysis 2010 
2010.08.25 Department manager 0:44 Yes Yes Yes Mindset analysis 2010 
2010.09.08 Device VP  0:42 Yes Yes Yes Mindset analysis 2010 
2010.09.09 Device VP  0:35 Yes Yes Yes Mindset analysis 2010 
2010.09.15 Senior project manager  0:44 Yes Yes Yes Mindset analysis 2010 
2011.04.07 Former CEO 1:11 Yes Yes Yes Historical case study 




43 interviews   
29 informants 0:58 All but one 
All but 
two 26  
 
Table III-1. List of interviews. (The 20 shorter follow-up interviews for the mindset analysis 2007-10 have not 




In order to identify the strategic phases and the linked transitions, two indicators were defined: 
 Strategic changes are defined as changes in: 1) overall vision for or purpose of the device 
area; 2) targeted customer segments and value proposition; 3) field of activities; 4) source of 
revenue. Changes in these parameters are identified via statements in interviews and 
archival data. 
 Structural changes are defined as organizational restructurings, in which the entire device 
innovation area at Novo Nordisk is moved around within the Novo Nordisk organization; 
internal restructurings within the device area are disregarded. Structural changes are 
identified via the organizational charts.  
Data analysis 
For the analysis of the historical data, I followed the “steps in research on strategy formation” as 
described by Mintzberg (2007, p. 380-390).  
The main steps are (based on Mintzberg, 2007): 
1. Basic data: collect data to develop chronologies of decisions and actions, trends and events, 
and results – across all key strategy areas as well as aspects of the environment. 
2. Determination of strategy patterns: map each track of events on a common timescale, if 
possible as visualized graphs under each other.  Determine vertically the concurrent changes 
and identify and label the strategic periods. – See a list of the mapped tracks below.  
3. Analysis of each major period: investigate intensively each period of the strategy, including 
drivers that shaped it, the underlying causes of changes in strategy and interrelationships. 
Conduct systematic theoretical analysis of each period of change in strategy by use of the 
chosen theoretical framework. – The outcome of this step forms the basis of Chapter 4. 
4. Theory building: Extract the core of each period and its drivers. Interpret, brainstorm, make 
hypotheses and extract conceptual insights, for each period and for the overall pattern in the 
whole study.  – The outcome of this step forms the basis of Chapter 5.  
 




1. External environment: 
 Management dogmas (i.e. the prevailing concepts of management practice) 
 Pharma industry trends 
 Medical device inventions for diabetes 
 Impact of Type 2 diabetes 
 Insulin inventions 
 Pressure from competitors 
2. Novo Nordisk corporate level: 
 Corporate management cognition and identity 
 Corporate strategy and events 
 Product tracks (drugs)  
3. Novo Nordisk medical device level: 
 Product tracks (devices) 
 Device strategy  
 Device R&D organization  
 Portfolio of ongoing device innovation projects  
-------------------------------------------------------------------------------------------------------------------------------- 
Table III-2. The tracks mapped for the “Determination of strategy patterns” – step 2 in Mintzberg’s (2007) 
methodology (p. 381-383).  
 
The construction of a narrative 
In the method described by Mintzberg (2007), the phases of the historical development are set via 
identification of concurrent events at the different tracks in the map of patterns (see Table III-2): “in 
scanning vertically for concurrent changes in a number of important strategies, delineate overall 
periods for the whole study and label them” (p. 381).  Even it sounds straightforward, it is not. The 
determination of phases totally depends on the perspective of interpretation. It took me a couple of 
years to arrive at the phase model applied here; and I have seen many other classifications of the 
historical epochs of Novo Nordisk’s device activities. Van de Ven (2007) writes:  
 “Thus, as we move from surface observations towards a process theory, we move from 
description to explanation. Explanation requires a story, and stories can be understood as 
process theories (Pentland 1999). In narrative theory the story is an abstract conceptual model; 
it identifies the generative mechanisms at work. At a minimum this story must describe a 
progression or sequence of events. In narrative theory, however, the ‘story’ includes a great deal 
more than just event sequence. In particular, a process theory should hold the following 
features in the story…” (p. 223) 
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Van de Ven then continues by describing five elements, respectively: 1) sequence in time; 2) focal 
actors; 3) narrative voice; 4) frame of reference; and 5) other indicators. Especially element 4 
deserves to be illuminated here. Van de Ven states: “Narratives carry meaning and cultural value 
because they encode, implicitly or explicitly, standards against which actions of the characters can be 
judged” (p. 224). He concludes the description by saying “These five steps in theory building are easier 
said than done” (p. 224).  
My frame of reference was the content and nature of the innovation strategy for the device activities 
at Novo Nordisk A/S. Key questions were which sort of product-markets the innovations were 
targeting (e.g. was glucose monitoring products included in the strategy?); the degree of systemic 
and patient-centered approach to the innovation activities; and the definition of either the 
pharmaceutical drugs or the medical devices as most central. Only through such story, the narrative 
provides meaning and explanation. A concrete example could be the phase division around the 
merger of Novo and Nordisk in 1989. I have seen narratives setting the discriminating year as 1989 
(the merger was announced in the beginning of 1989 and the implementation started later that year) 
or 1990 (where the organization was in place). I have chosen 1988, since the visionary strategy 
about patient-centered homecare was launched in the beginning of 1988, organized in the new 
Medical Systems Division within Nordisk – although this was one year before the merger. The reason 
for my choice is that the strategic intent and the organizational setup was continued after the merger 
– the much smaller device activities of Novo were integrated into the strategy and organization of 
MSD. Thus, data in itself does not provide the narrative; you need an underlying story.  
It is also clear from this description that only a qualitative in-depth study can provide the data 
needed for establishing such narrative. It is the voice of many different informants, inside and 
outside the case organization, which accumulates not only into a sequence of events, but into an 
explanation of the change processes at the case organization.  
 
Validation of findings 
My mapping and interpretation of data was continuously, from 2008 on, validated in the way that I 
presented my findings to different audiences at the device area of Novo Nordisk at many occasions – 
such as large seminars for employees, management team meetings etc. This gave me the opportunity 
to capture comments from many sources, which helped the further data capture and interpretation. 
Based on this iterative validation, I am absolutely sure that my findings are robust, concerning the 




2. Research method for the analysis of the device 
innovation project portfolio 
The current research project builds on the understanding that strategies belongs to a mental realm of 
theory or reasoning as well as to a physical realm of action; and that strategy making evolves in 
learning or reinforcement cycles between these two realms. Accordingly, I investigated whether this 
relationship between strategy in theory and strategy in practice was traceable in empirical reality: 
are changes in innovation strategy and changes in the actual innovation projects linked? Or do these 
realms live their own, separate lives? 
The product innovation activities were mapped, quantitatively and qualitatively. This was established 
by a combination of 1) objective data from internal documents regarding year of project start-up, 
project closure or product launch, and 2) inter-subjective assessments of the nature of each project. 
For the latter, each project was classified with regards to Burgelman’s (1991; 2002) concepts of 
induced and autonomous strategic initiatives. The inter-subjective assessment was established via 
interviews with managers and employees, as well as by the author himself; in the latter case based on 
project documents, informal conversations with project managers or firsthand experience. See the 
qualitative categories and empirical definitions in Chapter 4, in the section about the project 
portfolio.  
A good starting point was an overview of the historical device development pipeline, made by two 
device managers in 2003. These data were compared to two internal lists of previous and current 
development projects, the one including one-page descriptions of each project. The information was 
then matched with a comprehensive historical report about the Novo Nordisk device activities, made 
by a former device production manager in 2006. The remaining ‘holes’ in corporate memory were 
partly solved by visits in the archives and conversations with former project managers. To validate 
the findings, all device ‘veterans’ were invited to a meeting, where they were confronted with the 
results. This meeting resulted in even more details and identification of several historical 
development projects, which had not been discovered yet. All data were compiled in a spreadsheet 
for statistics.  
The research resulted in the identification of 233 official development projects. These were first 
classified to sort out a) product development projects, e.g. injection devices; b) explorative research 
projects regarding technologies and materials, internally called ‘technology projects’; c) development 
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of accessories and packaging material, e.g. new generations of needles for the insulin pens; and d) 
process improvement projects like lean management initiatives etc. As result, 102 product 
development projects were registered; 95 could be classified and analyzed (with regards to the data 
sample for 1980-2008; not including data from 2009 and 2010). Only these 95 projects were 
included in the further quantitative analysis5. The analysis was made by use of a traditional 
spreadsheet, compiling objective data (year of project start-up, duration, launch/closure) and the 
subjective classification of each project.  
Statistics on the product innovation portfolio were made for the number per year of: product 
development projects initiated; development projects in parallel; new product launches; project 
closures; in all cases distributed per category.  
Data validation   
The qualitative findings were continuously presented to informants and verified through their 
comments. Also the project data behind the quantitative research were tested by presenting these to 
knowledgeable project managers. Their comments and additional information brought the analysis 
further and filled out many gaps, as for example identification of not yet registered projects or 
classification of projects, which had not been classified until then.  
 






5 The restriction to the 95 product development projects was made because it showed to be very difficult 
to gather detailed information about the historical projects; in many cases the only information left was 
the name of the project. Therefore, it would have been impossible to establish the basic information about 
all 233 projects.  
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3. Research method for the mindset analysis 2007 
The purpose of this empirical investigation was to identify and analyze the ‘dominant logic’ (Prahalad 
& Bettis, 1986) of the device innovation area with regards to the management mindset on innovation 
– here termed ‘dominant innovation logic’. 
Prahalad & Bettis (1986) in their implications for further research request ‘rigor approaches’ for 
identifying the dominant logic of a firm, beyond simple conversations with managers. The current 
empirical investigation builds such method for identifying the dominant logic of an organizational 
unit. Therefore, the research method in itself can be said to hold a novel research contribution at 
methodological level. Consequently, I have included a detailed description of the entire method in 
Appendix A. For reasons of business confidentiality, all information after 2008 had to be excluded. 
Hence, the comparative analysis of the two investigations in 2007 and 2010 could not be included. 
In this section, I therefore only describe the overall research method for the mindset analysis in 2007 
(for details, see Appendix A). The findings from the 2007 analysis are presented in a separate section 
of Chapter 4.  
Sample and data 
The unit of analysis was the device innovation area of Novo Nordisk A/S. A sample of 10 managers 
was selected as informants. These 10 were chosen in order to represent the organizational functions 
as broadly as possible. First of all, the VPs of the three functional areas were chosen, plus a VP from a 
governance unit, who was a former VP from the device area. The other 6 were department managers.  
The interviews were conducted as qualitative, semi-structured in-depth interviews throughout the 
summer of 2007. See total list of interviews, table III-1. – All interviews were recorded and 
transcribed.  
The interviews were based on lists of questions, which mainly included the themes  
a) industry identification; b) value proposition; c) core capabilities; d) product innovation portfolio; 






 What is the value, we produce for our customers? (we = device R&D) 
 Which are our most essential capabilities? 
 Could we be an independent company?  
 Which industry would we then become a part of? 
 What are the drivers of this industry? 
 Who are the jokers within this industry? 
 Could you mention 3 highlights from the history of device innovation at NN? 
 Are we still creating history? 
 What would it take to ensure that we have success in 2015? 
 What is holding back and what is advancing our device innovation? 
 Our current development projects: How innovative are they? 
 Which are the most crucial factors, when deciding if an idea or a project is either supported or 
stopped? 
 What are the external blocks and dilutors? – and the internal? 
 What are our fears/concerns/doubts that prevent us from giving our best? 
 Do we tend to stick to what we already know? – Why (not)? (Where have we settled in our comfort 
zones?) 
 What’s the biggest learning we have made at device R&D? 
 If time: Actant modeling (subject, goal, provider, receiver, supporter, opponent) 
 If we were a car, which car would it be? 
 
 
Table III-3. The list of key questions for the interviews in 2007. 
 
Summaries of the interviews were made in a format resembling ‘cognitive maps’ (Eden, 1988; Fiol & 
Huff, 1992; Barr, Stimpert & Huff, 1992; Bougon, 1992), containing condensed statements clustered in 
themes. Short follow-up interviews were conducted to get approval from the informants of the 
summaries. The follow-up interviews were not recorded, but the corrections by the informants were 
noted and approved at the interviews. These follow-up interviews typically lasted 15-30 minutes. 
Thereafter, the data analysis was based on the summaries as data input. The summaries contained 
680 condensed statements in total, corresponding to 0.9 condensed statement per interview minute.  
Data analysis 
The condensed statements were taken from the individual cognitive maps into a spreadsheet, 
reformulated in 107 yet more generic terms, termed ‘constructs’, so that each reformulated construct 
could cover several informants’ condensed statements. At the same time, the language was changed 
from Danish to English.  
For the analysis, the constructs were clustered in three main spheres, Foundation-Innovation-Future 
(FIF), which basically formed a timeline of past, present and future. The FIF structure emerged out of 
the data analysis. Within each sphere, the constructs were clustered in groups. See table III-4 with 







Strategy - Business Drivers - Business Model  
Competition 
Core Capabilities – strengths and weaknesses  
Organization – Structure, governance 
Identity - Culture 
 
INNOVATION 
Innovation enhancers  
Innovation barriers  
Portfolio management  
The current portfolio – balance radical/incremental  
 
FUTURE 




Table III-4. The generic FIF structure which emerged out of the data analysis.  
 
The FIF structure was applied for the data analysis in the spreadsheet of the total constructs. The 
spreadsheet was used as an instrument for quantification; each construct was correlated with the 
data to determine exactly which of the informants who supported the construct in question in their 
individual statements. This way I could quantify how widespread each of the constructs was amongst 
the 10 informants. For traceability, the exact timestamps from the interview transcriptions of the 
statements in support of each construct were also noted. 
The ‘dominant logic’ is a worldview shared across the management team. Arguably, idiosyncratic 
individual viewpoints cannot belong to the ‘dominant’ logic. Therefore, to get a clearer picture of the 
management thinking, all constructs with less than 5 supporters (of 10 possible) were deleted. As 
references for this criterion, Tyler & Gnyawali (2002) similarly assess the concept of ‘shared 
cognition’ in a management team such that 50% must agree in a small group; 40% in a large group 
(where 30 managers make a large group).  
The relatively few constructs left (28 of 107) were then ‘translated’ into full sentence narratives, 
which concluded the dominant innovation logic of the device management team. See the result in the 
specific section of Chapter 4. 
 
Validation of findings 
The only validation – after the informants’ approval of the condensed statements – were two 
workshops for the entire device management team held in 2008, where they were presented for the 
results from the 2007 interviews, including the ‘dominant logic’. The research findings served as 
input for discussions on the identity and strategy of the device area. 
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In the current longitudinal case study of the medical device innovation at the pharmaceutical 
company Novo Nordisk A/S, the main focus has been on: 
 The most defining events at three levels: external environment (insulin industry); corporate 
level, with emphasis on top management cognition and corporate strategy; and local device 
area events. 
 The integration of medical devices as a complementary product innovation area, compared 
to the core product (insulin).  
The analysis is structured in three parts, as result of three empirical investigations: 
1. The overall historical case study, providing the basic narrative 
2. The evolution of the portfolio of medical device innovation projects 
3. A close-up portrait of the management cognition in the device innovation area in 2007. 
The first investigation about the historical development has been divided into phases. Ideally these 
phases should reflect changes in innovation strategy. However, as will be clear from the data, the 
exact beginning and end of a strategy is not always easy to determine. Changes in organizational 
structure, in contrast, are made explicit via organizational charts. Furthermore, changes in structure 
are often connected to changes in strategy (cf. Chandler, 1992). Therefore, as a pragmatic empirical 
solution, the phases of the historical case description in the narrative have been separated by the 
years of major organizational changes at the medical device innovation area, with two exceptions:  
 The start has been chosen to 1980. Organizational changes did not occur until 1984, with 
establishment of the first Medico-Technical Department in Nordisk Gentofte. However, since 
the first insulin pump was launched already in 1983, the development activities must have 
started around 1980. 
 In 1988, Nordisk Gentofte established Medical Systems Division for the device activities. In 
1989, Nordisk Gentofte and Novo merged. However, since Medical Systems Division was 
continued in the joined company, only the year 1988 has been chosen for phase separation, 
even though the merger in 1989 of course also implied organizational changes. 
 
Before we turn to the case study, some background information about diabetes, Novo Nordisk and 
the diabetes industry should be provided. 
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Diabetes and devices 
Diabetes is defined as having too high blood sugar levels, and is caused by disturbances of the 
metabolism due to malfunction of the pancreas, which produces the hormone insulin. Insulin is a 
protein, which acts like a key, opening the cell pores for glucose molecules, thereby triggering the 
glucose metabolism. Type 1 diabetes patients have no insulin secretion from the pancreas at all, 
whereas Type 2 diabetes patients have reduced insulin secretion, often combined with reduced 
insulin sensitivity of the cells. Type 1 diabetes is also called juvenile diabetes or insulin-dependent 
diabetes, since the patients typically get the disease in a young age; within few months, the pancreas 
totally stops producing insulin, making insulin treatment a necessity. Until Canadian researchers in 
1921 discovered the function of insulin, Type 1 diabetes patients simply died. Type 2 diabetes 
previously was referred to with terms like ‘old-men’s diabetes’ or ‘non-insulin dependent diabetes’; 
however, these terms are misleading. The patients truly are older in average when diagnosed, but 
Type 2 diabetes is partly a lifestyle dependent disease, and some patients get Type 2 diabetes already 
as teenagers. Type 2 diabetes does not imply a sudden malfunction of the pancreas; rather, the 
insulin secretion decreases over a couple of decades, combined with a decreasing ability of the cells 
to response to the insulin. The symptoms gradually get worse and many Type 2 patients end by 
having to treat themselves with insulin injections, just like Type 1 patients.  
Both Type 1 and 2 diabetes patients must try to compensate for the bodily dysfunction by taking in 
carbohydrates, if the blood sugar gets too low, or taking in medicine, if the blood sugar gets too high. 
Insulin injection has an immediate lowering effect on the blood sugar level, but besides insulin a 
range of less intrusive treatments exist, such as tablets (so-called OAD’s, Oral Anti Diabetics). The 
tablets either support the insulin secretion of the pancreas or the insulin sensitivity of the cells.  In 
less serious cases of diabetes (i.e. Type 2 in an early stage), diet and exercise can be enough to lower 
the blood sugar levels.  
To control the blood sugar and perform self-treatment, the patient has to monitor the blood sugar 
level by use of technical devices (blood glucose meters, BGM) and, in the case of insulin treatment, 
also has to inject insulin manually by the use of syringes or insulin ‘pen’ systems, or eventually by 






Figure IV-1. Left: Insulin in vial (Levemir® from Novo Nordisk). Middle: For each injection, the insulin dose 
must be taken from the vial to a disposable syringe. Right: insulin pens (NovoPen® 3), containing insulin for 
several injections in a cartridge. 
 
 
Figure IV-2. An insulin pump (here the Nordisk Infuser from Nordisk Gentofte). The pump, containing the 
insulin in a cartridge, is carried in the patient’s pocket. Via a tube ending in a needle, the insulin is 
continuously infused into the body. 
 
Figure IV-3. A blood glucose meter (OneTouch Ultra2 from LifeScan; a company in the Johnson & Johnson 




Novo Nordisk in brief 
Novo Nordisk A/S came to existence in 1989 as a merger of two former rivals, Novo Industry and 
Nordisk Gentofte, both Danish insulin manufacturers established in respectively 1925 and 1923. 
Novo Nordisk today defines itself as a leader in the diabetes care market, mainly active within the 
insulin business, producing the insulin drugs as well as the injection systems for the drug delivery. 
Novo Nordisk also offers an OAD (Oral Anti Diabetics) product for tablet treatment, NovoNorm®6, 
but this product holds a minor share of both the total tablet market and of Novo Nordisk’s revenue.  
By yearend 20107, Novo Nordisk had a global market share of the insulin market of 51% (measured 
in volume) and was by far the world’s largest insulin manufacturer. The company employed 30.000 
people worldwide by yearend 2010. Medicine for diabetes accounted for 75% of Novo Nordisk’ 
turnover; the other business areas being growth disorder, hemophilia and menopause treatment. 
Headquarters are in Denmark.  
Key figures from the 2010 account are inserted below. 
 






6 Prandin in the U.S. 
7 2010 has been chosen, because it is the last year of my empirical research. However, due to 








The diabetes industry 
From a societal perspective, far the largest part of the costs for treating diabetes and its co-
morbidities are the costs for hospitalization and treatment in clinics and at private doctors 
(healthcare services, so to speak). Novo Nordisk actually owns a diabetes hospital, the Steno Diabetes 
Center in Copenhagen, which is driven as a public hospital. However, the operation of the hospital is 
not perceived as business – rather as means of building expertise in diabetes treatment and for 
building credibility within the community of diabetes experts. The same could be said about many 
other diabetes related activities, which Novo Nordisk is engaged in, such as the World Diabetes 
Foundation, the Oxford Health Alliance or various diabetes research initiatives. The only explicit 
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diabetes business of Novo Nordisk A/S is the pharmaceutical drug business, covering insulin, GLP-1 
(another blood glucose regulating hormone) and tablet treatment. 
Besides the institutional care at doctors, clinics and hospitals, the diabetes care industry consists of 
the following sub industries within pharmaceuticals and medical devices, with estimated turnovers 
from 20108: 
- Insulin: 90 BDKK 
- Insulin pumps (devices and utensils, exclusive insulin): 10 BDKK 
- GLP-1 (a new drug for Type 2 patients): 5-10 BDKK 
- OAD tablets: 90 BDKK 
- Blood glucose monitoring (BGM) devices and test strips: 50 BDKK. 
At Novo Nordisk there have, as can be seen in the historical case description, been attempts to 
expand the business into the blood glucose monitoring (BGM) market. Traditionally, the BGM and the 
insulin market have represented two separated sub industries, because the value chains of the two 
businesses have little in common, apart from serving the same end users. Thus, no global industry 
players were persistently active on both the insulin side and the glucose monitoring side in the focal 
period of this longitudinal case study (1980-2008). 
In general, the insulin industry is a relatively stable industry, dominated by a few of well established 
companies, displaying ‘low velocity’ (slow rate of change, long product lifecycles). As an example, the 
NovoLet® prefilled insulin system was launched in 1989 and had a product lifecycle of no less than 
20 years (undergoing incremental improvements). The industry today is dominated by three global 
players: Novo Nordisk, Eli Lilly and Sanofi. Lilly and Sanofi both have a much broader pharmaceutical 
product portfolio – Novo Nordisk is the only of the players, which is focused on diabetes (app. 75% of 
the sales come from diabetes products).  
The most substantial change in external market conditions within the studied period (1980-2008) 
was the enormous growth in the market due to the pandemic of Type 2 diabetes beginning in the 
later decades of 20th century. However, the Type 2 diabetes market is very different from the Type 1 
market, in terms of patient population, prescribed treatment and partly also the profile of the 
healthcare professionals dealing with the patients. Therefore, it took many years for the industry 
players to re-orientate their businesses towards the Type 2 market.  
From the discovery of insulin in 1921 and forward, the general development on the product side was 
a competition in purifying animal insulin. From 1982, manufacturing of human insulin was possible, 
by using gene modification technology on yeast cells. In the 1990’s, insulin ‘analogues’ were 






8 The turnover for 2010 has been estimated by a strategy manager of the NN device area 
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introduced. These are insulin molecules, which have been artificially modified to achieve certain 
characteristics, such as prolonged effect or very fast effect. Since 1985, where Novo introduced the 
NovoPen®, injection devices also have been a competitive factor.  Thus, in 2004, only 44% of the 
insulin sold worldwide was sold in traditional vials – the rest being sold in cartridges for devices 
(durable insulin pens) or in pre-filled devices (prefilled insulin pens).  
Like the rest of the pharmaceutical industry, the insulin business chases the ‘block buster’ business 
model; i.e. it’s a game of massive investments in R&D as well as in clinical trials and manufacturing, 
which are paid back by large volume sales, creating a revenue stream of 1 billion USD per year from 
each drug as the minimum target. 
 
Structure of the rest of the chapter 
The chapter follows the structure of the 3 empirical studies: 
1. First, the case study analyzes the historical development of the strategy for the medical 
device innovation activities at Novo Nordisk 1980-2008, beginning with a brief summary of 
the development of the entire period. Thereafter, the period has been divided in 6 phases, 
divided by major organizational changes. These phases are analyzed one by one, looking for 
drivers and processes of change in innovation strategy. 
2. Following the historical case study, the development in the innovation project portfolio 
throughout the studied period is analyzed.  
3. Thereafter, the dominant management logic within the medical device innovation area in 
2007 is analyzed. 
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Part 1: The historical case study 
Summary  
The medical device activities began separately in the two companies Novo and Nordisk around 1980. 
Several factors paved the way: a) the prevailing management dogma of diversification, where devices 
fit well in as yet a business opportunity; b) developments in diabetes treatment made multiple daily 
insulin injections necessary for the patient, and continuous infusion from insulin pumps was 
discussed as the future; c) Eli Lilly developed and launched recombinant human insulin in 1982, and 
this disruptive technology threatened to make animal insulin obsolete – both Novo and Nordisk were 
years behind, and hence were looking for other parameters of competition. After some years of 
positive experiences with medical devices, the two companies merged in 1989 and organized the 
device activities in a separate division, in parallel to the drug divisions. The ‘honeymoon’ after the 
merger was a very optimistic and entrepreneurial period, and devices (especially disease monitoring 
devices) were envisioned to become a substantial business of its own. However, the corporate 
business portfolio after the merger was far too broad – a focusing process started, also inspired by 
the new management dogma of ‘core competencies’ (Prahalad & Hamel, 1990). In 1992, a crisis hit 
the company badly, and this amplified the ongoing process of divesting ‘non-core’ business areas. 
The device activities were confined to only comprising insulin pens – insulin pumps and monitoring 
devices were terminated. In 1995, the device area was moved to a Production subunit. Within the 
limited scope of insulin pens, there was here a blooming activity of incremental product innovation 
until the next strategy shift in 2001; now devices were again envisioned to create substantial new 
business, including glucose monitoring and ‘everything the patient needed to control his/her disease’. 
As a new organizational frame, the device innovation activities were separated from device 
production and got status as an independent R&D unit within corporate R&D, having the same status 
as the drug R&D units. This new phase experienced a setback already in 2002, due to a new crisis 
which made the corporate top management team far more cautious and conservative. Thus, the 
glucose monitoring projects were closed down in 2004. The strategy, however, was not officially 
altered until 2005, where the device innovation activities were integrated into a drug research unit.  
The strategy now was ‘back to basics’, i.e. insulin pens. In this period, the device innovation was 
modest, both quantitatively and qualitatively. By yearend 2008, the device innovation activities were 
reorganized again.  
All in all, there have been two waves of device-based innovation strategy, where devices were 
foreseen to create a business of its own – 1988-92 and 2001-05 – the rest of the period 1980-2008, 
devices have been perceived as complementary assets for innovation, which should sustain the drug-
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Table IV-1. Overview of the historical epochs of the device activities at Novo Nordisk. The following sections of 
Chapter 4 describe the phases in detail, one by one.  
The phases are here defined by structural changes. If the structural change took place in the middle of a year, this year is 
attached to both periods – for example, DRU was established in the summer of 2005, hence the year 2005 is attached to 
both the PDS and the DRU period. 
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Phase 0: Maturing for medical devices (1923-1980) 
The corporate DNA 
Nordisk Gentofte9 was founded by the Nobel Prize winner in physiology, August Krogh. His wife, 
Marie Krogh, practiced as a doctor and researched in human metabolism. Furthermore, she had 
diabetes (Type 2) herself, and she consequently had a natural interest in diabetes. In 1922, August 
and Marie Krogh therefore went to Canada to visit the scientists, who had discovered insulin the year 
before. Being a Nobel Prize winner in physiology 1921, August Krogh easily persuaded the Canadian 
scientists to give him a license to manufacture insulin in Denmark. So, if we are looking for the roots 
of the internal corporate identity (Tripsas, 2009), I think it is fair to identify these as the combined 
scientific and medical standpoint of the founders (Novo being a break-out from Nordisk). This 
identity had impact of the framing of the business (Kaplan, 2008) and thus laid the ground for the 
learning cycles which established and reinforced the dominant logic (Prahalad & Bettis, 1986) of 
Nordisk as a science-based, pharmaceutical company. The impact of the founders’ scientific and 
medical standpoint on Nordisk’s identity can be recognized as late as the 1970’s in this quotation 
from the official corporate history book: “At the beginning of the 1970’s, the situation at Nordisk was 
critical. The company had almost no exports. The reason for this was that the management, led by 
Hagedorn, did not want increased marketing of the company’s products. What mattered most, the 
management felt, was research and the treatment of diabetes”. 
Novo had a more engineering oriented starting point: to build up the production, August Krogh had 
employed his manager from the mechanical workshop at his university laboratory, Harald Pedersen. 
Harald’s brother, Thorvald Pedersen, who was a pharmacist, was also hired in. However, due to 
collaboration problems, the two brothers left Nordisk and founded Novo in 1925. Harald Pedersen 
was an engineer, and he designed a special metal syringe for injection of the insulin already in 1925. 
This Novo Syringe was the first customized insulin device and it was sold until World War 2, where 
supply problems stopped the production. Thus, if the ‘founding fathers’ of a company have impact on 
the internal identity of the company, then Novo from the outset would have a more production and 
engineering oriented approach to doing business, combined with higher emphasis on broad 






9 Both Novo Industry and Nordisk Gentofte have changed names several times during their history. For 
the sake of readability, I discard this information and shall from here on refer to the two companies as 
respectively Novo and Nordisk. 
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commercialization: due to Nordisk’s strong position in the home market, Novo was from the 
beginning forced to be more international. 
Industry dynamics 
Both Novo and Nordisk were active in improving the insulin products. The first problem to be solved 
was “that the effect of the existing insulin products was too short – a serious disadvantage because 
patients had to inject themselves with insulin several times a day. Therefore, Nordisk and Novo turned 
their attention to developing a longer-acting type of insulin” (quotation from “Novo Nordisk history”). 
Thus, Nordisk launched their long-acting insulin in 1936; Novo followed in 1938.  
The next big problem was to get rid of the ‘impurities’ left from the basic animal material, since these 
substances made all patients form antibodies against insulin, and some patients even became allergic 
to insulin. After long research, Novo launched highly purified insulin in 1973; Nordisk followed in 
1974. 
According to an executive informant, the highly purified insulin meant great competitive advantage, 
which especially Novo used to capture market shares in Europe. The European insulin market had 
been very fragmented, with 21 European insulin manufacturers in 1972. These rather small 
companies could not make the technologically difficult leap to highly purified insulin, and hence 
competition got concentrated on fewer players, with Novo and Nordisk based in Denmark and 
Hoechst in Germany. Eli Lilly dominated the American markets. 
Even though both Nordisk and Novo thus were successful in the competition within the core 
business, both companies diversified into many other business areas, in accordance with the 
management trends of their time (e.g. see Ansoff, 1965, on diversification). Nordisk for instance 
developed growth hormone for treatment of children with growth disturbances in the 1960’s and 
blood plasma products for treatment of hemophilia in the 1970’s. Novo, on their side, started up 
production of penicillin in 1947 and began producing industrial enzymes in the 1960's. The enzyme 
business grew rapidly and forced Novo to become even more international. In the late 1970’s, the 
enzyme business had become bigger than the insulin business, and the enzyme managers at Novo 
joked about selling off the insulin business; it didn’t grow so much, anyway.  
Diagnostic systems 
One more example of diversification from Novo deserves to be described, since it implied some 
learning for the top management team with relevance for device innovation. Around 1976-77 Novo 
acquired a small Danish company, which had developed a so-called Cerebrograph – an electronic 
equipment for measuring the blood circulation in the brain. Hereby Novo established ‘Novo 
Diagnostic Systems’ as a business area. However, sales never really took off. An executive informant 
explains: “This taught me two things: first of all this was a highly specialized field. Secondly, this was an 
area, where you competed with Siemens, Japanese companies etc., and therefore it was no good that you 
came with just one product. The other companies competed on modularity: measuring equipment, 
which ‘talked’ with each other – so it was systemic solutions being sold...the possibility of getting a 
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significant position in the market, as a one-product-company, was small. It was an area where we were 
not so sharp, and the competition was quite different from insulin: when you develop your diagnostic 
scanners, the competitors can just take a screwdriver and dismantle it and see how it is made. – [Why 
did you then acquire this company?] – That was also a wrong decision. But we were looking for 
opportunities for growth, you know. ...You can say that the reason why we jumped into it was the 
aspiration for new opportunities – and then an analysis, which was insufficient, due to lack of expertise”.  
Concluding on the period 1923-1980 
The early development shaped the corporate DNA in the form of internal identity (Tripsas, 2009). 
From the founders, Nordisk inherited an orientation towards science, pharmaceuticals (insulin) and 
medical (specialist) treatment of diabetes. Novo seems to have inherited a more pragmatic and 
commercial identity, compared to the extremely science and research grounded Nordisk. These 
initial identity traits of course affected the management cognition, when top management set 
direction for the business; the basic identity will always affect the worldview or core beliefs, on 
which strategic cognition is based.  
Both companies were successful with their insulin business; still, they went through an era of 
diversification in search of growth opportunities, which led them into many other business areas. 
Only in one case, a new business area took over from the original insulin business: the enzyme 
business of Novo in the 1970’s and 1980’s became bigger than the insulin business and in fact drove 
the internationalization of the company further. 
At Novo, the experiences from Novo Diagnostic Systems shaped the cognition at corporate 
management level about the importance of deepening the competencies within the selected business 
areas and about developing a full portfolio of complementary products within each area. This 
learning seems very important for the later entrance to medical devices as part of the product 
offering within diabetes, since it defined a rationale for complementing the basic insulin offering with 
medical device products.  
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Phase 1: Early attempts within device innovation (1980-
1988) 
Insulin industry  
The introduction of highly purified insulin in the beginning of the 1970’s meant a strong competitive 
advantage for the four companies, who mastered this complex process technology: Eli Lilly, Novo, 
Nordisk and Hoechst (mentioned in order of market size). However, the insulin molecules still were 
animal, derived from the pancreas of cows and pigs. Therefore, research was made in order to find 
methods to produce an insulin molecule identical to the human. The small biotech company 
Genentech Inc. was founded 1976 to explore and commercially exploit “a new scientific field called 
recombinant DNA technology10”. The first application was human insulin, achieved via genetic 
engineering of yeast cells, which would then produce human insulin molecules as result of the 
fermentation process. They licensed out the technology to Eli Lilly, who thereby were able to market 
the first recombinant human insulin in 1982, setting back competitors. Hoechst was hit worst, 
because they were not even able to experiment with the new technology because of German 
legislation against gene manipulation techniques.  
Novo had increased the company’s global market shares since the introduction of highly purified 
animal insulin.  However, the recombinant human insulin represented a truly disruptive technology, 
which could make highly purified animal insulin obsolete. As long as insulin was manufactured based 
on animal pancreases, the production volume would be limited by the supply of animal material. At 
the same time, there was increased awareness about Type 2 diabetes and the possibility of applying 
insulin treatment at earlier stages, in order to avoid late complications of the disease. In combination 
with the explosion of Type 2 diabetes, this intensified treatment led to an enormous growth in the 
global demand for insulin in the subsequent decades, with two-digit growth rates. Without the 
invention of the recombinant technologies, which made the manufacturing process independent of 
the supply of animal pancreases, it would simply have been impossible to meet this explosion in 
demand. In other words, both technologically and market wise, the invention of recombinant insulin 
had crucial impact.  
Confronted with the threat from the recombinant technologies, which Novo must have known about 
at least from 1976 on, Novo made two moves: 






10 http://www.gene.com/gene/about/corporate/history/timeline.html accessed 2011-06-05 
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 Novo developed a new technology, by which animal insulin molecules chemically were 
altered to become identical with the human insulin molecule; so-called semi synthetic or 
biosynthetic human insulin. This way, Novo was able to launch what they called ‘human 
insulin’ in 1982, the same year as Lilly; thus Novo could claim to be on par with Lilly 
(however, Novo’s manufacturing process was still based on animal material). 
 1982, Novo bought shares in ZymoGenetics Inc. in the USA to get access to similar 
recombinant technologies as Genentech had provided to Lilly. This collaboration resulted in 
Novo being able to launch recombinant insulin in 1987 (five years after Lilly). – Novo took 
full ownership of ZymoGenetics in 1988. 
Nordisk took a similar approach as Novo, and developed biosynthetic human insulin, which was 
introduced 1984, two years after Novo. Nordisk also started research on recombinant technologies 
but never managed to get recombinant insulin on the market before the merger with Novo in 1989. 
Hoechst, as already mentioned, was prevented from acting because of German legislation against 
gene modification technologies.  
Novo’s and Nordisk’s move into medical devices, see below, partly can be explained in the 
perspective of the competition from Lilly’s recombinant insulin.  
Corporate management cognition 
Back in the late 1970’s, Novo was aware of the research in recombinant technology; but they did 
perhaps not perceive Eli Lilly as a technology leader. An executive informant explains: “Lily truly was 
first with the biogenetic human insulin. But that was the first invention they had made since they 
introduced insulin in 1921 or 1923. They had built their business on a license from Nordisk to 
manufacture NPH-insulin [long-acting insulin patented by Nordisk] and a license from Novo to 
manufacture Lente-insulin [long-acting insulin patented by Novo]. When I came to Novo [in 1972], the 
sales of Eli Lilly was split in one third in traditional, old fashioned insulin, one third NPH  and one third 
Lente. In other words, two thirds of their sales were based on products licensed in from Danish 
companies. And in many cases insulin was sold over the counter in USA – I’ve stood in pharmacies and 
supermarkets and seen it myself – where Lilly sold it as ‘pay for two, get three’. It was a totally different 
market.” 
“Novo never really was under pressure commercially. Lilly of course had a marketing advantage or at 
least an image advantage by being first, but when you look at where they were present, then it was 
mainly in the U.S. They tried getting into our overseas markets, and they tried winning tenders in Latin 
America, but we slowly won market shares from them, also because our sales approach was different; 
our approach was still highly technical sale, meaning high science content, not trying to sell it cheaper 
and all that stuff…” 
“When we compared Lilly and Novo, then there was a huge difference in financial muscles. So we didn’t 
get anything easy. On the other side, we were sure that it would take Lilly long time to build up the same 
basic knowledge in diabetes. It’s characteristic that when they speeded up in late 1970’s and introduced 
recombinant insulin, it was again via licensing in. They go out and buy technology. They are good at 
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marketing. [And Novo’s strength is research?] – It’s two things: It’s the research, and it’s the close 
relation to the patients… I don’t remember exactly when, but it’s a very important side track; during the 
70’es, our goal was to be the world’s best insulin manufacturer. We changed this to being the world 
leader in diabetes care. And if your goal is to be the best insulin manufacturer, then it’s important that 
the packaging is fine and the referral note is folded neatly and the product is as it should be. But if you 
start saying “I want to be the world’s best in diabetes care”, then suddenly you place yourself on the 
other side of the table and look at it with the view of the person with diabetes”.  
Besides the above illustrations of Novo’s science-based and patient-oriented identity, one should not 
forget that the corporate management mindset in the 1980’s still was oriented towards growth via 
diversification. As an example, Novo in 1984 was developing and/or marketing: pharmaceutical 
products for diabetes, infections (e.g. penicillin), cardiovascular diseases, menopause hormonal 
treatment, etc. – veterinary products for a range of infections, vaccines, drugs against worms, feed 
supplements, hormones etc. – diagnostic systems for brain scanning, bone minerals, heart frequency 
etc. – and enzymes for a range of industrial uses. The attitude of diversification is clearly illustrated 
with this quotation from Novo’s annual report for 1986 (my translation and emphasis): “We continue 
to invest in products, which improve the life for diabetics. We target enzymes and enzymatic processes 
for our industrial customers. However, we believe that we can develop products in other areas, which 
will make life better – every day – for patients, other users, their employees, our own employees and for 
our environment. With our tradition of research and our ability to product development we shall utilize 
our experience in production and marketing to further create business opportunities within areas 
such as: Pharmaceutical drugs, especially for treatment of blood diseases, female diseases and nervous 
diseases – Procedures and devices for delivery of medicine – Natural, functional food ingredients – 
Special food, e.g. for patients – Special chemicals – Environmentally friendly substances for agriculture – 
Analytical reagents, amongst others for clinical diagnostics and food control.” As can be seen, medical 
devices were seen as one of many diversification opportunities.    
Entering medical devices 
In the 1970’s, several inventions within diabetes care had been introduced, such as blood glucose 
meters (BGM) for home use, which enabled patients to measure their blood glucose much more 
reliable than by using urine tests. A new treatment regimen for Type 1 diabetes had been presented: 
the ‘basal-bolus’ regimen, in which the patients should inject a long-acting insulin once or twice daily 
to provide a basal insulin level in the body, on top of which so-called ‘bolus’ injections were added at 
each meal to adjust for the effect of the extra carbohydrate intake. This resulted in a more stable 
blood sugar level, but also meant that the patients would have to inject insulin 4-6 times throughout 
the day instead of once or twice. As an even more advanced and expensive option, insulin pumps had 
been introduced; these devices continuously infused a steady supply of insulin.  
At both Novo and Nordisk, the initiation of the device activities was encouraged by external 
discussions on diabetes treatment within the community of diabetes experts.  
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At Nordisk, the inspiration came from the ongoing discussion on the possible development of an 
artificial pancreas. The CEO of Nordisk initiated R&D projects for two of the core elements of an 
artificial pancreas: an insulin pump for the infusion of insulin, plus devices for monitoring the blood 
glucose level. Nordisk launched its first insulin pump, Nordisk Infuser®, in 1983. It was developed 
and manufactured externally and was one of the first insulin pumps in the world.  To maintain the 
insulin pump product and to start own development of follow-up products, Nordisk established a 
Medico-Technical Department in 1984. As result, Nordisk launched a second version of the pump, 
Nordisk Infuser® Mark II, in 1988, as an improved substitute of the first version. This second version 
was both developed and manufactured in-house at Nordisk. Nordisk was relatively successful with 
the insulin pumps, in the sense that market shares grew from zero to above 50% in Europe. The total 
market, however, remained small – the customer base only counted app. 5,000 users as late as 1992, 
where Novo Nordisk divested the pump business. 
At Novo, the competitors’ interest for insulin pumps was discussed.  An executive informant says: 
“We thought a LOT about entering the pump business or not. But Novo people evaluated that it was not 
something for us. The basic idea of wearing a device, which mimics pancreas, perhaps was good; but the 
disadvantages socially, personally, hygienic and so forth by wearing a pump weighted against the idea. 
Also, the first pumps were constructed so that you almost needed to be an engineer to set them; there 
was no user friendliness. But there was no doubt that the basic idea of delivering small injections of 
insulin, whenever your body needed it, was right. So we started playing with the idea of making a pen, 
which could be “the poor man’s pump”. Simply, let’s make something much more accessible, which 
everybody can use”.  
A case study from 1993 (Freeze, 1993) describes it this way:  
“All Novo's major competitors, including Nordisk, were developing pumps. Novo's marketing director at 
the time, Sonnich Fryland, was given the task of deciding whether Novo should do the same. “We 
determined that our expertise was in insulin, not in electronics. We didn't have the vaguest idea about 
such devices.” Fryland also believed intuitively that patients, when all was said and done, “would not 
want to wear something on their bodies.” Fryland discussed his conclusions with Novo's research 
director and the director of Hvidøre Hospital [Novo’s diabetes hospital at that time] and decided that 
Novo would not develop a pump. Instead, they would:  
a) continue to develop insulin;  
b) collaborate with companies that made pumps so they would choose materials appropriate for 
Novo's insulin; and  
c) develop other devices for multiple injections.” 
The inspiration for the solution came straightforward. An article in the medical journal ‘The Lancet’ 
(Paton et al, 1981) described a fountain pen like device, based on a disposable syringe, which made it 
easier for a patient to inject everywhere. Novo’s marketing director found this interesting and 
conceptualized the idea of an insulin pen with replaceable insulin cartridges. A development project 
was organized more or less as ‘skunk work’, hosted by the Packaging department. NovoPen® was 
then developed partly by external partners, but managed from Novo, and production took place in-
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house of Novo. Even if the pen was not an electronic device like the pump, it was still challenging. 
“Had we known how difficult it was, we would never have started the project”, an executive informant 
says. Not only was the technology, also the market unknown. Another executive says: “Novo didn’t 
know how big it was, what they started with the pens”. Thus, parts of top management viewed the idea 
merely as a ‘marketing gimmick’, and based on this perception some crucial decisions were taken, 
some of them having long term impact on the subsequent development of the medical device 
industry. As examples: 1) no patents were applied for, leaving it open to competitors to copy the idea 
(being the first such product, the patent options would have been broad and effective) and 2) it was 
decided to give away most of the pens as free ‘samples’ instead of selling them. This made sense for a 
marketing gimmick: the pens were meant for creating customer loyalty, with the expectation that the 
patients hereafter would buy the Novo insulin – very much like the Gillette razor/blade business 
model (i.e. selling the razors at low prize in order to profit from the blades – here, the insulin would 
be the profit generator). 
After the launch in 1985 it quickly became apparent that the NovoPen® had hit an unmet market 
need and the product became popular. But according to a production manager, NovoPen® was not 
technically robust and not suited for mass production (the size of the demand had not been 
foreseen). Therefore Novo looked for an alternative, which could fulfill the needs for a mass-
produced insulin device. The solution was a prefilled, disposable insulin pen made of plastic – which 
meant that insulin and device was one integrated unit, to be disposed when empty. The resulting 
NovoLet® project belonged to a joint venture company, Diabetes Care Products, which Novo had 
established together with a Danish plastic manufacturer, Pharmaplast11, in order to develop and 
manufacture this plastic device. The launch of NovoLet® happened in the next period (1989). 
Concluding on the evolution of the early attempts 1980-1988 
Nordisk:  
At Nordisk, the insulin pumps were seen as a door opener to dialogue with the diabetes specialists, 
who were perceived as the key customers. Thus, the strategy making was a theory-driven process. 
From the outset, insulin pumps were seen as enhancers of the existing insulin business – as 
complementary assets, in other words. In this sense, insulin pumps expanded the existing insulin 
business and hence could be seen as an ‘induced’ strategy. (See the definition of autonomous and 
induced strategy in the Definition section of the Introduction). On the other hand, the insulin pumps 
opened a new business based on devices via creating a separate revenue stream by selling the 






11 Pharmaplast was owned by the huge Danish conglomerate, Maersk.  
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expensive insulin pumps and the utensils (infuser sets) for these. Therefore, since the insulin pumps 
created new business and opened new product-markets, the strategy per definition was 
‘autonomous’.  
Novo:  
Novo of course had witnessed the same external development, but chose to stay out of insulin pumps. 
According to their analysis, insulin pumps would never become a mass market, and this argument 
seems more important to Novo than the potential access to dialogue with the diabetes experts. 
Perhaps we here see a footmark of the two companies’ slightly different internal identity (Tripsas, 
2009): Nordisk with a deeply scientific and treatment oriented identity, setting the diabetes experts 
as the key customers; Novo being more pragmatic and forced to broad commercialization, because 
Nordisk from the outset had a dominant position in the home market.  
According to an executive informant, Novo’s top management had reformulated the overall corporate 
goal from being world leader in insulin manufacturing to becoming world leader in diabetes care. 
This shift in identity opened for vertical integration of other elements of the value chain of ‘diabetes 
care’ than the drug itself. The shift matured top management cognition for embracing medical 
devices as part of the diabetes care business.  
Consequently, Novo’s managers welcomed the idea of the ‘insulin pen’ from the article in The Lancet 
in 1981 (Paton et al, 1981). The way they established the project in the Packaging department, 
implying large degree of external development, could call for a characterization as ‘skunk work’ or an 
autonomous initiative. On the other hand, the insulin pens were only envisioned to enhance the sales 
of Novo’s insulin – not to create a business of its own. The insulin pens were perceived as 
complementary assets for innovation, which should support marketing of the insulin. In this sense, 
Novo’s launch of insulin pens could be seen as an induced initiative, which expanded the existing 
strategy. However, in Novo’s annual report for 1984, there’s a 2-page article on the coming launch of 
the NovoPen®, written by the representative from Marketing in the development team, and it 
concludes (my translation): “After more than sixty years of treatment with insulin based on vials and 
syringes, the development of the NovoPen® system seems a breakthrough in the insulin injection 
technology”. Even though NovoPen® was not foreseen to create revenue streams, one could 
therefore also regard the insulin pens as the entrance to new product-markets, and hence this 
entrance could represent an autonomous strategy. 
General:  
If we focus on the internal drivers of change in innovation strategy, it is clear that in both companies, 
the initiation of medical device activities is theory-driven, inspired by the dialogue within the 
community of diabetes experts (including article journals). This corresponds to Burgelman’s (1991, 
2002) description of induced strategy processes, which formulate the vision ‘ex-ante’, before starting 
the practical activities. The initiation of the device activities was not based on internal 
entrepreneurial experiments (as normally for autonomous strategy), but on reasoning or ‘theory’. 
However, if we base the classification on Burgelman’s (2002) explicit criterion of either expanding 
within or exploring outside the current strategy and its product-market environments, we must 
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classify the strategic initiatives introducing medical devices as autonomous strategy. The 
classification is not clear, because the initiatives on the two other parameters (see ‘Definitions’ in the 
Introduction), being top management driven and based on ‘ex-ante’ vision, do not represent 
Burgelman’s normal case of autonomous strategy (Burgelman, 1991). If we instead look at another 
part of Burgelman’s theoretical framework, then these early device activities clearly lacked an 
institutionalized strategy and therefore represent the emergent state (Burgelman, 1988).  
In contrast to Burgelman (1991), the most important driver of change in strategy was probably 
external: The introduction in 1982 of recombinant human insulin, which had the potential to make 
traditional insulin obsolete (which it also did). It was a ‘Strategic Inflection Point’ (Burgelman & 
Grove, 1996) and called for action. Both Novo and Nordisk were several years behind Eli Lilly in this 
drug race and hence must have been looking for alternative parameters of competition; devices fit 
perfectly as such instrument of market differentiation. 
If we apply the model of strategic learning (figure I-1 in the Introduction), the learning cycle starts as 
theory-driven and, over successful experiments with insulin pumps and pens, leads to reinforced 
commitment to medical devices as part of the future strategy. See figure IV-4.  
 






















Phase 2: The period around the merger (1988-1992) 
Insulin industry 
Ely Lilly remained the biggest insulin manufacturer in the years to come, supported by the 
introduction of recombinant insulin. In the beginning of the 1990’s, Lilly had at least 75% of the U.S. 
market12 and therefore probably did not feel threatened by Novo’s and Nordisk’s launch of insulin 
pen systems. At least, Lilly did not respond to Novo’s insulin pen; and in fact, insulin pens had a very 
slow adoption rate in the U.S.  Perhaps Lilly had invested so much identity and pride in the invention 
of recombinant insulin that they insisted in seeing the drug as the market differentiator and 
therefore disregarded the new insulin pens. But I’m only guessing here. The fact is, however, that 
Lilly didn’t enter the pen market until 1995. If we disregard Nordisk, who was less successful with 
their Insuject® pen, the first competitor product to NovoPen® was an insulin device introduced in 
1990 by the U.S. company BD (Becton, Dickinson and Company), which was designed to fit the insulin 
cartridges from Novo. Being a pure device company, BD did not threaten Novo in the core insulin 
business. An executive informant from Novo said: “What surprised me most, was how long time we 
were alone on the market. Throughout the 80s, the two market drivers are respectively the pen systems 
from Novo and the premixed insulin from Nordisk”. Obviously, Eli Lilly must have perceived the 
market drivers differently.  
Corporate management cognition 
Novo’s top management registered some trends within the pharmaceutical industry, as explained by 
an executive informant: “There always have been waves, where the large pharma companies became 
interested in the diabetes market; now they wanted to enter. At this time also biotech firms emerged 
[like Genentech and Zymogenetics], so we had to calculate with biotechnical insulin manufacturers too. 
Or the scenario could have been that the two of us [Novo and Nordisk] competed in the European 
market until we both were completely tired out, and then one of the large companies would come and 
make a bet on one of us…There was no doubt that Novo had a very strong position with the pens and 
Nordisk with the premixed insulin – so you didn’t need an Einstein to figure out that it would be a good 
idea to merge the two”.  The merger was announced January 1989. At that time, Novo was 4-6 times 
bigger than Nordisk, measured on all key parameters. Therefore, it became crucial for top 










management to avoid the feeling of Novo taking over Nordisk. Consequently, each functional area 
was analyzed one by one and compared between the two, and the most competent unit would 
continue. This way, the reorganization after the merger was completed around September 1989 and 
resulted in appointment of more managers with a background from Nordisk compared to Novo. This 
signal was perceived as crucial for building a common corporate identity. Similarly, both companies’ 
CEO’s continued jointly– however, the CEO of Nordisk had cancer and died 1990. 
The merger resulted in managerial optimism – as explained by an executive informant: “By the 
merger, we suddenly get in new product areas, the palette is much larger, and everybody is excited – 
now we can join in with the large companies and so on…” 
Medical device level  
In Nordisk, top management had followed a vision of making medical devices the ‘third business leg, 
besides two existing pharmaceutical divisions, Diabetes and Biopharmaceuticals (the latter taking 
care of other diseases than diabetes). Consequently, Medical Systems Division (MSD) was established 
in 1988. The overall vision was patient-centered homecare, supported by a medical system, 
comprising the drug, the delivery system and the monitoring system. See figure IV-5. 
 
 
Figure IV-5. The Nordisk vision of a medical system, from around 1988. “Monitoring” in diabetes refers to 
glucose monitoring devices. “Drug delivery” refers to injection and infusion systems: insulin pens and pumps. 
 
As a genuine division, MSD comprised the usual business functions: Marketing, R&D, Production, 
Quality, Regulatory, Logistics etc. The revenue stream for the business unit was envisioned to come 
from the sales of insulin pumps as well as utensils/accessories for the pumps (infuser sets etc.), to be 
supplemented later with revenue from selling monitoring devices and utensils for these. According to 
an informant, the monitoring devices were seen as the future revenue generator for MSD – injection 
devices were seen as less important (remember that the insulin pens were usually given away as free 
‘samples’ and would therefore not create revenue by themselves).  
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The CEO of Nordisk, assisted by another member of the executive team, played a major role in the 
establishment of MSD. The activities grew rapidly, and by the merger in 1989, MSD employed 119 
persons. “It was a dynamic period, something happened all the time – it was full steam ahead all the 
way through”, as one informant puts it. 
At the merger, Nordisk was recognized by Novo as having the strongest organization for medical 
devices. Consequently, MSD was continued as the organizational frame of the joined device activities 
with the status as one of five divisions in the Health Care Group of the merged company (see 
organization charts from before and after the merger in respectively figure IV-6a and IV-6b). MSD 
continued to cover the usual business unit functions.  
 
 
Figure IV-6a.  The MSD organization before the merger in 1989. Biopharm = non-diabetes related. 
 
 
Figure IV-6b. The Novo Nordisk organization after the merger in 1989, with MSD as a division of Health Care 
Group. 
 
The time after the merger has been described by informants in the device area as very optimistic and 
entrepreneurial, opening for a lot of innovation projects. Furthermore, the innovation projects 
established before the merger were continued. The most significant of these projects was Novo’s 
development of the prefilled insulin pen, called NovoLet®, which was launched the same year as the 
merger (1989).  NovoLet® changed the business model: the drug and the device until then had been 
separate parts, of which only the drug generated revenue for Novo Nordisk. With the new NovoLet®, 
the device could neither be sold nor sampled (given away for free) apart from the insulin – instead, 
the drug-device system was sold together at a higher price per insulin unit, compared to insulin sold 
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in traditional vials or in cartridges for durable pen systems. The NovoLet® system therefore 
introduced a third insulin business paradigm, besides insulin sold in traditional vials and insulin sold 
in cartridges for durable pen systems (or for pumps). Eli Lilly saw this; they followed with their 
similar prefilled pen system in 1995.  
Because of its simplicity13 (no filling of insulin or shift of insulin cartridge was needed) the new 
product category was well suited for the broad segment of Type 2 diabetes patients. Hence, the 
integrated drug-device systems gained success. A 1997 Financial Times report states: “Insulin was the 
largest single product category [in the total diabetes market in Europe], helped by the success of the 
more expensive disposable pens, prefilled with insulin, which are rapidly becoming the standard form of 
insulin therapy in most countries” (Adamczak, 1997, p. 1). 
NovoLet® was established as a joint venture between Novo and a Danish plastic manufacturer, 
Pharmaplast. The plastic components were produced by Pharmaplast, and the first part of the 
assembly process was carried out by the joint venture company, Diabetes Care Products, at 
Pharmaplast’s site. Thereafter, the products were handed over to Novo, who took care of the final 
assembly of the drug container (the insulin cartridge).  
Novo Nordisk then took the strategic move to acquire the joint venture company, Diabetes Care 
Products, from the partner Pharmaplast. The decision was driven by management recognition of the 
future importance of this integrated product. As a key informant states: “Marketing saw it as pure 
packaging. But if you look at it, then we actually make more money on the plastic then on the insulin. 
Damn it, if we sold all our insulin in vials, we would have no business. What makes the difference? - That 
we fill it in cartridges and put them into devices. That’s our business. That’s why I’ve fought for making 
devices part of Novo Nordisk’s core business; both in development and production wise”. Following this 
logic, Diabetes Care Products was acquired in 1990 after initiative from the MSD top. The 
manufacturing of prefilled pen systems was integrated into MSD, in parallel to the existing 
manufacturing of durable pen systems. 
Since both Novo and Nordisk had their durable insulin pen systems, it was natural to initiate a 
common development project for a Novo Nordisk insulin pen. The result was NovoPen® 3, launched 
in 1992. The brand name of NovoPen® was kept, because it had the widest market acceptance, 
almost as a generic name for the product category. Technically, NovoPen® 3 was a compromise 
between principles of the pen systems from both companies. After solving some initial technical 
problems, NovoPen® 3 became robust and gained market acceptance as the most sold durable 






13 ”NovoLet” is Danish for NovoEasy  
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insulin pen for more than 15 years. In 2010, it was still sold; but it was being phased out in favor of 
NovoPen® 4 country by country.  
Concluding on the evolution of innovation strategy 1988-1992 
Although driven by top management, the establishment of medical devices with Medicals Systems 
Division can be interpreted as an autonomous strategic initiative for two reasons: 
1. The idea implied a complementary business model (revenue stream from devices instead as 
only from the two drug areas). Hence, devices were internally labeled ‘the third business leg’. 
2. The vision of homecare opened for entering new product-markets, such as glucose 
monitoring products, which represented a distinct market served by a separate industry.  
The aim of MSD was to make a revenue stream of its own based on medical devices, also by selling 
devices to other companies; devices were to become the core asset of this new business unit. 
Thereby, the device innovation strategy differed from the established strategy. On the other hand, the 
medical device business was perceived one ‘business leg’ in a diversified corporation; medical 
devices were not envisioned to substitute the drug business. The device organization should 
continue also to support the two pharmaceutical drug divisions with insulin pens etc. for their drugs; 
so from the drug divisions’ point of view, MSD was seen as a supplier of complementary assets for 
their drug business. 
Consequently, the move into medical devices could be seen as an induced strategic initiative, 
extending the current drug strategy. However, following the explicit definition by Burgelman (2002), 
the MSD initiative explored new product-market environments, for example insulin pumps and 
glucose monitoring products, and in conclusion must be defined as an autonomous strategic 
initiative.  
If we apply the model of strategic learning (figure I-1), then the entrepreneurial management 
approach within MSD surely led to trial-and-error learning. A typical example is the learning from the 
collaboration with Pharmaplast in the joint venture company Diabetes Care Products, which ended 
with Novo Nordisk taking over the joint venture. However, the entrepreneurial experiments did not 
alter the vision of patient-centered homecare; only substantiated it. The overall strategic direction 
was envisioned by Nordisk’ top management team from the outset in 1988 (or probably already in 
1987). Consequently, the innovation strategy must be characterized as theory-driven rather than 
experience-driven. The strategic learning cycle of MSD is modeled in figure IV-7. The vision of 
homecare led to the exploration of medical devices as a new business, with diverse product 
innovation experiments. The results were mixed: the pump business was successful, but the 
monitoring projects never succeeded (only one product was launched; and had to be recalled, due to 


























Phase 3: The quality crisis (1992-1994) 
Insulin industry 
After the introduction of recombinant human insulin, the next step was the invention of so-called 
insulin analogues. These are insulin molecules, based on the human insulin molecule, but artificially 
modified for achieving special effects, such as very rapid metabolic effect or a very long lasting effect. 
Eli Lilly was engaged in research on insulin analogues, and also Novo Nordisk had done some 
research, but had given it up, due to potential cancer risks from these drugs.  
The growing Type 2 diabetes market continuously attracted attention within the insulin industry, 
since it became more common to prescribe insulin to Type 2 patients. Novo Nordisk’ response, 
amongst others, was to invest in and push the market towards insulin sold in cartridges for devices 
or in prefilled devices, and to position these product categories as more user friendly (compared to 
traditional vial and syringe) and therefore well suited for the broader segment of Type 2 patients.  
The use of insulin for treatment of Type 2 diabetes was enhanced by the publication of the first of the 
so-called major outcome studies, namely the public research program ‘Diabetes Control and 
Complications Trial’ (DCCT), which was a large study on treatment of diabetes patients in the U.S., 
which concluded that intensified treatment with insulin provided better treatment outcomes. 
Corporate level – cognition and crisis 
Top management seems to have been inspired by the new management dogma about focus on core 
competencies (Prahalad & Hamel, 1990), facilitated by dialogue with external consultants. An 
executive informant explains: “After the merger, the company suddenly gets bigger, we get more 
competencies and business areas, and more resources – and the subsequent business strategy is very 
broad, also broader than the resources and competencies could cover. I guess that’s why the progress 
was not as immediate as hoped for… a very broad portfolio, much bigger than our resources and 
management competencies could cope with”.  
The focusing of the business began already in 1991 when Novo Nordisk divested the veterinary 
business, and continued thereafter. Let me quote the annual report for 1991 (my emphasis): “In 
accordance with our strategy of focusing our efforts on our main business areas, we divested Novo 
Nordisk Diagnostics Ltd, UK.” In the following years, numerous business areas were closed down or 
sold.  
These focusing efforts were amplified by the fact that Novo Nordisk ran into problems at both 
internal and external frontiers. Internally, top management realized that the company was lagging 
behind the competitors on the drug side; the pipeline of new diabetes product was too weak. A newly 
appointed management team of the Diabetes Care Division therefore initiated two projects for 
developing insulin analogues – first a project for fast acting insulin, and later the same year (1993) 
also a project for long-acting insulin. “Now we also had long-acting insulin on the way, and after many 
years it began to look a bit brighter. But we were behind – we had simply nothing [in the pipeline 
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before]”, as stated by an executive informant, who added: “We were still frontrunners on insulin pens. 
We had the NovoLet®, which had full steam ahead, and we were surfing on the NovoPen® wave, and 
even though NovoPen® 2 never became a success, we still had total device leadership at that time”. 
Externally, however, other problems occurred. In 1993, the U.S. Food and Drug Administration (FDA) 
criticized the insulin manufacturing at Novo Nordisk; according to FDA, the manufacturing did not 
live up to the U.S. standards of Good Manufacturing Practice (GMP) with regards to the sterilization 
process. The sterilization of the insulin, when filled into vials or cartridges, is one of the core steps in 
the manufacturing process of insulin. The critique from FDA were received with skepticism from 
many internal experts; they perceived Novo Nordisk as the world’s leading insulin company, so of 
course they knew better than FDA how to manufacture insulin – as an executive informant described 
this skepticism. The perception of FDA’s requirements as not being valid might have deepened the 
conflict or postponed a proper reaction. Therefore, the conflict with FDA escalated and resulted in 
Novo Nordisk losing a large part of its insulin sales in the USA throughout 1994, leaving the market 
open to Eli Lilly. As a culmination, the head of the Health Care Group at Novo Nordisk was forced to 
leave his position in 1994. In the end, Novo Nordisk had to comply with the requirements from FDA. 
The crisis meant an internal shock in the organization, since it hit the core of the core of Novo 
Nordisk’s business and historical identity. As an executive informant says: “It shook the very 
foundations of the company”. The crisis is internally referred to as ‘the GMP crisis’ and is still a 
sensitive issue; even if it implied a steep learning curve for the organization by starting a long-lasting 
program for assuring quality throughout the manufacturing process. In the annual report for 1993, a 
new corporate vision is announced, listing 7 topics, one of them being Quality; “The name Novo 
Nordisk must be synonymous with quality”. The crisis is here touched upon indirectly: “In the last few 
years the US authorities, in particular, have set far more stringent requirements concerning 
documentation of the many processes in the development and production of pharmaceuticals. As a 
result, we have greatly intensified our efforts in the quality assurance field. During the year the number 
of employees working on quality assurance tasks more than doubled” (my emphasis). The annual 
report for 1994 is closer to admitting the severity of the crisis. The Directors’ report begins with the 
words “In many ways, 1994 was a difficult year for Novo Nordisk” and few lines later goes on: “a year 
when the company incurred substantial extra costs in connection with significantly increased quality 
assurance and documentation activities” and “…the delivery problems that arose mainly in the wake of 
the company’s effort to fulfill the increasingly stringent quality and documentation requirements of the 
authorities. The net effect for Novo Nordisk of these delivery problems was a loss of global market share 
in 1994 of approximately 2 percentage points. While Novo Nordisk lost insulin market share in the US 
and Southern Europe, it consolidated its position in several other countries…By the end of the year, the 
[production] plants had resumed normal business” (my emphasis). 
The crisis amplified the movement for focusing the business on fewer areas. The official book of Novo 
Nordisk’s history (“Novo Nordisk history”, 2011) mentions a new business strategy: “In 1994, Novo 
Nordisk implemented a new business strategy to ensure progress in a rapidly changing and ever more 
competitive world. Focus was on the two core business areas, Health Care and Enzyme Business, while 
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other areas such as Ferrosan (dietary supplements and other over-the-counter products) and Plant 
Protection (biological plant protection) were divested.” In the annual report for 1994 is stated: “1994 
was also the year when Novo Nordisk changed its business strategy. The sharpened business focus 
provides the basis for and belief in renewed profitable growth…The essence of the new strategy is 
increased focus on the company’s core businesses”. According to the annual report, the new strategy 
was launched “towards the end of 1994”. The new strategy also affected the corporate structure. The 
annual report for 1994 says: “Implementation of the new strategy required a substantial adaptation of 
the organisational structure. The former divisionalisation of business areas was replaced by a 
functionalized and process-oriented structure, and a number of staff functions were gathered at a 
corporate level.” According to my informants, this restructuring was implemented in 1995, implying a 
‘reverse Chandlerian’ restructuring from a multidivisional to a functional organizational structure. 
Such U-form structure (Chandler, 1992) was a logical consequence of the corporate move from 
diversification towards focus on core business. 
An executive informant, who was part of the creation of the new strategy in 1994, explains it this 
way: “The strategy process was amongst others a result of the quality crisis. Corporate management 
was not sure that we had the right strategic focus. I was asked, together with [name] and some 
consultants to analyze the long term pharmaceutical strategy…we should lay down the future track in 
order to become competitive. And today you can see how we since then [1994] have narrowed down 
and narrowed down, so that we are now [2011] a very diabetes focused company. We regard our core 
competencies as understanding proteins for treatment of chronic diseases, especially diabetes; the 
formulation and administration of these, the modification of these – and then to understand and relate 
to a group of people, who has a chronic disease, and the responsibility which follows…So it was just too 
broad [before 1994] – we didn’t have the structures and procedures and evaluation models and 
management competencies to secure the success of all this. Hence there has been a narrowing, a 
professionalization process, making it more effective… there has been a sharpening of the core 
competencies both at Novo Nordisk and Novozymes, as I see it – also due to changes in the environment. 
Other companies began being able to make similar products, which could compete with ours, and we 
lost market shares”. The same informant concludes on the learning from the quality crisis: “From the 
quality crisis we learned how important a well developed and robust quality system is, with training and 
documentation, - that might even become a competitive advantage, which I actually think it has become 
today”.  
Medical device level 
When the focusing process started in 1992, medical devices were disregarded as ‘core business’. It 
was suggested to give Medical Systems Division status as supplier in the form of an independent 
company, but this proposal met resistance by the MSD management: “We did not want to be treated 
like suppliers. At that time, insulin was a generic product. The whole value creation was in the 
innovation of the pen systems – so we said that we would rather give up our independence and become 
a part of the diabetes division and have influence there, than just being placed as a supplier”. The 
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company was (since the merger in 1989) organized in two main business units, Health Care Group 
(pharmaceuticals) and Bioindustrial Group (the enzyme business).  Each of the business units was 
split into several divisions, as result of the fusion of multidivisional setups in both companies. 
Eventually, the device area became a subunit to the Diabetes Care Division in the reorganized Novo 
Nordisk in 1992 under the name Medical Systems. See figure IV-8 for an organizational chart.  
 
 
Figure IV-8. Medical Systems placed under the Diabetes Care Division in 1992. As can be seen, MS kept the 
usual functions of a division; except for a marketing function. The structure is ‘M-form’ = multidivisional 
(Chandler, 1992). 
 
As response to the corporate quality crisis, MS was told from top management to discontinue both 
the insulin pumps and the monitoring projects; focus should be on insulin pens. An informant 
comments: “The idea of being able to cover all aspects of treating diabetes was shot down. Medical 
Systems was only allowed to develop and produce pens. Hereby the strategy of Medical Systems Division 
was winged.”  The informant here refers to the ‘vision of homecare’ as shown in figure IV-5. 
The pump projects were discontinued, and the existing customer base was handed over to a 
competitor. For several reasons: top management did not believe that insulin pumps would ever 
become a big market (at the end there were about 5,000 users of the Nordisk Infuser®), and at the 
same time these products required a costly service-oriented organizational set-up, including call 
centers to assist patients when using the complex insulin pumps. “It’s a different type of business than 
just pouring drugs out to the pharmacies”, as stated by an informant. Furthermore, the customer 
complaint rates from the complex pumps were high compared to pharmaceutical drugs. Selling drugs 
via pharmacies only rarely results in customer complaints, so Novo Nordisk was not used to handling 
a relative high amount of direct complaints from the users. “Novo Nordisk was not geared to this, it’s 
was alien for the organization”.  
The development projects for disease monitoring devices were then stalled, partly due to technical 
problems, but also because of lack of business synergy, despite the obvious link in usage between 
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glucose monitoring and insulin injection. The pharmaceutical insulin business was primarily 
targeting the medical specialists, who prescribed the medicine to the users – it was a business-to-
business market. Glucose meters were sold at pharmacies or even supermarkets; it was a consumer-
driven business, which had no attention from the side of the specialists; they left it to the nurses to 
advise the patients. Therefore, the synergy with regards to customer base and distribution channels 
was absent. “Strategically, it’s very difficult to make monitoring fit in; because it’s a totally different 
sales channel…so it’s because of lack of sales synergy that it doesn’t make sense”, as an informant states. 
In other words: even though the device activities since 1992 were integrated in the Diabetes Care 
Division, the value chains (Porter, 1991) of the disease monitoring business and the drug business 
had little in common. As a consequence, the latitude of the medical device innovation was narrowed 
down when Medical Systems was restructured again during the corporate reorganization from 
divisions to a functional (U-form) structure, implemented in 1995.  
Still, even in these difficult years, there was room for radical innovation. March 1993, device 
managers created a vision about “developing and marketing a third generation insulin device” – the 
first two generations being the NovoPen® product line (including NovoPen 2 and 3) and the prefilled 
product line (NovoLet®). In October 1993, a new development project was formally established, 
which in 1999 resulted in the world’s first electronic insulin device (see the PDS epoch, 2001-2005). 
“The project was started as a defensive move; we were behind the competitors in the drugs”, an 
informant states, referring to the weak drug pipeline, see above.  
Concluding on the evolution of innovation strategy during the crisis 1992-1994 
Several factors led to the retreat from the autonomous MSD strategy. External events were important 
drivers, accompanied by top management interpretation:  
 Apparently, top management realized that the business portfolio of the merged Novo 
Nordisk in 1989 was far too broad, held up against the management resources and 
organizational capabilities.  
 Further, the shift in general management paradigm from ‘diversification’ (e.g. Ansoff, 1965) 
to focus on ‘core competencies’ (Prahalad & Hamel, 1990) probably has strengthened the 
wish to focus the business, brought to top management’s attention by external consultants.  
 Top management also perceived the drug pipeline of Novo Nordisk as being behind 
competitors – especially with regards to insulin analogues.  
 The GMP crisis amplified the corporate focusing process, and drove the change in device 
innovation strategy towards focusing only on insulin pens.  
Thus, the focusing of the device innovation strategy was a theory-driven process, in which several 
external events were interpreted via top management cognition. The process aligned the corporation 
around the classic elements of the established business strategy – so it’s a clear example of an 
induced process. The most salient drivers were the above mentioned external events. Thus, the 
‘internal ecology’ seems less relevant for explaining the strategic change than the ‘external ecology’.  
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Where the MSD period opened for seeing medical devices as a core asset for innovation, the 
withdrawal from the MSD strategy implied an explicit view of medical devices as complementary 
assets, which should merely support the drugs.  
Interestingly, even within this period of crisis and conversion to the traditional dominant logic 
(Prahalad & Bettis, 1986), there is one clear example of an autonomous initiative in the ‘classic 
Burgelman’ (1991) understanding: In 1993, the local device management initiated the so-called ‘third 
generation insulin device’, which led to the world’s first electronic insulin device, Innovo®. The 
project aimed for an insulin injection device, and consequently was within the corporate induced 
strategy in that sense; but the mere perception of creating a ‘third generation’ product category is 
quite explorative in itself – and the integration of electronics in a medical device required a range of 
competencies, which did not exist in the company at the time. Furthermore, the project was initiated 
and hosted by the local device organization. Therefore, I regard this particular project as an 
autonomous initiative in the ‘classic Burgelman’ meaning.  
However, when analyzing the portfolio of projects in this period, it is marked by the crisis, both in 
terms of few initiated projects and because most of the projects had a purely incremental nature (see 
the section in the present chapter analyzing the project portfolio). 
The strategic learning cycle for this period is shown in figure IV-9. The main ‘theory’ was the concept 
of ‘core competencies’, in search of which the insulin pumps and disease monitoring projects were 
terminated, because they were seen as ‘non-core’. The successful definition of core competencies 
reinforced the strategy.  
 
























Phase 4: Harvesting (1995-2001) 
Insulin industry 
The pandemic of Type 2 diabetes became salient within this period, which amplified the gradual 
reorientation of the industry towards the Type 2 diabetes market segment. Type 2 patients are 
typically middle age to elderly and settled when diagnosed and often not motivated for radical 
changes of their lifestyle. Consequently, this market segment calls for simple and less intrusive 
solutions. In 1995, Metformin tablets were introduced by Bristol-Myers Squibb, which quickly 
became a de facto standard for treatment of Type 2 diabetes in early stages. Novo Nordisk developed 
a similar tablet, NovoNorm® (Prandin® in the U.S.), which was launched in 1998. Also, research on 
insulin for inhalation was started (amongst others by Nektar Therapeutics in California, who began 
testing this in 1999), based on a vision that treatment without injections would enhance the 
acceptance of insulin treatment for patients with Type 2 diabetes. This research made Novo Nordisk 
license in a development project for inhaled insulin in 1998 from the U.S. company Aerodigm 
Corporation. 
In 1998, the main results of another public research program were published; showing clear 
evidence that intensified treatment of Type 2 diabetes resulted in better immediate glucose control 
and reduced late complications. It was the United Kingdom Prospective Diabetes Study (UKPDS); the 
largest clinical research study in diabetes ever conducted at the time. The study was carried out in 
the UK in 1977-1997. This study had substantial impact on the attitude of diabetes specialists, 
leading to more widespread use of insulin treatment for Type 2 diabetes. 
Human insulin, introduced 1982 (see previous sections), now dominated the market. “Use of human-
type insulin has rapidly become the universal standard: animal insulin has virtually disappeared in 
several countries, and is little used in the rest.” (Adamczak, 1997, p. 2, about the European market). 
Also the user-friendly premixed human insulin (combining fast-acting and long-acting insulin in one), 
continued to grow, driven by the Type 2 pandemic. In 1996, premixed insulin accounted for 57% of 
the total insulin sales in Europe (Adamczak, 1997).  
The research in the so-called insulin analogues was successful. However, Novo Nordisk was behind 
the competitors in the ‘drug race’, due to a weak drug pipeline in the beginning of the 90’es (see 
previous section). The first of the new drug products was a fast-acting insulin analogue, Humalog®, 
introduced by Eli Lilly in 1996 (Novo Nordisk launched a similar drug, NovoRapid®, in 1999), 
followed by the long-acting Lantus® introduced by French Aventis in 2000, who in 1999 had taken 
over the insulin activities from Hoechst (Novo Nordisk launched a similar drug, Levemir®, in 2004).  
Novo Nordisk invested in and pushed the market towards prefilled devices, also as a response to the 
Type 2 pandemic, since prefilled pen systems were perceived as the most simple to use. Eli Lilly 
entered the prefilled market with their Humalog® Pen in 1998. The pen had a dosing mechanism 
allowing a dose accuracy of 1 insulin unit – NovoLet® could only be set with increments of 2 insulin 
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units.  Hence, Novo Nordisk started development of a new prefilled device, FlexPen®, launched in 
2001, which again assured Novo Nordisk device leadership as perceived by the market.  
Corporate management cognition 
The crisis 1992-94 seems to have provided substantial learning for Novo Nordisk’s corporate 
management team, but also other factors influenced the strategy towards focusing the business. An 
executive informant says: “But in the 90’es we became aware of the mega-mergers within the pharma 
industry. For me and my colleagues it was important not to be taken over by somebody else; we wanted 
to continue as an independent company, and we had some discussions about how to stay as such. Our 
research colleague [name] expressed, what became our belief; namely that we should not end up as 
‘mini-big’ pharma,  trying to have a foot in all camps, being small everywhere… with our resources, we 
could perhaps put one horse in the race, but the big players would have 10 horses; and even quantity not 
always counts in research and development, then you still have higher chances with 10 horses than with 
one…so we decided that we wanted to compete with the big companies in areas, where they could not 
keep up with us. We were convinced that the knowledge we had within enzymes and insulin – on market 
and development, and the technologies, we possessed – even though others saw it as narrow, we 
perceived it as deep – lots of things could be harvested.” – Such was the reasoning behind the focusing 
of the business, which resulted in divesture of units such as Ferrosan A/S, Plant Projection and 
Plasma Product Unit in 1995-96. Furthermore, it was decided in 1998 “to work towards a separation 
of Health Care and Enzyme Business into separate legal entities” (1998 annual report). This demerger 
was finalized in 2000 and marked the culmination of the efforts to focus the business. The Health 
Care business was continued as Novo Nordisk A/S; the enzyme business was established in a new 
company, Novozymes A/S.  
This development deserves to be illustrated by the following long quotation from an executive 
informant – because he touches some fundamental aspects of complementarities and business 
synergy: “There has been a fantastic synergy between the enzymes and the pharma part. When I 
worked in the enzyme business, it was bigger than the pharma part, and it was the enzyme business 
which first expanded globally. In the economic cycles, the need for technical enzymes, such as for food 
production, textiles and detergents, occurs before the ability to pay for healthcare. That’s why it was the 
enzyme business, which was the first to establish own organization in the USA, in Brazil, in Japan, in 
China – and then, via institutionalized understanding of the foreign markets through the enzyme 
colleagues around the globe, you had a first mover advantage, when time was ripe for establishing 
pharma units. We already exported our pharmaceutical products to these markets, but we did not have 
our own organizations, and we did not have detailed political knowledge. When I worked in USA for the 
enzyme business, there were five pharma colleagues, or something like that – it was in the early 80’es – 
there were only 5 pharma colleagues in USA! – When I negotiated a license to manufacture enzymes in 
China, we got the license for pharma production as a spinoff – so when the company was split in two, we 
suddenly had an independent pharma company in China with independent business license to produce 
in China. But Novozymes had the biggest factory, likewise in Japan. It was also Novozymes, who took 
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care of the fermentation process when producing insulin, because they had the fermentation knowledge. 
Then, because of Good Manufacturing Practices – the separation of food from pharmaceuticals and all 
this, combined with the completion of the globalization, then the synergies between the two businesses 
became less and less tangible. This, amplified by the rapid growth in the pharma part, led to the decision 
about splitting up the company. Indeed an exciting development”. 
Besides the focusing of the business, another initiative from top management – also partly ignited by 
the GMP crisis – was to focus on performance, i.e. efficiency, profitability etc. Some of the 
background was rooted in the historical identity: Already in 1924, Nordisk was legally established as 
an independent institution, which had in its purpose statement that any profits should be used for 
scientific and humanitarian purposes. Also the merged Novo Nordisk was organized with a 
foundation as the owner of all A shares: “the Novo Nordisk Foundation – an independent institution 
whose objectives were to create a solid basis for the operation of Novo Nordisk and to support scientific, 
humanitarian and social causes”, as it is written in the official corporate history. The starting point in 
science, combined with such overall purposes, seem to have influenced the internal identity (Tripsas, 
2009) towards altruistic values. According to one executive informant, the research environment at 
Novo Nordisk in the beginning of the 1990’es was university like, holding an academic arrogance 
towards the need of marketing new commercial products. Scientific research and medical treatment 
of diabetes was highly valued in this culture; ‘commercialization’, ‘sales’ and ‘profit’ were seen as less 
valuable (or even negative) concepts. Another executive informant says: “We had some managerial 
challenges, because we said that we wanted to stay an independent company. There was an attitude, 
perhaps I exaggerate, that ‘here is peace and no danger, because we are owned by a foundation’. Where 
my attitude was: who wants to own a company which doesn’t perform? So if we run a company, we 
should be as profitable as anybody else…It was tough to get an organization, who perceived itself as the 
world champion within its area, to live up to what you actually could expect from a world champion, 
and this meant that we had to become much sharper in our objectives and much sharper in living up to 
our values, and we initiated a range of activities in order to secure our ability to survive [as 
independent company]”. Quality management and lean management were parts of these activities, 
but also the creation of the so-called triple bottom line, which made the classical altruistic values 
measurable.  
Looking towards the external environment, the diabetes experts these years preferred tablet 
treatment for Type 2 diabetes – and hoped for the development of inhaled insulin. An executive 
informant states: “At this time, mid 90s, all prognoses said that Type 2 treatment would be tablet 
treatment…No doubt, we have a history of being a Type 1 company. Then, in the 90s, a huge market for 
Type 2 treatment emerges, and it is seen as primarily oral treatment [tablets] – even though some of our 
insulin is being used for Type 2 patients. That led us to enter the market for tablet treatment of Type 2”. 
Hence, Novo Nordisk launched NovoNorm® in 1998. Furthermore, top management felt a pressure 
from competition to enter the development of inhaled insulin. As explained by an executive 
informant: “I supported inhaled insulin, mostly for defensive reasons…when it showed that Pfizer 
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followed the track and then also got it approved – we couldn’t risk not to have inhaled insulin, if this 
suddenly would take over”. 
Medical device level 
After the reorganization in 1995, Medical Systems, including both device R&D and device production, 
was placed as a subunit to corporate Production. See organizational chart in figure IV-10.  
 
 
Figure IV-10. Medical Systems placed under Product Supply (i.e. Production) after the restructuring into a 
functional organizational structure, implemented in 1995. 
 
The strategy for the device area was now to focus solely on supporting the pharmaceutical drugs with 
superior injection devices. In spite of this narrow scope, there is in fact an impressive list of new 
product launches (most of them representing incremental innovations) from the Medical Systems 
period, with a broad spectrum of insulin pens and accessories. On top of this, the world’s first 
electronic insulin device with a memory function, Innovo®, was launched 1999. Innovo® had a 
display, which made it possible for the diabetes patient to see the time since the last insulin injection 
and how large a dose, which had been taken. This is a highly desired feature, since human memory 
sometimes plays games with us. Innovo® was a result of the “third generation insulin device” project 
initiated in 1993 (see previous section), and in the 1999 annual report it is also mentioned as a 
“completely new insulin injection system”. 
 According to an internal document, the device strategy aimed at fulfilling needs of various customer 
segments. Hence, the InnoLet® device was developed and launched 2001, targeting elderly people, 
where the electronic Innovo® was targeting a younger segment; and other devices were customized 
for children. A specific product launch deserves attention: Novo Nordisk made a partnership with the 
company LifeScan in U.S., owned by Johnson & Johnson. The partnership aimed at developing an 
integrated insulin device and glucose meter. The result was InDuo®, which had the Innovo® insulin 
device as the core, covered by a shell holding a glucose meter unit from LifeScan. Even both parts 
were electronic, there was no electronic connection between the two units. However, InDuo® was in 
fact the first product ever launched with physical integration of insulin delivery and glucose 
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monitoring. Such physical integration was often desired by patients in market research studies. 
InDuo® was launched in 2001, but flopped for several reasons, primarily marketing issues. A specific 
reason was the business model: reusable devices as Innovo® were usually ‘sampled’, i.e. given away 
for free to create customer loyalty. Innovo®, being an electronic device, was far more expensive than 
mechanical devices, and this extra cost would have to be held by the local subsidiaries, which would 
in the first place see this extra cost as a loss of profit.  
Forced by competition, Novo Nordisk licensed in a development project from Aradigm Corporation in 
1998 on inhaled insulin. This project required massive investments, also in the device system. The 
development was kept at Aradigm in California, and Medical Systems was not directly involved.  
According to an informant, Medical Systems was still run much like an independent business unit, 
despite its displacement under Production. Consequently, there was a pressure from the rest of the 
organization to force Medical Systems into the same (functional) logic as the rest of the firm; the 
autonomy of Medical Systems was seen as a problem. Thus, in 1996, the production of disposable 
pens was separated from Medical Systems. At the next restructuring in 2001, device R&D and device 
production were fully separated.  
Concluding on the evolution of strategy in the harvesting period (1995-2001) 
For corporate management it was vital to keep Novo Nordisk as an independent company. In order 
to secure independence it was perceived necessary to focus on selected areas and build deep 
competencies within these; "we will compete with the big boys in areas where they cannot compete 
with us" as expressed by an executive at that time. Michael Porter (1980) would have called this a 
‘focus strategy’.  
The efforts to focus the business led to the corporate reorganization into a functional, U-form 
structure (Chandler, 1992) in 1995, which was better suited for deepening the competencies within a 
narrow area. When analyzing the internal drivers, the focusing process thus first and foremost is 
theory-driven, based on the reasoning just described; however, the external pressure of competition 
from large pharma companies drives the process as well; management reasoning interprets the 
external pressure from competition.  
In the period after the corporate restructuring in 1995, the device area was placed as a functional 
area under Production. This implied relatively little attention from corporate management, and also 
relatively high degree of freedom, as long as the overall strategy was not challenged – i.e. focus 
should be on insulin pens. Some informants have mentioned this relative freedom as a positive side 
effect – and in fact, the product innovation seems to have bloomed, even though it was within a 
confined area, mostly unfolding incremental innovation projects (see the analysis of the project 
portfolio in a separate section of Chapter 4). Such an environment could be seen as ideal for 
autonomous initiatives in the classic Burgelman (1991) sense; but the actual innovation projects 
extended the established strategy – for example, supplementary products were developed such as 
needle inserters, and the devices were customized for different customer segments. There were no 
attempts to create new business or independent revenue streams based on devices, or to explore 
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new product-markets. In other words, with regards to device innovation strategy, the induced 
strategy was continued unchanged from the previous period, and the status of devices as 
complementary assets compared to the drug was never questioned. 
The strategic learning cycle of the harvesting period (1995-2001) therefore displayed theory-driven 
search of market differentiation opportunities via product innovation, aimed at specific customer 
segments. The success with these activities reinforced the strategy of devices as means of market 
differentiation. See figure IV-11.  
 


















Phase 5: The vision of closed loop (2001-2005) 
Insulin industry 
The reorientation of the industry towards the diabetes Type 2 market continued. Hence, the long-
acting insulin analogue Lantus®, launched 2000 by Aventis, gradually gained market share as typical 
insulin for treating Type 2 diabetes, since it was marketed as a ‘once-daily’ insulin, implying a simple 
and easy-to-understand treatment regime. In 2003, Lantus® had gained a 14.6% market share of the 
Western insulin market (USA-Europe), mostly based on sales in the U.S. This corresponds to sales 
revenues for Lantus in 2003 of 569.4 m$ in Europe and U.S.A. (Hamilton, 2004). Also other insulin 
analogues gained increasing market acceptance. Thus, in 2002 Eli Lilly’s fast-acting analogue, 
Humalog® (introduced 1996), passed the sales of the previously leading insulin product, the human 
insulin Humalin® in the U.S./E.U. market (Hamilton, 2004).  
To address the exploding Type 2 market segment, the diabetes companies aimed for developing new 
drugs, first of all the hormone GLP-1 (glucagon-like peptide-1), which is well suited for treating early 
Type 2 diabetes, before the onset of insulin treatment. GLP-1 lowers the blood sugar level in a stable 
and slow-acting way, without the risk of hypoglycemia, which always is present when treating with 
insulin.  A 2004 report states: “Future growth drivers include the non-invasive insulins [e.g. inhaled 
insulin]…and the glucagon-like peptide-1 (GLP-1)” (Hamilton, 2004, p. 13). In 2005, Eli Lilly 
introduced the first GLP-1 drug, Byetta®, licensed in from Amylin Pharmaceuticals. Novo Nordisk 
was several years behind in the development of their GLP-1.  
However, Novo Nordisk was still successful in pushing the market towards devices. By 2002, insulin 
sold in cartridges for durable devices or in prefilled devices had overtaken insulin sold in traditional 
vials; 52% of the global volume of insulin was now sold in devices (according to internal statistics). 
Novo Nordisk especially pushed the prefilled insulin systems (NovoLet® and FlexPen®). During the 
5-years period 2000-2004, the total market growth in volume of insulin sold was 0% annual growth 
for insulin in traditional vials, 7% for insulin in cartridges for durable pens systems and 16% for 
insulin in prefilled pen systems.  
Novo Nordisk had also success in other ways. Besides the device-based strategy, an increased sales 
effort in the U.S. resulted in Novo Nordisk these years taking over the position as the world’s largest 
insulin manufacturer, leaving Eli Lilly as number two. 
In 2004, Aventis (including the insulin activities of the former Hoechst) was acquired by the French 
pharmaceutical company Sanofi-Synthélabo, forming Sanofi-Aventis. This merger gave financial 
power to the third largest insulin manufacturer.  These three companies (Novo Nordisk; Eli Lilly; 
Sanofi-Aventis) now totally dominated the global insulin market. However, a new player had found 
an entrance: In 2004, the pharmaceutical giant Pfizer licensed in the development project for inhaled 
insulin from Nektar Therapeutics. Inhaled insulin was foreseen to have great advantages in the Type 




The change of strategy began at a special workshop in 2000 for the team of corporate managers from 
Operations (production, sales and marketing). The background was discussions in the 
pharmaceutical industry about diversifying from medical drugs into total healthcare solutions, as 
well as general attention to potential revolutions in diabetes treatment. The workshop was ignited by 
input from an external management professor on topics around possible future changes in diabetes 
treatment: What could change the whole business model? What were the unique strengths of Novo 
Nordisk? Why didn’t Novo Nordisk set more outrageous ambitions for diabetes control and 
convenience for the patients? Why didn’t Novo Nordisk play the role as system integrators and then 
deliver the most convenient products to the patient? – During the next half year, a taskforce driven 
by managers outside the device area made a detailed plan for a new device organization. After some 
consideration, the Executive Management Committee approved the plan and released the funding.  
The new device strategy was based on the so-called ‘closed loop’ vision: A system mimicking the 
functions of the healthy body by combining an insulin delivery system with a blood glucose 
monitoring system. This meant that the monitoring of the blood glucose level and the infusion of the 
needed amounts of insulin could be maintained automatically in a ‘closed loop’ of delivery and 
feedback. “Closed loop was broadly discussed in the diabetes society – it was like the ‘holy grail’ of 
diabetes treatment”, as a key informant put it. The ‘closed loop’ might resemble the 1988 vision of 
‘homecare’ (see figure IV-5). However, the big difference is the continuous monitoring of blood 
glucose and infusion of insulin, carried out by a more or less automatic system. Thus, to construct 
‘closed loop’, the devices had to move from mechanical products to ‘intelligent products’, enabled by 
electronics and software solutions. Detailed business plans were created for the needed development 
projects, and the emphasis was on business creation, since the strategy again (like in the MSD phase) 
opened for entering the market for glucose monitoring. “Yes, we wanted to develop total systems. 
Everything, the patient needed to control his/her blood glucose level. We wanted to be a ‘one-stop-shop’ 
to diabetes”.  
A Financial Times report from 1997 might shed light on the background behind these visions (my 
emphasis): “The trend has been towards greater product sophistication: urine testing has largely 
been superseded by blood monitoring, and insulin syringes are rapidly giving way to user-friendly 
injector pens. … In the more distant future, hi-tech monitoring systems could transform implantable 
infusion pumps into a functioning artificial pancreas”. “However, the main opportunities in the near 
future lie in the exploitation of new technologies, particularly for noninvasive glucose monitoring, 
especially continuous monitoring; and in more rapidly absorbed types of insulin, probably as inhaled 
insulin.” “The market leaders of the future are likely to come from alliances already formed between the 
producers of insulin delivery products and the manufacturers of monitoring systems.”  “A number of 
alliances have recently been formed between manufacturers of insulin, insulin delivery systems, and 
monitoring systems…These strategic moves are expected to lead to a new generation of diabetes 
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products based on noninvasive monitoring technology and improved, probably in vivo, insulin delivery 
systems.” (Adamczak 1997, p. 3-4). 
The systemic strategy, including glucose monitoring products, was envisioned to multiply the 
revenue from every diabetes patient, a so-called ‘value upgrade’, which in the strategy documents 
was related to the market evolution created by the introduction of insulin pens. One of the key 
persons involved comments: “Novo Nordisk could get a bigger share of the pie via diversification into 
other parts of the diabetes market. And the executive committee saw that if anybody could do this, it 
was us. Also the board of directors approved that we should be more expansive”. The needed 
competencies for developing new glucose monitoring devices and for the system integration were 
envisioned to be partly sourced in from external partners, partly built up via resource upgrades. Also 
acquisitions of specialized firms were considered – but in each case given up.  
An informant, who assisted the creation of the new strategy, lists three main factors as driving the 
plans: 
1. The vision of medical devices seen as ‘the third business leg’ (stemming all the way back from 
Nordisk in the 1980’s and the MSD period) had not been forgotten. 
2. CGM: Continuous Glucose Monitoring, was introduced in 1999. Instead of single blood 
glucose measurements, a device could continuously measure the glucose level in the 
subcutaneous tissue, thereby enabling the patient to see the glucose level at any time, as 
easily as seeing the time at a watch (in principle).  
3. The insulin pump market now grew rapidly (around 40% p.a.), driven by new types of 
pumps being introduced. The pumps represent the other side of the ‘closed loop’: the 
continuous insulin infusion.  
The responsiveness from corporate top management to the new visions was influenced by optimism 
following the establishment of Novo Nordisk as an independent pharmaceutical company in 2000, 
where the enzyme business was demerged. Yet another factor was the fear of being left behind by 
competitors, in case they succeeded in exploiting the new technologies: “If they succeeded, then we 
could risk getting reduced into suppliers of this muddy liquid, which was inside the pumps and devices, 
which were controlled by others”.  
The top management team, coming from the Health Care part of Novo Nordisk, was new in the role as 
a corporate management team.  The new team saw the logic in the proposed strategy plans for lifting 
the device research and development activities out of Production; “time was against having the R&D 
of Medical Systems placed in Production”, as an informant says. Hence, device production and device 
R&D were separated, and the device R&D activities were moved from Production to the corporate 
R&D function. The two existing R&D units, the drug areas Discovery and Development, respectively 
responsible for early drug research and late drug formulation, were thereby supplemented with a 





Figure IV-12. The device R&D unit, Protein Delivery Systems, placed in corporate Research & Development 
from 2001, in parallel to the two drug units, Discovery and Development. 
 
A drug formulation department from the drug Development unit was transferred to PDS to ensure 
better system integration. PDS was publicly announced in August 2001, and the plan was to double 
up of the device related R&D activities. A part of the expansion was due to formal start up of a 
technology research unit for devices – such research previously had been embedded in the product 
development projects. Protein Delivery Systems was presented with these words in the annual 
report for 2001: “Novo Nordisk has committed itself to leadership in drug delivery. One primary 
research area is Protein Delivery Systems (PDS), and a new unit has been set up to develop innovative 
methods of administrating insulin and other therapeutic proteins. In practical terms, PDS combines 
Novo Nordisk’s expertise in diabetes protein formulation and insulin injection systems, for developing 
convenient and fully-integrated protein delivery systems for patients in several therapeutic areas. The 
unit focuses on injections devices, advanced continuous infusion systems and glucose monitoring 
systems.” In the same annual report, there’s a 3-page long article on “Leadership in insulin delivery 
devices”. 
For the new corporate management team, the creation of PDS was also a way of opening a window 
for making medical devices a business of its own. I let an executive informant explain: “When we had 
carried out the split of the company in 2000, and we had experienced the boost in motivation it gave to 
make a sharper, better defined profile and strategy for the company…with some vision one could 
imagine the company from 2000 develop into a device company, a diabetes company and a biopharm 
company. It’s three different business areas, three different types of innovation and risk – therefore one 
could imagine that it would attract different types of investors…With PDS there was an ambition that 
we could sell our device knowledge and make it commercial to other companies. We believed that we 
were world champions within devices, so there ought to be somebody who could make use of this. One 
should also not exclude that we would actually learn something from working together with partners”.  
However, in 2002 the new corporate executive team was shaken by a crisis. The sales revenue for the 
first quarter of 2002 did not live up to the expectations – it even was necessary to announce a profit 
warning and adjust the budgets for the whole of 2002. An executive informant comments: “This 
implied a breach of confidence. The causes were partly internal – there were things, which we could do 
better, our internal control and forecasting systems probably were too poor – but it was also the global 
economy; it was just after 9-11 in 2001, which had provoked a sudden depression”. Furthermore, in the 
summer of 2002, a research project for tablet treatment had to be terminated, due to cancer risk. The 
annual report for 2002 begins with the words: “The year 2002 has been a very challenging time for 
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Novo Nordisk. On 10 April 2002 we announced that due to unexpected factors, full-year performance 
was not likely to meet our previous guidance”, and states on the same page “On 22 July 2002 we 
suspended the phase 3 trials of ragaglitazar (NN622), a promising dual-acting insulin sensitiser. This 
was done based on urine bladder tumour findings in one mouse and a number of rats.” The 
confrontation with these problems of course had implications for the new corporate management 
team. An executive informant comments: “I think we got a rap on the knuckles as new management 
team in 2002. It made us swear that we should show them that we, damn it, could manage – so there 
was not much internal wrangling or fighting, we simply wanted to survive and show that we could do it. 
Therefore, we have had a high degree of continuity and internal trust within the team”. One of the 
effects of the events in 2002 was the retreat from development of tablet treatment.  An executive 
informant explains: “We decided to concentrate on what we were good at, namely proteins. So no more 
synthetic chemistry and small molecules… It was partly a reaction to the NN622 project, which was 
stalled in 2002. We had a large portfolio of these projects; therefore it took some years to withdraw. But 
it showed that there was increasing distrust in this whole class of drugs, so we decided to stop”. 
According to the same informant, the combination of financial problems and drug research problems 
in 2002 turned the corporate management team into a more conservative or internally oriented 
mode of management: “In the following period, we strengthened our control and forecasting systems, 
and the whole management team focused on basic issues to ensure that we had a good understanding of 
our markets and where we were going. That was perhaps also a reason behind that it took so long time, 
before we took the strategic decision to terminate the research within small molecules. Remember, at 
the same time the dollar exchange rate decreased dramatically, so we needed to increase our 
productivity, because many of our expenses are paid in Danish currency. So this was principally a period 
with internal focus in order to become better at controlling the business and increase our productivity 
because of the weak US dollar…We overcame both the breach of confidence and the productivity crisis”.  
In such management climate, risk willingness of course decreases, and this development hit back on 
the ambitious visions behind PDS, comprising complex ‘closed loop’ systems and business creation 
based on devices. I will let an executive informant explain the change in management view: “We saw 
that there were problems within devices in getting new versions [of existing products] ready, and on top 
of that we were engaged in much more complicated devices, which we from desk analysis thought would 
be fantastic, including ideas of closed loop and all this. We made this integration of Innov®o and BGM, 
it was called InDuo®, but we were not able to do it in a way, which was accepted by the market. The 
market turned towards more simple and convenient solutions – injections once daily, disposable devices 
etc. And in the end, we also moved in that direction, because we said ‘enough with all these complicated 
things’. We decided that we should not serve people outside our own business as long as we had 
problems with developing our own devices, which were one of the competitive advantages of Novo 
Nordisk.  So as result, PDS was folded back again and we said ‘this is an internal part of Novo Nordisk 
and we don’t sell devices to others’”. This development in top management cognition implied a melt-
down of PDS in the years 2004-2005.   
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Medical device level 
With PDS, Novo Nordisk again aimed at entering the blood glucose monitoring market. This time the 
entry ticket was new continuous glucose monitoring technologies – that was, measuring the glucose 
level via a three-day sensor, which was inserted under the skin, instead of the single measurements 
via finger pricking. These technologies were premature, and the development had highly explorative 
character.  
R&D for inhaled insulin was still carried out by the partner Aradigm Corporation in the U.S., but from 
2004 Novo Nordisk took full ownership of the project by acquiring Aradigm Corporation. The project 
remained in the U.S., organizationally anchored in Novo Nordisk at Product Supply (i.e. Production), 
but PDS began to play a more active role in the development than the device area had previously 
done. This so-called AERx project continued to require massive investments. 
According to some informants, the PDS strategy left little attention to the need for lifecycle 
management of existing products; that is maintaining the existing products with continuous 
improvements (often production-wise) or developing new versions with incremental improvements. 
One informant says “There were skeptical people saying that we would risk losing our leading position 
in our core area. I guess this partly also happened. For a time we did not develop ‘engines’ for our 
injection pens. I guess it gave some sort of set-back. On the other hand, top management was not willing 
to increase the frequency of introducing new pen generations”. An executive informant puts it: “We 
kind of diluted the classical virtues – our resources within the classical disciplines – in such way that we 
lost momentum. And at the same time we placed our resources in high risk areas; it was too much ‘blue 
sky’ – we were too optimistic, we believed the solutions were just around the corner.” A development 
engineer comments: “We were happy to become a part of R&D; that’s where we belong. But the closed 
loop visions – well, it’s easy to write down such buzzwords…”. The latter statement represents a critical 
attitude towards the new strategies, which was widespread in the device area; remember that the 
strategy plans for PDS were developed outside Medical Systems. A device manager expresses it: “The 
establishment of PDS was not our choice [from Medical Systems]. It was driven from the top and by 
consultants with business plans for ambitious product areas – this was driving it, rather than knowledge 
on technologies. They were very little attentive to allocating resources for maintaining our injection 
systems. It was business plans all over”. 
Besides this internal skepticism, the ambitious strategies ran into some other challenges, namely the 
2002 crisis (see above). One of my informants comments: “It was an annus horribilis”, and continues: 
“Then we were in a chaotic situation with regards to financing our R&D activities – what did we really 
want? – which path should we follow? – with regards to drugs as well as devices. The whole trend was 
like: perhaps we should move back to basics, meaning only bet on insulin and GLP-1 on the drug side 
and injection devices on the device side…”  
This ‘annus horribilis’ had implications for the strategies of PDS. Initially, it was planned to acquire 
specialized companies within both continuous glucose monitoring and continuous insulin infusion in 
order to build on their competencies and technologies. The chaotic situation meant a setback in the 
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willingness to invest in such companies. Consequently, the only available way forward was in-house 
development. However, the complexity and risk of the projects had been underestimated, according 
to an informant; the technological challenges were much harder than envisioned. Hence, the 
continuous glucose monitoring project was given up in 2004, which was a de facto strategy change, 
as seen by a device manager. Furthermore, the drug formulation unit, which had been integrated into 
PDS, was transferred back to the drug development area to ensure the development of a GLP-1 drug, 
leaving PDS back with the device competencies solely.  The skepticism towards the ‘closed loop’ 
vision increased and the visionary strategy behind PDS slowly was falling apart: “the dream about the 
role as system integrator died”, as stated by an informant. “The PDS visions were like romantic 
dreams”, as another informant stated it. This informant also points to the existence of different power 
bases behind respectively the initiation and the closure of PDS: The closed loop strategy behind PDS 
was driven by Operations (production, sales and marketing), who did not focus on the risk of such 
radical innovation projects – “they did not assess the scientific reality”, as he puts it. According to this 
informant, the withdrawal from the closed loop strategy was driven by R&D.  
On top of these internal factors, which gradually made the PDS strategy fall apart, the competition in 
the traditional insulin device market began to threaten Novo Nordisk’s leading position in devices. As 
result, reorganization was carried out in the summer of 2005. 
Concluding on the evolution of the PDS strategy (2001-2005) 
The second ‘revolutionary’ period (after the MSD period 1988-92) was initiated as result of a 
reasoning process, which can be traced back to a particular management seminar at an international 
business school in the summer of 2000. The strategy was then worked out via desk analysis during 
the next half year, driven by a management team outside the device area, supported by external 
consultants. The aim was to create advanced ‘closed loop’ systems and to include more elements of 
the value chain of diabetes care into a ‘one-stop-shop to diabetes’, just like in the MSD period. Hence, 
this top management driven, theory-based process in content was a truly autonomous strategic 
initiative; because it explored product-markets outside the existing strategy (cf. Definitions).  
The vision was again to create a business of its own, based on the competencies within medical 
devices, which eventually could be demerged as a separate company. Thus, medical devices changed 
role from complementary to core assets for innovation.   
Some inputs from the external environment played a role. Other pharmaceutical companies had tried 
integrating more elements of the value chain the years before (e.g. Lilly buying a distributor 
company), so vertical integration was seen as a potential trend, which might alter the market. Also 
the emergence of Continuous Glucose Monitoring in 1999 was seen as a potential threat, in case 
other companies would be able to develop integrated solutions, which would reduce Novo Nordisk’ 
role in the value chain to supplier of ‘muddy liquid’. In conclusion, the transition into the PDS strategy 
was partly ignited by external factors, such as the potential future competitive landscape, in case the 
competitors succeeded with their initiatives. However, the external drivers were again mediated by 
management interpretation; top management reacted to the perceived potential risk.  
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The strategic learning cycle of PDS is a straight-forward theory-driven search for technologies, based 
on the visions of ‘closed loop’ and ‘one-stop-shop to diabetes’, resulting in explorative innovation 
activities, which never succeeded; hence the reinforcement from the experiences was negative. See 
figure IV-13. 
 






















Phase 6: Integration into the drug research area (2005-
2008) 
Insulin industry 
Eli Lilly introduced the first GLP-1 drug, Byetta®, in 2005, and this totally new drug category grew in 
popularity driven by the increased Type 2 diabetes prevalence: September 2008, more than 6.6 
million prescriptions had been dispensed14 and the sales had reached 0.59 billion USD15.  
In 2006, Pfizer introduced the world’s first inhaled insulin, Exhubera®. This product was, however, 
withdrawn again from the market by yearend 2007 due to slow market acceptance and concerns 
about increased risks of longue cancer. As a consequence, Novo Nordisk stopped its development 
project for inhaled insulin (AERx) from January 2008.  
Sanofi-Aventis, who already had massive success with their Type 2 targeted insulin Lantus®, in 2007 
launched this drug in a new prefilled device, called Solostar®, which was perceived as being on par 
with the FlexPen® from Novo Nordisk. For the first time, Novo Nordisk did not have absolute device 
leadership.  
Tablet treatment for Type 2 diabetes ran into problems. Several new products showed to have side 
effects of increased cancer risk. These problems resulted in growing interest for insulin and GLP-1 
treatment in the fight against the explosion of Type 2 diabetes.    
Corporate management cognition 
When asked if he regretted the PDS period, an executive informant replied: “Yes and no. I of course 
could regret that the PDS period implied that we got a bit behind within the classical disciplines, 
because we had a different focus. The reason why I don’t regret it is that it meant renewed focus on the 
drug delivery part, which we lacked; it gave the device area a feeling like ‘we are somebody – they count 
on us, we are important, we are an organization with independent responsibility’ and so on. And I think 
it also created some thoughts at corporate management that this [device] innovation needs attention. It 
should not just be an appendix to the drug; it is in itself a differentiating factor. So I don’t think PDS 
lived in vain”.  






14 Source: FDA (2010-06-26 at) 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm
113705.htm  
15 Source: http://www.faqs.org/periodicals/201001/2019750421.html, accessed 2011-06-25 
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The organizational response to the failure of the PDS strategy was to integrate devices within the 
drug research, which until then had been organized in the Discovery unit. Drug research was now 
split in two functional areas: Diabetes Research Unit (DRU) and Biopharmaceuticals Research Unit 
(BRU) – the latter taking care of research within other diseases than diabetes. According to an 
informant, the reason for this split was to create transparency regarding input and output within 
each research area. The device innovation was transferred to DRU, since most of the devices were 
targeted for diabetes. An executive informant explained:  “The logic behind was to gather 
responsibility for all diabetes innovation in one place with the formation of the DRU unit”.   
The problems with side effects from new tablet treatments for Type 2 diabetes opened for an 
expansion of the insulin market. “The insulins got a renaissance” as an executive informant puts it. He 
continues: “Today you can say that the proteins have moved forward from being the severe final 
treatment to something you can apply much earlier in the treatment. Also now with GLP-1, which is 
another protein, you can perhaps even start before the onset of diabetes, to prevent the disease. This 
means that our core competence area, where we are world champions, suddenly gets a much 
broader application to many more patients – even before diabetes and perhaps for prevention, in 
future. This understanding has emerged over time” (my emphasis). The executive here explains the 
gradual growth in application of treatment of diabetes with protein-based drugs: First, insulin was 
used only for the relatively small market of Type 1 diabetes. Then, insulin got accepted for treatment 
of the much larger Type 2 diabetes market. And finally, the other protein, GLP-1, potentially opens 
the market for prevention of Type 2 diabetes.  
Medical device level 
When PDS was discontinued in August 2005, the device activities were divided into three functional 
areas, which were integrated into the new Diabetes Research Unit, DRU. Besides the device activities, 
DRU consisted of the drug research areas from the former Discovery unit. See organizational chart in 





Figure IV-14. The device area placed as three VP areas within DRU, from August 2005. 
 
The strategy for DRU was to secure the leadership of Novo Nordisk within the diabetes care market by 
building on the strength and synergy of integrated drug and device development within one 
organizational unit. The core competence was termed the “value added pharmaceutical product” as a 
description of the integrated drug-device system. The activities were focused, and the most radical 
innovation projects from the PDS phase were stalled. “It was back to basics: let’s do what we are good 
at and know we can do”, as one informant commented. Another informant calls it a return to the logic 
of the period of Medical Systems (1992-2001). One can say that the new strategy was still based on 
system integration, but now only integration of drug and device using the existing product systems, 
which Novo Nordisk had introduced two decades ago in terms of the durable and prefilled insulin 
pens. The system integration towards glucose monitoring as a parallel business to insulin delivery 
was given up.  
A statement from an informant may illustrate the integrative view: “That is our strength: we are the 
only [pharmaceutical] company, where device development is integrated; because it’s two different 
worlds [drugs and devices], and when it comes to quality and production, you can learn from devices. 
That’s the innovative and smart about it. The competitors cannot make the same quality, and it’s not 
integrated in their setup. So they’ll stay behind – at least, that’s my philosophy.” 
At project level, new drug candidates required new device innovation projects, GLP-1 being the most 
significant. To support the new drugs, a range of new device projects were started up – most were 
incremental, but also radical and explorative projects were initiated. However, within the relative 
short lifetime of the DRU phase, only few new products were launched. The only major product 
launch was NovoPen® 4 in 2006, and this rather incremental innovation project was actually started 
up years before the DRU period. The DRU phase was discontinued by yearend 2008 – for reasons, I 
cannot disclose, since these point into the next phase.  
Novo Nordisk 






















Concluding on the formation of the DRU strategy (2005-2008) 
The background for establishing DRU should be understood as a strategic retreat from the former 
PDS period. External events had large impact on the withdrawal from the PDS strategy: the financial 
shake in 2002 implied decreased risk willingness, amplified by the failure of the tablet treatment 
project NN622 (see the description of the PDS period). These events moved top management to focus 
inwards, on control systems, profitability etc. This was clearly a mode of exploitation (March, 1991) 
at corporate level, which of course undermined the explorative strategy behind PDS. Furthermore, 
the fierce competition within the classic insulin pens threatened Novo Nordisk’s historical device 
leadership, and also this external factor drove management towards a retreat from the explorative 
‘closed loop’ strategy.  
Another external event was the failure of certain competitors’ tablet products in the market, 
displaying cancer risk, which increased the request for insulin and GLP-1 for treatment of Type 2 
diabetes. This growth opportunity might have reinforced the investment in the ‘closed loop’ strategy, 
but instead led to a return to a purely drug-based strategy. The technical problems with the advanced 
device solutions, combined with the fear of getting behind within the classic insulin pens, pushed 
management in the direction of retreat rather than investment in the PDS strategy. 
Thus, the DRU strategy was a return to a drug-based innovation strategy. Top management perceived 
the market changes as a ‘renaissance’ for the classic core competencies – therefore, the strategy of 
DRU was induced – it was ‘back to basics’, staying within the well-known territories. Similarly, 
medical devices changed role from being core assets for innovation in the PDS strategy to being 
complementary assets in the DRU strategy – seen as value-adding.  
Conclusively, the strategic learning cycle of the DRU period was anchored in a theory of ‘back to 
basics’, which again was a result of negative reinforcement of the PDS strategy. Since the process held 
an element of learning from the mistakes of the previous period, one can see the evolution as 
experience-based, learning from trial-and-error. The strategic search of DRU aimed at exploitation of 
the classic skills. See figure IV-15.  
 





















Part 2: The product innovation portfolio 
 
A basic trait of corporate strategy is the existence at two levels, or in two realms: in the mental realm 
of reasoning, or ‘theory,’ and in the physical realm of action, or ‘practice’.  The current research 
project builds on the understanding that strategy making evolves in learning cycles between these 
two realms. Consequently, it is highly relevant to check the empirical validity of this presupposed 
connection: are changes in innovation strategy and changes in the actual innovation activities linked? 
Or do these realms exist independently of each other? 
To conduct such empirical study, we need indicators of changes in strategic vision, or ‘theory’, on the 
one side; and the actual activities on the other side.  
Changes in the ‘theory’ of strategy can be traced via changes in the formulated innovation strategy, as 
identified via the interviews. A more objective indicator is changes in the organizational structure, 
since these often reflect changes in strategy (cf. Chandler, 1992). An interesting question here could 
be to examine, which of these indicators (changes in the content of the formulated strategy; or 
changes in the organizational structure) that shows the highest interrelatedness with changes in the 
actual activities.  
The composition of the device innovation project portfolio serves as indicator of the actual innovation 
activities. The portfolio of device innovation projects is analyzed throughout the studied period 
(1980-2008). By the collection of historical data, 102 device development projects were identified. 
Sufficient information for data analysis could be gathered for 95 of these (such as the nature of the 
project, year of start-up and year of project termination / product launch). 37 of these 95 projects led 
to new product launches within the studied period (39%). 43 of the 95 projects were terminated 
(45%). 15 projects were still ongoing by yearend 2008 (16%). When analyzing the nature of the 
project portfolio, two indicators seem especially relevant: a) the portfolio of ongoing projects (= the 
number of projects in operation per year); b) the portfolio of projects initiated in a given year. Also 
here, it is interesting to see, which of these indicators that shows the strongest relationship to the 
envisioned strategy.  
For classification of the projects throughout the historical evolution, the concepts of autonomous and 
induced initiatives (Burgelman 1991, 2002) are applied.  Burgelman & Grove (2007) make a similar 
attempt to classify the historical innovation activities at Intel as respectively induced or autonomous, 
measured by the relative deployment of development resources at critical times in Intel’s evolution 
(Burgelman & Grove 2007, table 2), estimated by Andy Grove based on personal experience and 
company documents.  The relative deployment of resources for autonomous initiatives in their 
assessment varies from 13 to 50% at different times in Intel’s history. Unfortunately, I did not have 
access to data about the resource deployment at the different epochs of Novo Nordisk’s device 
innovation activities, so I could not make a comparable assessment. However, it is interesting in itself 
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to see if a similar assessment of the balance between autonomous and induced activities can be 
established using the project portfolio as indicator.  
Definitions 
For practical categorization of development projects, the definitions in Burgelman (2002) are 
applied: “Induced strategy exploits initiatives that are within the scope of a company’s current 
strategy and that extend it further in its current product-market environment. Autonomous 
strategy exploits initiatives that emerge through exploration outside of the scope of the current 
strategy and that provide the basis for entering into new product-market environments” (p. 327; 
my emphasis). Based on the emphasized parts, the device development projects are classified as 
‘induced projects’, if they aim for developing products within the product-market categories currently 
established by Novo Nordisk at the given time in history; and as ‘autonomous projects’, if they aim for 
developing products outside the product-market categories currently established by Novo Nordisk at 
the given time in history.  
For the empirical classification, the intended aim of the development project is related to the 
product-market categories currently established by Novo Nordisk by the year of start-up of the 
project. This method results in relative high percentages of autonomous initiatives, compared to 
Burgelman & Grove (2007), because of the long development cycles in the pharmaceutical industry. 
If we for example take the new drug type GLP-1, Novo Nordisk launched its first product, Victoza®, 
in 2009, using the existing FlexPen® device. Taken by my empirical definition, all device innovation 
projects aiming for a device for GLP-1 that were started up before the launch of Victoza® in 2009 are 
therefore categorized as autonomous, since the product category was not yet established by Novo 
Nordisk. Hence, this empirical definition does not take into account at what time GLP-1 became a 
part of the intended corporate strategy (which would have been more correct for defining the degree 
of strategic alignment) – but such decisions can be almost impossible to track historically. By using 
the first product launch as the distinguishing year for the establishment of a new product-market, I 
get a pragmatic grip for the empirical classification.  
The nature of the development projects is below related to both structural periods and strategic 
periods. Structural changes are defined as restructurings, in which the entire device innovation area 
at Novo Nordisk is moved around within the Novo Nordisk organization. Internal restructurings 
within the device area are disregarded. Structural changes are identified via the organizational 
charts. Strategic changes are defined as changes in: overall vision for or purpose of the device area; 
targeted customer segments and value proposition; field of activities; source of revenue. Changes are 
identified via statements in interviews and archival data. 
Expectations 
From my empirical definition of induced and autonomous, it is self-evident that the start-up period of 
the device activities would hold mostly autonomous projects, since the product categories first had to 
be established in the market and the strategy had to be institutionalized. For example, until the 
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launch of the first durable insulin pen (NovoPen®) in 1985 and the first prefilled insulin pen 
(NovoLet®) in 1989 all projects within these two categories were autonomous. Once these product 
categories were established, one could expect the relative number of autonomous projects to 
gradually decline; until the strategy was altered next time, most activities would aim for developing 
improved versions of the already established product categories (staying within the strategic frame). 
If – and only if – the strategy for the device innovation was changed and opened for exploration of 
new product-markets, one could expect to see changes in the nature of the development portfolio in 
the form of increased autonomous activity. As known from the historical case study in the previous 
sections, there was only one such strategic change after the initial institutionalization of the device 
strategy in 1988, which opened for entering new product-markets: namely the PDS strategy, 
formulated in 2000, implemented in 2001. The other strategic changes turned the strategy back to 
already established positions and capabilities within durable and disposable insulin pens. Hence, one 
could expect two peaks in autonomous activity: the early phase, up to the institutionalization in 
1988, eventually including the MSD phase, and then again in connection with the establishment of 
PDS. The rest of the periods would be expected to be colored mostly by induced activities.  
Basic measurements 
The structural changes were set as follows: 
1. 1988: Establishment of the Medical Systems Division. 
2. 1992: Moving the device area to the Diabetes Care Division, as Medial Systems. 
3. 1995: Moving Medical Systems to Production. 
4. 2001: Establishing Protein Delivery Systems (PDS), thereby transferring the entire Medical 
Systems R&D to corporate R&D. 
5. 2005: Moving the device R&D activities to Diabetes Research Unit. 
The strategic changes were set as follows: 
1. 1987: The strategy for making devices a separate business area, building on the vision of 
homecare centered on the patient (since MSD was established in the beginning of 1988, the 
strategy must have been formed during 1987). 
2. 1992: Termination of the homecare strategy, hereunder the disease monitoring projects and 
the insulin pumps – the new strategy only included insulin pens. 
3. 2000: The formulation of the ‘closed loop’ strategy, leading to the establishment of PDS in 
2001 (delayed only for financial reasons). 
4. 2005: Official termination of the closed loop strategy. Focus now on the ‘value-added 
product’ as the integrated device-drug system.  
The restructuring in 1995 is not included in the strategic changes, because the strategy for devices 
was not altered.  
The total portfolio of device development projects (not differentiated in autonomous and induced) is 
shown as the number of ongoing development projects per year in figure IV-16. The number of 
‘ongoing projects’ includes all projects in operation that year: some were launched as new products, 
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others were stalled during the year; and some were still ongoing at yearend. Overall, the number of 
ongoing projects increases throughout the studied period, which is partly to be explained with 
increased resource input.  
Interestingly, the development displays recurrent waves, following the structural changes: the 
number of development projects increases after each restructuring to reach a peak 2 years after (for 
the MS period 1995-2001 also displaying a second peak 4 years after), and then declines. This 
pattern shows also in the case, where the restructuring is not accompanied with strategic changes (in 
1995). I first interpreted this pattern as the effect of a motivational boost after each restructuring: 
each reframing ignites entrepreneurial activity; after some years, the ‘frame’ gets worn, and in order 
to release a new period of growth, a new reframing takes place. This way, the repetitive cycles of 
expansion and contraction (the ‘pulse beat’) form an overall growth in the project portfolio. Perhaps 
the metaphor of a hermit crab could be used: it finds a shell for protection and lives in it until the 
shell gets too constraining; then it seeks a bigger shell and drops the old. When presenting this 
interpretation of figure IV-16 to a device manager, he replied: ‘this gives a wrong picture of what 
happens; it is like as if the activity level decreases in the second part of each period. Rather, we focus the 
activities on a fewer number of projects’. His statement clearly points to the weakness of using the 
number of projects as a measure: the resource input is not visible. His explanation implies that each 
restructuring opens a ‘divergent’ period, meaning that the latitude of the activities expand and the 
possibilities of the new organizational frame are explored – then a ‘convergent’ phase begins, where 
the portfolio of projects is narrowed down in order to exploit the most viable projects. If this 
explanation is valid, we should be able to track a pattern of two peaks within each period: the project 
initiation curve should peak in the beginning of each period, and the project termination curve 
should peak in the middle or end of each period. I have analyzed the data and indeed, this 
interpretation was supported: the number of project initiations peaked either by the year of 
reorganization or the year after. The number of project terminations peaked either in the middle or 
the end of each period. It therefore seems as if organizational restructurings have an impact on the 
activities, displayed as lifecycles of exploration and exploitation, reflected in the total number of 




Figure IV-16. The total number of ongoing device development projects, year by year. Dotted vertical lines: 
Strategy changes. Full vertical lines: Structural changes. ‘Ongoing projects’ include all projects in operation 
that year – some were launched as new products, others were terminated during the year; and some were 
still ongoing at yearend. 
 
The development of the nature of the innovation project portfolio 
The nature of the project portfolio can be analyzed by using different sets of metrics. One way is to 
count how many ongoing projects that are in operation simultaneously, year by year, split in the two 




Figure IV-17. The portfolio of ongoing projects, split between autonomous and induced. Dotted vertical lines: 
Strategy changes. Full vertical lines: Structural changes. The graph indicates a cyclic pattern, which is 
analyzed in the subsequent text. 
 
To see the link between strategy/structure and the project portfolio more clearly, each 
structural/strategic phase can be characterized by the relative distribution of projects in respectively 
induced and autonomous initiatives.  Table IV-2 and IV-3 show this distribution for respectively the 
structural and the strategic periods.  













in average, per year 
2.7 6.7 5.0 4.7 10.7 11.2 
Induced projects in 
average, per year 
1.5 7.0 6.7 9.5 5.5 8.5 
Total average, per 
year 
4.2 13.7 11.7 14.2 16.2 19.7 
% autonomous per 
period 
65 49 43 33 66 57 
% induced per period 35 51 57 67 34 43 
Table IV-2. Relative distribution of ongoing projects for each structural epoch. 
Portfolio of ongoing projects (= number of projects in operation per year) 
















Value add  
2005-08 
Autonomous 
projects in average, 
per year 
3.0 5.6 4.6 9.8 11.2 
Induced projects in 
average, per year 
1.0 6.6 8.5 6.2 8.5 
Total average, per 
year 
4.0 12.2 13.1 16.0 19.7 
% autonomous per 
period 
75 46 35 61 57 
% induced per 
period 
25 54 65 39 43 
Table IV-3. Relative distribution of ongoing projects for each strategic epoch. 
 
These figures demonstrate that structural and/or strategic changes are in fact correlated with the 
distribution of development projects between autonomous and induced activities. In both tables, the 
percentage of autonomous projects starts at a high level (65% for structure and 75% for strategy), 
where after it decreases as expected until the ‘closed loop’ strategy results in establishment of PDS, 
where it jumps to a new height (66% for structure and 61% for strategy), to decrease after the 
termination of PDS. The distance between the lowest and highest percentage of autonomous projects 
is respectively a factor 2.0 for structural evolution (from 33 to 66%) and 2.1 for strategic evolution 
(from 35 to 75%).  This evolution of the portfolio is graphically shown in figures IV-18 and IV-19. 
 
 
Figure IV-18. The relative distribution between ongoing autonomous and induced projects during the 
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Figure IV-19. The relative distribution between ongoing autonomous and induced projects during the 
shifting strategic epochs. 
 
The above statistics were based on the average number of ongoing projects per year. However, one 
could argue that ongoing projects not necessarily reflect the current strategy; projects are not so easy 
to kill, when they first have a business case, technological feasibility and a handful of missionaries to 
fight for their ‘child’ – thus, a project might often survive in spite of a changed strategy. Therefore, 
you only see a gradual decrease in autonomous activity over several phases, after each peak created 
respectively by the early attempts and by the PDS strategy. Some of the autonomous projects ‘hang 
out’ after the bar had closed, so to speak.  
Following this logic, the impact of strategy on the product innovation portfolio is best obtained by the 
number and nature of the projects initiated, year by year. This is shown below in figure IV-20. 
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Figure IV-20 The number of initiated projects per year, split between autonomous and induced. Dotted 
vertical lines: Strategy changes. Full vertical lines: Structural changes. The evolution is analyzed in the 
following. 
 
Furthermore, similar calculations as above have been made concerning the relative percentage of 
autonomous projects among the population of projects initiated year by year. Table IV-4 and IV-5 
below display the results.  
 













projects initiated in 
total 
6 9 2 9 12 7 
Induced projects 
initiated in total 
5 9 8 16 4 8 
Total initiated 
projects per period 




55 50 20 36 75 47 
% induced projects 
initiated per period 
45 50 80 64 25 53 







    

















































Value add  
2005-08 
Autonomous projects 
initiated in total 
6 9 10 13 7 
Induced projects 
initiated in total 
4 10 22 6 8 
Total initiated projects 
per period 
10 19 32 19 15 
% autonomous projects 
initiated per period 
60 47 31 68 47 
% induced projects 
initiated per period 
40 53 69 32 53 
Table IV-5. Relative distribution of projects initiated for each strategic epoch. 
 
The observation that the initiated projects might provide a clearer ‘portrait’ of a strategic/structural 
period than the portfolio of ongoing projects is confirmed in the sense that the variance between the 
values is higher for the initiated projects.  The pattern is the same: Starting with a high degree of 
autonomous activity, then decreasing until a jump in connection with the formation of PDS, 
thereafter decreasing again. The structural periods display the period of crisis in 1992-94 as a 
significant low of only 20% autonomous activity, whereas PDS jumps to an all-time high of 75% (a 
variance of a factor 3.75).  The strategic periods have same pattern, but vary less; from 31 to 68% 
(factor 2.2). This difference in variance can be explained: the structure was changed in 1995 (to a 
new functional corporate structure) after having overcome the quality crisis, whereas the strategy 
for devices was kept focused on basic insulin devices all the way from 1992 to 2001. Since the 
strategy period thus covers a longer time span, the variance in portfolio gets leveled.  The patterns 





Figure IV-21. The relative distribution between initiated projects in autonomous and induced during the 
shifting structural epochs. 
 
Figure IV-22. The relative distribution between initiated projects in autonomous and induced during the 
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Conclusion on the development of the project portfolio 
The composition of the project portfolio developed as expected: The ratio of autonomous projects 
was high at the entrance to the medical device activities, and then decreased until a peak in 
connection with the launch of the new autonomous PDS strategy in 2001. After termination of the 
PDS strategy, the ratio of autonomous projects decreased again. So, the product innovation activities 
(strategy in ‘practice’) and the formulated strategic intent (strategy in ‘theory’) were actually linked.  
When analyzing the interrelatedness between strategy in ‘theory’ and strategy in ‘practice’, we can 
do it both ways:  
 Going out from practice (i.e. project portfolio): For the total portfolio of ongoing projects 
(i.e. the total number of projects in operation in a given year), the strategic epochs provide 
higher variance in the balance between autonomous and induced projects than the structural 
epochs. For initiated projects, the structural epochs show higher variance than the strategic 
epochs; this can partly be explained by shorter lifecycles of organizational structures 
compared to the strategy lifecycles. 
 Going out from ‘theory’, as expressed either in strategic or structural epochs: The initiated 
projects provide higher variance in the balance between autonomous and induced projects 
than the total number of ongoing projects, for both strategic and structural epochs. This 
stronger link between strategic intent and project initiation (compared to the total ‘stock’ of 
projects) confirms the basic idea that new strategic visions imply new activities.  
We can also conclude that it is in fact possible to establish an assessment of the balance between 
autonomous and induced activities using the composition of the project portfolio as indicator: the 
nature of the project portfolio, classified in autonomous and induced projects, depends on the nature 
of the innovation strategy. Autonomous strategies indeed cause a significant higher ratio of 
autonomous innovation projects.  
An interesting observation is the cyclic development: that each organizational restructuring implies a 
period of exploration, where many new projects are started up, until a peak in project closures marks 
a period of exploitation, in which the number of project initiations decreases (because the portfolio is 
focused), until the next restructuring starts a new cycle. These cycles in the number of initiated 




Part 3: Close-up analysis of device level 
dominant logic 2007 
Since strategy framing is heavily influenced by the dominant general management logic of a company 
(Prahalad & Bettis, 1986), the case study includes a real-time study of the management cognition on 
innovation at the device area of Novo Nordisk, in order to determine the local ‘dominant innovation 
logic’.  The data capturing was done via in-depth interviews of a representative sample of 10 device 
level managers in 2007. Thereby, a ‘snapshot’ of the management mindset could be established. The 
method used is described in Chapter 3 and Appendix A.  
At the time of the interviews, the device innovation activities were organized as three functional 
areas within the drug research unit, Diabetes Research Unit, DRU (see previous sections), which was 
characterized by an induced strategy. 
Findings 
The findings are presented in table IV-6 below in the form of synthesized statements from the 
interviews. Only statements, which were supported by at least 5 of 10 managers, have been included, 
since the aim was to capture the ‘dominant logic’ (Prahalad & Bettis, 1986); statements with at less 
than 5 of 10 supporters are below ‘dominant’.  
The synthesized statements from table IV-6 were condensed further into the following portrait of the 
dominant innovation logic at device R&D management level at Novo Nordisk in 2007: 
 
The general management logic at Device R&D 
 The business driver is the pharmaceutical drug; and we are as a company driven forwards by 
competition from pharmaceutical rivals 
 Our core capabilities comprise user and market understanding; development of high quality 
products; and linkages to the Novo Nordisk organization 
 Our primary customer is the end user, to whom we offer increased quality of life. 
 
The innovation management logic at Device R&D 
 The primary innovation enhancer is competition within the industry 
 The primary innovation barriers comprise low risk willingness due to the ‘success trap’ (i.e. 
because of the vast success of the company, it is too risky to change anything – “don’t rock 
the boat”); and a culture and processes geared to ‘mainstream’ business  
 Consequently, our development portfolio is ‘mainstream’ = incremental innovation 
o And real breakthrough innovation would require alternative organizational setups 






THE FOUNDATION OF OUR BUSINESS 
 
Our value offering 
Our primary customer is the end user, i.e. the patient, to whom we offer the following value propositions: 
 Quality of life / lessen burden of living with diabetes 
 Convenient treatment systems 
 Easy and simple drug administration  
 Trust in quality and safety of our products  
 
Our business 
The business model is based on profit from the pharmaceutical drug and the drug is the business driver. As a 
company, we are driven forwards by our competitors, again based on the drug as the primary market driver. 
Our main competitors correspondingly are pharmaceutical companies, first and foremost Sanofi-Aventis and Eli 
Lilly, secondary Pfizer [inhaled insulin]. 
 
Our capabilities 
The core capabilities within the device area are, in order of importance: 
 User and market understanding  
 Ability to produce high quality products  
 The link to the pharmaceutical side of the business   
 Our integration into the Novo Nordisk organization   
 Our long experience within the field of medical devices, which has led to a specific culture around devices 
 Our technical product knowledge   
 
Our organization 
When considering if the device area could benefit from being an independent company, the answer is no; we 
need the integration with the rest of the Novo Nordisk organization. 
Our organizational identity is associated with a high quality image and solidity. 
 
 
OUR INNOVATION ACTIVITIES 
 
We see the following enhancers and barriers with regards to device innovation: 
 
Innovation enhancers primarily consist of the pressure from competition within our industry. 
Innovation barriers are several: 
 Our own organizational set-up and management systems often block new ideas 
 Our position as market leader; i.e. we are caught in the ‘success trap’: it’s too risky to change anything  
 Limited resources and lack of prioritization  
 Our culture and processes are geared to being ‘mainstream’ and therefore may hinder innovation 
 We are as an organization not willing to take risks  
 




OUR INNOVATION IN THE FUTURE 
 
As we see it, we could benefit from experimenting with our organizational set-up, e.g.: 
 ‘Sandbox approach’, setting up a creative sub-unit for early innovation 
 Independent units like R&D satellites or incubator units, for the more radical innovations 
Further, we think we should strengthen the project portfolio in terms of more early options, researching 
technologies. 
 
Table IV-6. The synthesized statements from the 10 interviews at the device management team in 2007. 
Concluding on the ‘dominant innovation logic’ 2007  
The ‘dominant innovation logic’ extracted here is a manifestation of the formal strategy formulation 
about the “value-added pharmaceutical product”, which again summarizes the perceived business 
synergy between the core pharmaceutical drug and the complementary medical devices. This 
integrative view on the value offering could be seen as synthesis of decades of learning from 
swinging the pendulum back and forth between drug-based and device-based innovation strategy.  
Another observation concerns the longitudinal perspective.  Where the innovation strategy for 
medical devices at Novo Nordisk has shifted between emphasis on either support to the 
pharmaceutical drug or creation of a business on its own, the ‘dominant logic’ of the pharmaceutical 
company, rooted back in the initial identity of the organization, seems robust; it is still retained in the 
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interviews from 2007, in the sense that devices are perceived as supportive or complementary to the 
overall Novo Nordisk business – no visions of making devices a business of its own are expressed. 
However, all interviews were conducted within one specific strategic period (the DRU period, 
holding a ‘back-to-basics’ strategy); I have no systematically gathered interview data from the 
‘revolutionary’ periods of PDS or MSD to compare with; theoretically, the dominant innovation logic 
of the device managers could have been different in these periods. 
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Introduction 
This chapter analyses the case story as a whole, across the individual phases. It also discusses the 
theoretical framework in the light of the empirical evidence. Based on this discussion, some 
proposals for building new theory are made. As such, the chapter is the result of ‘stage 4’ in the case 
analysis procedure prescribed by Mintzberg (2007), called ‘Theory building’.  
The chapter first outlines some overall trends in the development of the case organization and its 
context, across the entire period. Thereafter, it analyzes the overall pattern in the evolution of device 
innovation strategy, and the drivers behind. Subsequently, specific analyses are made of the roles of 
respectively top management cognition and of autonomous and induced strategy, in which the 
theoretical framework is discussed. Finally, the chapter integrates the analysis into a revised 
understanding of the induced strategy process.  
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Analysis across phases – the “whole story”  
Trends in the underlying development  
The changes in the insulin industry can be described both market-wise (the demand side) and 
product-wise (the technological progress):  
 The development of the insulin market unfolds two fundamental trends. The first trend 
moves towards perfection of the diabetes treatment, driven by the diabetes specialists’ 
desire for better glucose control of their Type 1 patients, who depend 100% on insulin 
injections for their survival. The second trend takes direction towards fulfillment of the 
exploding demand for treatment of Type 2 diabetes patients, driven by the pandemic of Type 
2 diabetes. Where the first trend calls for sophistication of the treatment instruments in 
order to fine-tune the glucose control, the second trend calls for simple and convenient 
‘good-enough’ solutions for the mass market of Type 2 diabetes patients.  
 Concerning the technological trends, there are changes driven by drug inventions as well as 
by the introduction of insulin devices. On the drug side, the invention of recombinant human 
insulin in 1982 was a truly disruptive invention, which made animal insulin obsolete within 
two decades, and which was a precondition for the ability to treat the exploding Type 2 
market with insulin. In the 1990’s followed the first insulin analogues, and these ‘designed 
drugs’ enabled the modified insulin molecule to establish a more stable glucose level by itself, 
thereby simplifying the treatment for the patient. The introduction of insulin devices, 
especially insulin pens, also changed the treatment for the patient, enabling a more 
convenient and flexible insulin administration. Hence, from the introduction of NovoPen® in 
1985, insulin sold in cartridges for pen systems gradually took over, and from around 2002 
more insulin was sold in devices than in traditional vials, globally.  
The trends within Novo Nordisk’s overall corporate strategy within the period 1980-2008 fall in 
three: 1) the shift from diversification to “core business”; 2) the efforts for performance 
improvement; and 3) the reorientation towards the growing Type 2 market.  
1. The shift from diversification to focus on core competencies and core business followed the 
shift in management dogmas, which was coincident with the merger of Novo and Nordisk, 
leaving the company with far too broad a business portfolio.  
2. The two crises – the quality crisis in 1992-94 and the financial shake in 2002 – called 
attention to the need for improving business performance and control systems, and several 
programs were successfully conducted; e.g. lean management to increase productivity.  
3. The reorientation towards the growing Type 2 market came gradually, enforced by the 
public research studies, such as the British UKPDS in 1998, and by the failure of certain tablet 
treatments in the first decade of the new millennium. In many ways, this reorientation is still 
taking place (2012).  
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The overall trends in the device innovation activities of Novo Nordisk reflect the overall trends in 
market development, displaying paths of sustaining as well as disruptive innovation. Christensen 
(1997) describes the introduction of NovoPen® as a case of disruptive innovation; this 
characterization is based on a concept of “disruptive technologies”, as in Christensen & Bower 
(1996). In later work, Christensen & Raynor (2003) define the concept from a more market-oriented 
perspective: “A sustaining innovation targets demanding, high-end customers with better 
performance than was previously available…Disruptive innovations, in contrast don’t attempt to 
bring better products to established customers in existing markets. Rather, they disrupt and redefine 
that trajectory by introducing products and services that are not as good as currently available 
products. But disruptive technologies offer other benefits – typically, they are simpler, more convenient 
and less expensive products that appeal to new or less-demanding customers” (p. 34).  From this 
definition it is clear that the market trend requiring sophistication of the instruments for fine-tuned 
treatment of the Type 1 patients, satisfying the wishes of diabetes specialists, calls for sustaining 
innovation; whereas the emerging mass market for treatment of Type 2 patients with ‘good-enough’ 
solutions implies a track of disruptive innovation. It is also clear that the introduction of the first 
NovoPen®, meant as a tool for Type 1 patients to practice the new basal-bolus treatment regimen, 
from the Christensen & Raynor (2003) definition was a sustaining innovation, allowing finer glucose 
control with small doses of insulin. Also Nordisk’s insulin pump served the high-end customer 
segment with their advanced needs and was seen as the ultimate solution from a technical 
standpoint. This sustaining track, serving the Type 1 market and the diabetes specialists with yet 
more sophisticated products continued to be pursued through device innovations at Novo Nordisk, 
adding new features, intelligence (in the electronic Innovo® device), and integration with glucose 
monitoring devices (the InDuo® device). Even the PDS strategy, launched 2001, with its vision about 
advanced closed loop solutions, continued this trend for sophistication and complexity. Devices fit 
well to this sustaining innovation path, since it’s easier to add features and performance functionality 
to a physical device than to a drug molecule.  
However, the devices also came to serve the disruptive path, pursuing simple solutions to the broad 
segment of Type 2 patients. The devices were able to fulfill this need, because prefilled insulin pens 
made the insulin administration procedure much simpler. Further, as commented by an executive, 
the invention of ‘intelligent’ insulin analogues allowed the device to be simple; the improved glucose 
control was instead achieved via performance characteristics of the modified insulin molecule.  
In conclusion, the device innovation activities at Novo Nordisk were caught in a dilemma between 
the two overall trends in the insulin market – serving the advancement and sophistication of tools for 
glucose control, primarily addressing the Type 1 market – versus serving the broad mass market of 
Type 2 with simple solutions. The solution to this dilemma was not a result of decisions by local 
device managers, but came out of the external development, orchestrated by corporate management. 
The mass market of Type 2 diabetes won, armed with numbers and business cases – but it implied a 
clash with the initial identity of the company (stemming from the founders August and Marie Krogh) 
which was tied to science and expert treatment of diabetes.  
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The overall pattern in the evolution of innovation strategy  
If we synthesize the phases of development of device innovation strategy as analyzed in the previous 
chapter, the development can be defined as five overall periods, divided by the transformations of 
device innovation strategy (see empirical definition in the methodology chapter), namely: 
1. The early attempts with medical devices at the two companies, Nordisk and Novo (1980-
88), where Nordisk started with insulin pumps and Novo with insulin pens. These were 
entrepreneurial activities, which still lacked a formal strategy. Thus, in Burgelman’s (1988) 
terminology, the period represents the emergent state; before institutionalization of strategy. 
2. The strategic vision of patient-centered homecare, based on a medical system, anchored 
in the new Medical Systems Division (MSD). MSD was established in 1988 as a business unit, 
which was envisioned to establish devices as ‘the third business leg’. Devices should create 
revenue streams of their own – partly by selling devices such as insulin pumps, partly by 
manufacturing devices for other pharmaceutical companies. The activities comprised drug 
delivery (pens and pumps) as well as disease monitoring devices (e.g. glucose monitoring). 
The MSD strategy was terminated in 1992. 
3. The focusing period, in which insulin pumps were sold off and disease monitoring projects 
were stalled – focus was directed explicitly at insulin pens, and devices were to support the 
drug business. Devices were not envisioned to create revenue streams of their own. This 
phase was partly evoked by the quality crisis in 1992-94, and partly by Novo Nordisk being 
behind competitors with regards to the insulin pipeline. Thereafter, as result of the corporate 
restructuring into a functional organization, the device activities in 1995 were transferred to 
Production, keeping the name Medical Systems (MS), without changes in strategy – focus was 
still on insulin pens only. This organizational setup was kept until mid 2001. 
4. In 2000, the new strategic vision for closed loop and ‘one-stop-shop’ to diabetes was 
conceptualized. The implementation was postponed until 2001, where Protein Delivery 
Systems (PDS) was established as the organizational frame for the new holistic device 
innovation strategy. Thereby device R&D was separated from device production, which 
remained under the corporate Production unit. The strategy included both insulin delivery 
and continuous glucose monitoring and envisioned substantial revenue streams based on 
devices, including complex and expensive ‘closed loop’ systems. 
5. A crisis already in 2002 undermined the risk willingness needed for the ambitious visions of 
PDS, and in 2004 the continuous glucose monitoring project was terminated; but the strategy 
was not officially changed until 2005, where the innovation strategy returned to a ‘back to 
basics’ mode, i.e. focus should be on insulin pens, like in the MS period. The device 
innovation activities were integrated into a drug research area, Diabetes Research Unit 
(DRU). By year-end 2008, DRU was terminated. 
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The strategic learning cycle of each strategic period was analyzed in the previous chapter. These 
cycles are depicted in figure V-1 below (as in Chapter 4, the focusing period of MS has been split in 







Figure V-1. The strategic learning cycles, phase by phase, as extracted in Chapter 4. 
 
The strategic learning cycles in figure V-1 were useful in Chapter 4 for analyzing the strategy-making 
processes of each phase. They also provide evidence for the ‘theory’-driven scenario of strategic 
reconfiguration, as shown in figure II-14. In the current case study, the strategic changes implied by 
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these learning cycles were driven by forward-looking search for exploration. Such vision-driven 
strategic search does not resemble the normal behavioral understanding of strategy change as result 
of bottom-up processes.  
However, these individual learning cycles are perhaps less useful for identifying patterns across the 
phases. To do so, the device innovation strategies can be classified as falling in two distinct modes: 
A. Autonomous, device-based strategy, including new business creation and a systemic or 
integrated approach to innovation. These strategies are ‘autonomous’, because they aim for 
creating new product-markets (see Definitions in Chapter 1). 
B. Induced, drug-based strategy, focused on devices as complementary to the drugs.  
The result of this distinction can be seen in figure V-2. 
 
 
Figure V-2. A model of the development of device innovation strategy at Novo Nordisk. The ‘early attempts’ 
have a dotted outline, since these activities represent the ‘emergent state’ (Burgelman, 1988) – before 
institutionalization of strategy. 
 
The model of the development, shown in figure V-2, of course leaves out many nuances of the 
strategic phases; that is the sacrifice you make in search of clarity from models. That being said, the 
cyclic nature of the development is striking. Generally spoken, one can identify the balance between 
autonomous and induced strategic activities in an a company at a given time – the analysis of the 
innovation project portfolio in Chapter 4 does so, and Burgelman & Grove (2007) do it for Intel 
Corporation at different moments of the company’s lifetime. Such analyses reflect a balance between 
autonomous and induced strategy ‘in space’ at a given moment. But only the longitudinal lens can 
provide the image of the balance between autonomous and induced strategy over time, as shown in 
figure V-2. 
It is apparent that the two ‘revolutionary’ periods (MSD 1988-1992 and PDS 2001-05) aim for 
innovation at a more systemic level than the normal periods, which focus on the physical product 
itself. As put by a PDS manager: “Novo Nordisk could get a bigger share of the pie via diversification 
into other parts of the diabetes market. And the executive committee saw that if anybody could do this, 
Mode A: 
• Autonomous strategy;  
new business creation 
• Device-based strategy 
including glucose monitoring 
• Systemic or integrated 













• Induced strategy; product 
innovation of injection 
devices only (mostly pens) 
• Drug-based strategy 






Focus on pens Focus on pens 




it was us”…  “We wanted to be a ‘one-stop-shop’ to diabetes”. In such view, the physical product is one 
element in or component of the innovation.  
The contrast between system and component has been expressed in theories on ‘architectural 
innovation’. This concept has been proposed at two levels of analysis. Abernathy & Clark (1985) 
describe ‘architectural innovation’ as follows: “Innovation of this sort defines the basic configuration of 
product and process...it lays down the architecture of the industry” (p. 7, my emphasis). “Using new 
concepts in technology to forge new market linkages is the essence of architectural innovation.” (p. 10, 
my emphasis). In a later paper, Henderson & Clark (1990) describe architectural innovation 
differently: “We define innovations that change the way in which the components of a product are 
linked together, while leaving the core concepts (and thus the basic knowledge underlying the 
components) untouched, as “architectural” innovation” (p. 10, my emphasis). In Abernathy & Clark 
(1985) ‘the system’ includes market linkages, whereas ‘the system’ in Henderson & Clark (1990) is 
limited to the physical product itself. (For instance, they use an electric room air fan to illustrate ‘the 
system’). The two meanings of the concept are reflected in the case study at hand: the two 
‘revolutionary’ periods (mode A in figure V-2) aimed for reconfiguration of market linkages, 
corresponding to the former definition of ‘architectural innovation’; the ‘normal’ periods (mode B in 
figure V-2) only aimed for reconfiguration of the product itself, referring to the latter definition. The 
challenges for corporate management seem to occur when the architecture of the industry is in play, 
i.e. when more elements of the value chain are included. In contrast, the architecture of the product 
as a system could be reconfigured throughout the entire period without disturbing the corporate 
strategy, so long as the product was defined as a system for drug injection. 
The case of medical devices at Novo Nordisk to a large extent is a case of integration of a new set of 
complementary assets for innovation. Nordisk had a vision of making medical devices a ‘third 
business leg’ (beside the two drug businesses: diabetes and biopharm), so here the ambition was to 
make medical device competencies a core asset for innovation. Novo, in contrast, had no such visions, 
when they launched NovoPen®; the medical devices were seen as purely complementary assets. The 
start-up of the medical device activities, however, was like letting in a Trojan horse – soon, the 
medical device activities strived for independence and for becoming a business of its own. Both 
autonomous strategic waves, respectively MSD 1988-92 and PDS 2001-05, made the attempt to 
establish medical devices as the ‘third business leg’. These cycles of innovation strategy show that the 
distinction between core and complementary assets for innovation is dynamic and negotiable, not 
static.  
The potential implications of the two ‘revolutionary’ strategies were profound, had they been 
realized; the consequences would have reached far beyond the device area alone. Why did corporate 
management at all let the medical device activities try to escape the role as complementary 
enhancers of the pharmaceutical drug? Well, perhaps it was exactly because the medical devices were 
seen as complementary assets that the corporate ‘immune system’ was not provoked – had medical 
devices from the outset been seen as a new business area, the corporate filtering mechanisms would 
perhaps have been more alert. The ‘camouflage’ as complementary assets made the experimental 
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strategies slip through the filter – since the strategic experiments were not perceived as a threat to 
‘core business’. A veteran device manager said: ““Why we succeeded with the only radical innovation 
ever in Novo Nordisk – the NovoPen® – ‘well, it sounds like a good idea, and it doesn’t really cost 
anything, and some 7,000 patients might benefit from it, why not try it’. So, in reality it was because we 
started in such small scale and with so small consequences for the firm that it didn’t really matter… it 
was so manageable and easy to oversee that it just slipped through. Management stalls if it something is 
so big that you risk the whole enterprise”. 
This context of integration of complementary assets differs from Burgelman’s research. Burgelman 
(1991) described the intra-organizational ecology of established and emerging businesses: in case, 
the established memory business and the emerging microprocessor business at Intel Corporation. 
The case of Novo Nordisk it not about two competing businesses, but about integration of some new 
complementary assets for innovation, which then repeatedly are utilized for visions about 
establishment of new business areas. Even though the two case contexts differ, the integration of new 
complementary assets for innovation at Novo Nordisk seems to generate managerial challenges just 
as serious as the integration and portfolio management of new business ventures, as demonstrated 
in the case of Intel. Still, the challenges are different. Where the management of alternative 
businesses requires portfolio management competencies, then the management of dynamics 
between core and complementary assets for innovation requires integrative competencies 
(Christensen, 2006).  
It’s interesting here that throughout the entire period of the case study at hand, devices and 
especially utensils like injection needles have in fact have created revenue streams, which – seen in a 
Danish context – are substantial. However, within the normal (drug-centered) strategic periods, this 
income is not seen as business – it is not accounted for separately and there’s not made a profit and 
loss account for devices16. In other words, the actual value creation has existed ever since the 
introduction of insulin devices, understood as revenue streams; but these revenue streams only 
became explicit elements of the strategy within the autonomous periods, where the income from the 
medical devices and utensils for these was part of the strategic framing. This fact elucidates the role 
of cognitive frames in strategy. 
 
The development of innovation strategy, as shown in the model of figure V-2, is the result of change 
processes, evoked by different drivers of change. We shall now turn towards these drivers; i.e. the 
events and processes of change behind the strategic transformations.  






16 At least, if such accounts exist, they are not communicated in the organization. 
147 
 
The drivers of change 
Based on the analysis in Chapter 4, table V-1 synthesizes the events and processes behind change in 
innovation strategy, transformation by transformation, divided into external and internal drivers 
(‘drivers’ understood here as events and processes).  
External drivers are split in  
a) Industry or market trends  
b) Technological discontinuities  
c) Competition 
d) Externally evoked crises.  
Internal drivers are divided into four dualities: 
e) The origin of the strategy: stemming from forward-looking cognition or back-ward looking 
experience. 
f) The ‘gravity’ towards the established strategy: does the strategic initiative stay within the 
established strategy = induced strategy, or does the strategic initiative explore new product-
markets, outside the established strategy = autonomous strategy? 
g) The integration of devices: are medical devices seen as core assets for innovation, to create a 
business of its own – or as complementary assets for innovation, to support or enhance the 
sales of the pharmaceutical drug? 
h) The actor: is the change process driven by top management or bottom-up, i.e. organization-
driven? 
Like the model in figure V-2, the scheme in table V-1 does not capture all details, which were 
analyzed in the previous chapter, but provides an overview. For each strategic transformation, I have 
emphasized the most salient drivers of change.  
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Drivers of change of innovation strategy – transformation by transformation 
Strategic phase 
 (year of start) 
1) Early attempts with 
medical devices  
 
2) MSD: vision of 
homecare  
(1987-88) 
3) MS:  
focus on injection pens 
(1992) 
4) PDS: 
vision of closed 
loop (2000-2001) 
5) DRU:  










Industry or market trends Diabetes specialists discuss 
artificial pancreas and pumps 
   Vertical integration tried out 
(e.g. Lilly buys a distributor) 
Cancer risk by tablet 
treatment  renewed focus 
on insulin 
Technological discontinuities Recombinant insulin (1982)    Continuous Glucose 
Monitoring (1999) 
 
Competition Eli Lilly 1982: recombinant insulin 
(in development from 1976) 
 Competitors 





 Fierce competition on 
insulin pens 
Externally evoked crises    FDA critique  
GMP crisis 
  Financial shake 2002 + 















The vision of patient-
centered homecare 
Need to focus on 
‘core 
competencies’ 
Wish for staying 
independent as 
company   
corporate focus 
strategy 
Desk analysis  vision of 
closed loop and ‘one-stop-













(Trying out pens 
– impact not 
foreseen) 
Building on positive 
experiences with pens 
and pumps. Learning on 
the way. 
Mixed results of 
MSD strategy 
Success in finding 
core 
competencies 
 Learning from mistakes 
(problems with advanced 













announced as a 
new paradigm 
New business unit for 
devices as a ‘third 
business leg’ 
  Creating new business – 








Pens as market 
differentiator 
 Focus on classic 
strategy – devices 
seen as market 
differentiator 






Pumps as new 
product 
 Devices core, as a ‘third 
business leg’ 
  Devices core for new 








Pens as a 
marketing tool 
Complementary assets, 
serving drug divisions 
with injection devices 
Devices only seen 
as support to 
drugs 





Top (CEO) Top (marketing 
executive) 
Top (NG CEO) Top (executive 
committee) 
 Top (Operations) Top (executive committee) 
Organization 
(bottom-up) 
  Local MSD management  Relative freedom 
(outside radar of 
top management) 
  
Table V-1. Synthesized overview of the drivers (i.e. events and processes) of change of device innovation strategy at Novo Nordisk, transformation by transformation.  
Based on the analysis in chapter 4, the key drivers are identified and marked here as emphasized and underlined. 
The pattern which emerges is: 
 The first entrepreneurial initiatives with medical devices (early attempts, 1980-88) were 
driven by external events: the discussion amongst diabetes experts on making an artificial 
pancreas, and the market introduction by Eli Lilly of recombinant insulin. 
 The MSD strategy implemented 1988 was driven by internal processes: top management 
cognition (the vision of patient-centered homecare) and autonomous strategy. 
 The retreat from the MSD strategy in 1992 was driven by external events: FDA’s criticism 
leading to the quality crisis, and competitors being ahead of Novo Nordisk with regards to 
the insulin pipeline. 
 The next transformation, implemented with PDS in 2001, was driven by internal processes: 
top management cognition (the vision of closed loop) and autonomous strategy. 
 The gradual withdrawal from the PDS strategy, ending in 2005, was driven by external 
events: the financial shake in 2002 combined with increased competition on insulin pens. 
Interestingly, the pattern in this case study clearly shows that strategic ‘revolutions’, which differ 
from the established strategy and from the underlying dominant logic (Prahalad & Bettis, 1986), are 
result of a process where top management cognition creates autonomous strategy. In contrast, the 
retreat from these ‘mode A’ periods (see figure V-2) is defensive; caused by externally evoked crises. 
In conclusion, the formula extracted from this case study goes: Top management cognition drives the 
strategic renewal; external events drive the strategic retreats. 
I have modeled the overall evolution in figure V-3 below.  
 
Figure V- 3. Model of the evolution of innovation strategy of medical devices at Novo Nordisk, displaying the 













homecare Vision of closed loop 













 Diabetes specialists 
discuss artificial 
pancreas and insulin 
pumps. 
 
Eli Lilly introduces 
recombinant insulin 
(1982). 
 The vision of 
patient-centered 
homecare. Devices 
as ‘3rd business leg’. 
Setting up new 








 GMP crisis. 
 Interpretation: 
Focus on core 
competencies. 
Stopping insulin 
pumps and disease 
monitoring  device 
projects. 
 The vision of closed 
loop and ‘one-stop-
shop’ to diabetes. 
 
Separating device 







2002 + failure of 
tablet project. 
 Vertical integration 
tried out (e.g. Lilly 













 Market success with 
first devices 
(Nordisk: insulin 






 Interpretation: ‘Back to 
basics’ – away with 
small molecules and 
complicated devices. 
Device R&D integrated 
into drug R&D. 




Discussing theory in the light of the case study 
The role of management cognition  
The development in the present case study displays a cyclic pattern, unfolding two waves of 
institutionalized, yet autonomous innovation strategy based on devices (the ‘mode A’ waves in figure 
V-2: MSD 1988-92 and PDS 2001-05). In both cases these autonomous waves lasted about 4 years, 
after which the innovation strategy was turned ‘back to basics’, i.e. the traditional drug-centered 
strategy. The two autonomous waves were first and foremost initiated as result of top management 
cognition and forward-looking search, and thereby the case differs from the widespread behavioral 
view on top management cognition seen as a filtering mechanism, which unfolds cognitive inertia 
and hinders strategic renewal. In the case of Novo Nordisk, top management driven cognitive search 
had a clearly entrepreneurial role by initiating the two autonomous waves – until the crises occurred, 
where the filtering mechanisms came into play. The autonomous strategy waves thereby 
counteracted the forces of ‘co-evolutionary lock-in’ (Burgelman, 2002).  
In what sense did the autonomous strategies of MSD and PDS then differ from the established 
strategy? Here, we must look all the way back to the initial identity of the company in the 1920’s, 
rooted in science and medical treatment of diabetes with the newly discovered insulin. In general, 
the dominant management logic (Prahalad & Bettis, 1986) of a company is built by positive 
reinforcement of successful activities. In the case of Novo Nordisk, this positive reinforcement led to 
the logic of a pharmaceutical company, based on manufacturing of pharmaceutical drugs, primarily 
insulin. In the 1970’s, Novo changed the overall espoused goal from world leader in insulin 
manufacturing to world leader in diabetes care.  The term “diabetes care” covers treatment services, 
disease monitoring and many other things beyond the pharmaceutical drug itself – the drug is just 
one component of the value chain of care. Hence, the goal of being a leader in “diabetes care” should 
in theory open the business for many more areas than insulin manufacturing. However, it does not 
seem as if the corporate dominant logic ever took the shift in system level from insulin manufacturing 
to diabetes care; at least, the only business attempts to realize the higher system level vision of 
‘diabetes care’ were exactly the two device-based innovation strategies of MSD and PDS. These 
strategies contradicted the pharmaceutical dominant logic by not setting the drug in the center of the 
business. Consequently, these strategies were fragile – and at each externally evoked crisis, the 
corporate strategy bent back to the safe ‘fetal position’, focused on the pharmaceutical drug itself. 
The dominant logic thus seems deeply rooted in the internal identity (Tripsas, 2009) of the firm. 
Even in 2007, where I conducted the interviews at device management level, the extracted dominant 
logic was pharmaceutical; not device-based or ‘diabetes care’-oriented. The pharmaceutical business 
logic and internal identity seem to form both the starting point and the ‘safe harbor’ of the company, 
in case strategic experiments fail. This observation reflects the equilibrium theory of the dominant 
logic, formulated in Bettis & Prahalad (1995). If we apply their analysis as shown in figure II-10, 
neither of the two autonomous strategic waves at Novo Nordisk (respectively the MSD and the PDS 




strategy) achieved momentum enough to escape the gravity of the dominant logic before the two 
crises started the process of retreat. In both cases, the strategic visions were never fully 
implemented; partly because the needed product systems could not be developed within the 
available timeframe of four years. When external crises then reduced corporate risk willingness, the 
inherent uncertainties of these explorative ventures made corporate management withdraw from 
the autonomous, device-based strategies. One should also consider the observation from Prahalad & 
Bettis (1986) that the more successful a company has been, the more difficult it is to unlearn the 
dominant logic (p. 498). Novo Nordisk had indeed been very successful in the insulin industry, and 
consequently it was more difficult to change the prevailing paradigm of thinking. Imagine what it 
would have taken to make corporate management implement for instance the PDS strategy 
corporate-wide. Corporate management would have had to reformulate the strategy towards a 
device-based or systemic business strategy, based on complex treatment solutions, in which the drug 
was seen as one of many components in the total product offering. Such dramatic move would have 
required an immense success of the PDS strategy, implying revenue streams at least of the size of the 
revenue from the drugs. In other words, the envisioned ‘value upgrade’ of the market should first 
have proven to be viable. One can compare to Intel Corporation, where the official strategy was not 
changed from memory to microprocessor business until the microprocessor business had climbed to 
app. 75% of the corporate sales (Burgelman, 1991). This strategic inertia at Intel was partly a result 
of an internal identity, which was closely tied up with the memory business (Tripsas, 2009). If we 
return to Novo Nordisk, you should remember that an important element of the autonomous, device-
based strategies of MSD and PDS was the inclusion of glucose monitoring products. Even though 
glucose monitoring devices are needed in diabetes care, these devices do not directly support the 
sales of insulin, and they were seen as alien to the corporate ‘DNA’. For example, one veteran device 
manager told me that an executive manager had commented the inclusion of glucose monitoring 
devices back in the MSD period with the words: “take that crab out of the portfolio!”. This resistance 
is caused by the history: glucose monitoring products were not a part of the original pharmaceutical 
identity and had not been part of the learning cycles, which created the corporate dominant logic. 
Hence, strategies building on inclusion of glucose monitoring products required a ‘far move’, as 
described by Bettis & Prahalad (1995), in order to succeed in escaping the established dominant 
logic (cf. figure II-10).  
The reader might here make the objection to my analysis that the destiny of the two autonomous 
strategic periods (MSD and PDS) was instead result of lacking organizational plasticity, which 
characterizes mature companies, according to Gavetti & Rivkin (2007). However, the organization of 
Novo Nordisk did in fact adapt to the new strategies: new organizational structures were built, 
substantial new competencies were acquired and integrated, and new innovation projects were set 
up. So the ‘structural context determination’ (Burgelman, 1991) was in place; and still the new 
strategies failed, because the corporate dominant logic pulled the strategy back to the safe harbor, 
whenever external events threatened the ‘core’ business.  
 




The role of autonomous and induced strategy  
In 1980, both Novo and Nordisk were mature companies, which had dominant positions within the 
59 years old insulin market. Thus, their management systems and business strategies were in place, 
and their industry was relatively stable. This starting point is very different compared to the 
organizations, which Burgelman (1988, 1991) builds his empirical research on: respectively internal 
corporate venture units in large firms (Burgelman, 1988) or Intel Corporation in the 1980’s, which 
had been established in 1968 (Burgelman, 1991). Not only is there a difference between a 55 years 
old versus a 15 years old company, but also the two industries (the pharmaceutical industry versus 
the young IT industry) are very different. Consider Gavetti & Rivkin’s (2007) analysis, which 
characterized young companies and especially young industries as typically dominated by action-
based strategic search, whereas mature companies and mature industries were more likely to 
display cognition-based strategic search. For the 15 years old Intel in the young IT industry, it is 
therefore not surprising that the strategy making was marked by experimental initiatives growing 
from beneath in the organization – which is Burgelman’s classic description of autonomous 
strategies. For the case of Novo and Nordisk in 1980, the institutionalization of corporate strategy 
took place long ago, and therefore the starting point was two companies with top management 
driven induced strategy processes. Following Burgelman’s (1991) model of internal ecology of 
strategy making, new business ventures would in such case first be conceptualized locally, driven by 
middle managers. After series of successful experiments, the new ventures would be promoted for 
selection by top management, eventually to be integrated in the induced strategy – vision ‘ex post’, 
top management cognition in retrospect, after local experiences. This was not what happened with 
the medical device activities at Novo Nordisk. In contrast, the new explorative initiatives were the 
result of top management cognition. Both the MSD (1988-92) and the PDS (2001-05) strategies were 
formulated with ambitious business creation visions ‘ex ante’, before implementation of the 
strategies began. In the case of PDS, we are even able to track the birth of the strategy to a particular 
workshop for top managers within Operations in the summer of 2000, being worked out in detail 
over the subsequent half year; but the implementation was delayed for financial reasons until the 
summer of 2001. The strategy did not reflect ‘retrospective rationalization’ (Burgelman, 1988), but 
was rather proactive analysis and anticipation of novel opportunities. For both MSD and PDS, the 
retreat from the experimental strategy was also driven by top management, as reaction to external 
events. These retreats resemble what Burgelman (1991) labels ‘reorientation’.  
The MSD and PDS strategies were both autonomous in the sense that they explored new product-
markets; however, they still were top management driven. The strategy-making process and the way 
to strategic change therefore seem very different to the processes modeled by Burgelman (1988, 
1991). In the sense that the ‘revolutionary’ strategies at Novo Nordisk were deliberate, vision ‘ex 
ante’, they resemble Burgelman’s (1991) analysis of induced processes. Consequently, we could say 
that in the case of Novo Nordisk, the strategic experimentation was an integrated part of the induced 
strategy process. This analysis defines another role for induced strategy than modeled by Burgelman 




(1991). Where the induced strategy process in Burgelman (1991, 2002) has the overall role of 
selection and retention, the induced strategy process in the case of Novo Nordisk also holds the role of 
strategic variation. Via top management cognition, the induced strategy process mediates between 
the external and the internal ecologies: when top management cognition anticipates novel 
opportunities inspired by events in the environment, corresponding new strategies for innovation 
are envisioned, the internal organization is set up, competencies are acquired and projects are 
initiated. When the projects fail, or when external events force top management to rethink the whole 
situation, then the strategic experiments are stopped, and the innovation strategy is turned back to 
‘normal mode’. In this sense, induced strategy is far less ‘institutionalized’ than in the analysis of 
Burgelman (1988, 1991). In fact, induced strategies with their vision ‘ex ante’ can be seen as 
hypotheses; thought experiments, which are tried out for real.  
Burgelman (1991) recognizes the existence of variation created by induced processes, but this 
phenomenon is described as far more constrained than the creation of the strategies for MSD and 
PDS: “Of course, this does not imply that there is no planned variation in the induced process. Clearly, 
there is room for core technology advances, new product development for existing product families, 
new approaches to marketing and manufacturing and so on” (p. 246 – my emphasis). This 
characterization does not correspond with the revolutionary characteristics of the two strategic 
waves at Novo Nordisk.  
Should we instead, in the terminology of Burgelman (1991), understand the two ‘revolutionary’ 
waves at Novo Nordisk as top management driven autonomous strategy? Burgelman (1991) 
mentions this possibility – however, the concept has no real role in his internal ecology model. In 
fact, Burgelman (1991) states: “strategic renewal – major strategic change preceded by internal 
experimentation and selection – is the critical outcome of the autonomous process” (p. 255 – my 
emphasis) and “Autonomous initiatives can originate at all levels of management. But they are most 
likely to emerge at a level where managers are directly in contact with new technological developments 
and changes in market conditions, and have some budgetary discretion” (ibid, p. 246). Also, Burgelman 
(1988) clearly describes the creation of new strategies in the emergent state as driven from beneath 
in the organization, step by step finding resonance at yet higher management levels, as the new 
ventures gradually succeed. Further, the labels used by Burgelman contradict the phenomenon of 
top-driven autonomous strategy: the semantics of the label “autonomous” indicate something which 
emerges independently or bottom-up. By contrast, only top management has the power to “induce” 
strategies into the organization. So semantics alone lead the use of the labels ‘autonomous’ and 
‘induced’ strategy away from Burgelman’s (1991, 2002) explicit definition, which is linked to the 
content of the strategy (respectively outside or within established product-markets). Instead, the 
semantics lead towards the more widespread use of these labels in literature (and even in 
Burgelman’s own texts); namely linked to the origin of strategy as top-down versus bottom-up. Since 
this interpretation of the concepts is essential, I shall analyze the parameters for characterizing a 
specific strategic venture further.  




As described in Definitions in Chapter 1, three parameters must be in play in order to characterize a 
strategic initiative as either induced or autonomous. The normal distribution of these parameters in 
Burgelman (1991, 2002) is such that autonomous strategy per definition explores initiatives outside 
the current strategy, is typically driven by local managers and follows a learning-from-experiments 
process (vision ‘ex post’). In contrast, induced strategy per definition expands the current strategy, is 
driven by top management and follows a cognition-based process (vision ‘ex ante’).  
Compared to Burgelman’s normal characterization of autonomous and induced strategy, the 
‘revolutionary’ strategies of MSD and PDS at Novo Nordisk explored business opportunities outside 
the current strategy, and hence in content (and per explicit definition) were autonomous strategies; 
however, at the two other parameters, they reflected the traits of induced strategy processes, being 
top- and theory-driven. Consequently, it is fair to identify these strategic initiatives, which originated 
within a mature corporation holding an institutionalized strategy, as part of the induced strategy 
process.  Thus, I propose to label them induced strategic experiments. Such induced strategy making 
process, which aims for strategic renewal, is not present in Burgelman’s model of internal ecology of 
strategy making (Burgelman 1991, 2002). The most radical of the induced modes of adaptation in 
Burgelman (1991) is ‘reorientation’, in which major changes in strategy follow as response to threats 
or crises – this phenomenon is seen in the present case study at the two strategic retreats in 
respectively 1992 and 2005. However, the proactive establishment of MSD and PDS does not 
resemble ‘reorientation’. Compared to the evolutionary school of thought on strategy making, the 
case of innovation strategy for medical devices at Novo Nordisk represents an anomaly. 
The difficulties of defining the strategic transformations at Novo Nordisk as either autonomous or 
induced may have to do with the very wide use of these concepts in Burgelman’s framework. 
Sometimes the concepts ‘autonomous’ and ‘induced’ label concrete initiatives or projects (Burgelman 
& Grove, 2007), sometimes they label corporate strategies per content (Burgelman, 2002) and 
sometimes they label strategy making processes (Burgelman, 1991). This wide use may create 
confusion, since the induced process is characterized as vision-ex-ante, whereas the induced strategy 
content is defined as exploitation of established product-markets – this leaves no room for an 
explorative, yet vision-ex-ante strategy process.  
 
Does this imply that we are back to understanding Novo Nordisk’s strategy-making in a rational 
choice perspective such as in we find the positioning school? – I don’t think so – for two reasons: 
First, there’s the methodological reason. Rational choice theories are not concerned with the process 
of strategy formation – their focus is on variables and outcomes, in a variance theory tradition (Van 
de Ven, 2007). That makes the rational choice paradigm barren soil for cultivating a theory on the 
evolution of innovation strategy, which is the objective of the present research.  
Second, the long-term storyline of the case study speaks against a pure rational-choice perspective. 
Each strategic transformation was surely driven by top management out of ‘ex ante’ vision; but if we 
take a longitudinal look at the evolution of the innovation strategy, then there certainly was no 
deliberate ‘master plan’ for this evolution. There was no ‘vision ex ante’ behind the evolution seen 




over extended time. So, in a longitudinal perspective, the evolution represented trial-and-error. A 
rational-choice perspective does not necessarily exclude trial-and-error; for example, Lucas (1986) 
identifies a role for trial-and-error in the formation and change of the underlying rules and 
preferences, which guide the individual decisions. “Rational” is not opposite to “adaptive” in his view. 
Still, if we look for theories which analyze how the underlying rules and preferences (in case: the 
underlying strategic intent) change over time, then evolutionary theory on strategy making explains 
these change processes most directly.  
Consequently, I have applied evolutionary models of strategy making in the current research project; 
but I need stronger emphasis on the reasoning aspect of strategic search, in order to understand the 
empirical evidence. In the case study of Novo Nordisk, the strategy making is theory-based, in the 
shorter time perspective – but still undergoing trial-and-error, in the longer time perspective. This 
duality comes into play, because the individual strategic visions are not written in stone, like the 
tablets of Moses; rather they are hypotheses, which are subject to learning from experiments over 
extended time. The case of Novo Nordisk displays several examples of top management reasoning, 
which illustrate this hypothetic nature of the theory-based strategic search: 
 The executive informant openly talked about the strategic learning from the failed 
experiments with Novo Diagnostic Systems (my emphasis): 
o “This taught me two things: first of all … – [Why did you then acquire this company?] – 
That was also a wrong decision. But we were looking for opportunities for growth, you 
know. ...You can say that the reason we jumped into it was the aspiration for new 
opportunities – and then an analysis, which was insufficient, due to lack of expertise”. 
(See full quotation in previous chapter). 
o This statement illustrates that even such a serious decision as the acquisition of 
another company and the following attempt to build up a new business can be 
interpreted as a thought experiment or hypothesis, which is subsequently tried out 
in reality. 
 The entrance into inhaled insulin was explained by executives as a defensive move, because 
other pharmaceutical companies were pursuing this track – in other words, the initiative 
built on the hypothesis: ‘In case competitors succeed, we had better be prepared…’ 
 Similarly, one of the explanations for the establishment of PDS was to see PDS as a defensive 
move, in case other companies would succeed with continuous glucose monitoring and 
closed loop: “If they succeeded, then we could risk getting reduced into suppliers of this muddy 
liquid, which was inside the pumps and devices, which were controlled by others”. 
 The above examples display cognitive visions, which were implemented for a period of time 
and then withdrawn. There is also an example of a vision, which remained a vision, because 
the 2002 crisis changed the whole view: “…with some vision one could imagine the company 
from 2000 develop into a device company, a diabetes company and a biopharm company. … one 
could imagine that it would attract different types of investors…With PDS there was an 




ambition that we could sell our device knowledge and make it commercial to other companies. 
We believed that we were world champions within devices, so there ought to be somebody who 
could make use of this. One should also not exclude that we would actually learn something 
from working together with partners”. The hypothesis about establishing a separate company 
based on the medical device competencies was not realized; even though PDS was launched, 
representing the first step in the realization of the vision. 
 The establishment and especially the later termination of PDS were also partly explained by 
the hypothetical nature of the strategy: “we were engaged in much more complicated devices, 
which we from desk analysis thought would be fantastic”… “it was too much ‘blue sky’ – we 
were too optimistic, we believed the solutions were just around the corner”…“the dream about 
the role as system integrator died”… “The PDS visions were like romantic dreams”. 
 When asked if he regretted PDS, an executive informant amongst others stated: “I think it 
also created some thoughts at corporate management that this [device] innovation needs 
attention. It should not just be an appendix to the drug; it is in itself a differentiating factor. So I 
don’t think PDS lived in vain”. The executive here explicitly mentions the strategic learning.  
 Again, we should not forget that the visions and strategies behind the establishment of PDS 
were both initiated and endorsed by top management. It was not an autonomous initiative 
from beneath, which slipped through the ‘filter’. On the contrary, it was a top-driven induced 
strategic process formulating the vision ‘ex ante’.  
The current case analysis suggests an induced strategy making process at incumbents, which 
experiments with alternating innovation strategies over extended time, unfolding several lifecycles of 
strategy, which are launched and implemented as hypotheses, to be subject to learning. This 
understanding identifies an underresearched, entrepreneurial role of the induced strategy making 
process, in which top management cognition leads to strategic renewal instead of strategic inertia. 
Seen in contrast to the ‘internal ecology model’ (Burgelman, 1991), the present case study provides 
evidence for an alternative way of creating strategic variation over extended time within the setting of 
the ‘steady state’ (Burgelman, 1988) – i.e. after institutionalization of strategy: namely via vision-
driven, yet explorative experiments.  
The difference in the strategy making processes at Novo Nordisk analyzed here related to 
Burgelman’s analysis (1991, 2002) of Intel Corporation might have to do with different units of 
analysis: Burgelman deals with general business strategy, whereas the present study analyzes the 
development of innovation strategy for complementary products. Burgelman’s corporate perspective 
partly overlaps with innovation strategy: the emergence of the microprocessor business at Intel was 
surely a result of innovative activities. However, Burgelman (1991) primarily analyses how the 
microprocessor business gradually takes over from the memory products as the main business. This 
is a case study of the competition between two business areas (which both are established with each 
their customers) about the role as ‘core strategy’.  If we define innovation strategy as ‘the strategy for 
the individual innovation activities with the objective to create product or business innovations’, then 




an analysis of the evolution of the innovation strategy would focus on the much earlier 
development, in which the vision of developing future microprocessor products competed with other 
visions for alternative innovation activities.  If we relate to my case study: the visions about 
developing glucose monitoring products and create substantial business hereof never made to the 
launch of a product – no business was ever established. Still, alternative innovation strategies 
(respectively device-based and drug-based) competed for becoming the core innovation strategy, 
just like different business areas competed on becoming the core business in the Intel case. In 
general, business strategies aim for growth; innovation strategies aim for growth via creation of 
future innovations. Consequently, one can say that the innovation strategy of a corporation is per 
definition experimental, even in a mature company. Hence, the corporate induced strategy process 
can hold the innovation strategy as an explorative or variation creating branch; a kind of strategy 
laboratory. When the case then also concerns complementary products, as for example medical 
devices at a pharmaceutical company, then the innovation strategy becomes more loosely coupled to 
the core business; therefore such strategy is perhaps even more likely to be perceived as means for 
strategic experimentation, seen from a corporate management perspective.  
To conclude, the induced strategy process under certain circumstances may unfold vision-driven 
explorative strategic experiments as part of the evolvement of innovation strategy, which do not 
resemble the modes of induced adaptation as described by Burgelman (1991). These boundary 
conditions could be: a mature organization with an institutionalized corporate strategy, which via the 
innovation strategy experiments with the integration of complementary assets for innovation.  
Was the choice of Burgelman’s internal ecology model then at all appropriate for the present 
research project? – Yes, because Burgelman’s theory provided the best match to the empirical case 
study as well as to the overall research question. For the empirical case study, the concepts of 
autonomous and induced strategies gave meaning to the narrative I was constructing about the two 
modes of innovation strategy (see Figure V-2). Furthermore, Burgelman’s framework was the most 
direct and internally consistent theoretical reply to my research question “How does innovation 
strategy evolve?” – we just need to take away the word ‘innovation’. In Chapter 2, I identified some 
gaps with regards to the present case study, namely:  
1. It remains open, whether the theory can explain the evolution of innovation strategy 
2. Burgelman (1991) deliberately choses an intra-organizational perspective, which puts little 
emphasis on the influence of external dynamics  
3. Strategic variation in the induced strategy process is limited to ‘reorientation’, which terms 
reactive responses to changes in the environment. Strategic renewal is only seen as coming 
from the autonomous process.   
4. Managerial cognition is mentioned, but has no central role in the internal ecology model. 
The present case study has sought to fill out some of these gaps:  




 When studying innovation strategy of a mature, knowledge-intensive company in a relatively 
stable environment, induced (vision-ex-ante) strategic experiments seem to be more salient 
as drivers of strategic renewal than autonomous initiatives. 
 The external environment has vast impact, especially on strategic retreats – which resembles 
what Burgelman (1991) terms ‘reorientation’ of strategy 
 Top management cognition plays an important role for both proactive search (via 
formulation of strategic visions) and for the gravity of the induced strategy (via the settled 
dominant logic).  
The internal ecology model therefore provides a solid theoretical foundation, which can be expanded 
in order to explain the evolution of innovation strategy in a context of a mature, knowledge-intensive 
company.  
 




Building new theory – in the “middle ground” 
Strategy as a mediator between internal and external ecologies  
The positioning school in strategic management theory (e.g. Porter, 1980) obviously has a strong 
orientation towards the external environment; focus is on the position of the company compared to 
competitors, suppliers, customers and other stakeholders. In contrast, the evolutionary school of 
thought is more focused on the internal environment – Burgelman’s theory of ‘intra-organizational 
ecology of strategy making’ (1991) is the principal example. The present case study builds on 
Burgelman’s theory; however, external drivers seem at least as powerful as the internal drivers for 
the evolution of innovation strategy at Novo Nordisk. The pattern of evolution, which was extracted 
in the previous sections of this chapter, was that internal processes (first and foremost top 
management cognition) drove strategic renewal; whereas external events (competition and crises) 
drove strategic retreat.  
The case study at hand elicits the induced strategy process as a mediator between internal and 
external ecologies: Towards the internal ecology, induced strategy is a selection-retention 
mechanism, just as analyzed in Burgelman’s internal ecology model (1991). Towards external 
ecology, induced strategy is a variation-creating mechanism: it experiments with alternating 
innovation strategies, shifting between modes of exploration and exploitation (March, 1991), over 
extended cycles of innovation strategy. Through such learning cycles, the induced strategy process 
demonstrates plasticity in two dimensions: 
 Towards the internal ecology via ‘strategic context determination’ of autonomous initiatives 
(Burgelman, 1991) 
 Towards the external ecology via cycles of interception of changes in the environment, 
interpretation and strategy formulation, enactment of new strategies, interception of the 
response in the market and so forth. 
Revisiting the induced strategy process: induced strategic renewal 
Gavetti & Levinthal (2004) propose a new paradigm of strategy research based on the evolutionary 
school of thought, to be developed in the direction of rational choice perspectives. This requires 
evolutionary theory to overcome its narrow focus on organizational routines as the “DNA” of the 
company, which to a large extent excludes deliberation and cognition. Furthermore, according to 
Gavetti & Levinthal (2004), the traditional evolutionary view also is biased towards seeing routines 
and capabilities as developing “from below” in the organization, and the authors therefore suggest to 
“pay more attention to the linkages across actors within the organizational hierarchy” (p. 1315).  
Burgelman’s 1988 article on “Strategy making as a social learning process” is interesting here, seen as 
research in the ‘middle ground’, because it explicitly analyzes the strategy-making process as 
interplay between action and cognition, which unfolds throughout the hierarchical levels. However, 




Burgelman (1988, 1991, 2002) still sees strategic renewal only as coming from beneath in the 
organization, based on local experiments.  
Burgelman’s bias towards the behavioral perspective on strategic renewal may stem from the 
analysis of limited rationality and biased cognitive representations, going back to Simon (1955). 
Once could instead apply the understanding proposed by Nelson (2008): ‘bounded rationality’ is 
ability to reasoning (making a ‘crude’ theory) as well as to learning from trial-and-error (to adjust or 
renew the theory). In this understanding, deliberate strategy is not only about control, as phrased by 
Mintzberg: “If deliberate strategy is about control, then emergent strategy is about learning” – 
(Mintzberg, 2007, p. 5). To contrast Mintzberg’s statement, one could quote Porter (1991): “the task 
of strategy is to maintain a dynamic, not a static balance” (p. 97). In other words, deliberate strategy is 
also about learning.  
 Burgelman (1991) actually describes induced strategic learning cycles: after launch of a new induced 
strategy, a learning cycle begins, which identifies the basis for success in the market and integrates 
this learning into the vision (table 1, p. 254). This learning has the purpose to substantiate and 
strengthen the strategy, and Burgelman (1991) consequently sees it as the retention part of the 
induced strategy. The strategic renewal (the basic variation process) took place before this retention 
oriented learning. In fact, Burgelman (1991) states “Induced initiatives allow managers to propose 
projects that take advantage of the available organizational learning” (p. 250) and “In this 
[induced strategic] process, intentional strategy may serve the organization to leverage – do as much 
as possible with – its currently available learning” (p. 249) (my emphasis). So the induced 
strategic learning in Burgelman’s analysis is a mainly matter of exploitation; not exploration (March, 
1991). The analysis in the present case study discloses a different kind of strategic learning. The yet 
hypothetical innovation strategies are enacted for learning in the market as part of the creation of 
strategic variation. The process is induced, driven from top management; but still displays trial-and-
error learning in the external environment, as suggested by Nelson (2008).  
 
Let’s look at PDS (Protein Delivery Systems, 2001-2005) as an example. Corporate managers from 
Operations formulated the vision about ‘closed loop’ systems in the summer of 2000. Over the next 
half year, corporate managers worked out strategic plans for realizing the vision, supported by 
external consultants and later also by selected managers from the device area. In the summer of 
2001, the funding was released and PDS was established by separation of device R&D from device 
Production. Substantial new resources were hired in (adding app. 50 employees to the existing app. 
80 employees; plus the integration of a drug formulation area). Executive management saw great 
corporate perspectives for the new innovation strategy of PDS – it was envisioned to lead to a 
revenue stream potentially as large as the insulin business and eventually to the establishment of an 
independent device company. However, as noted by Gavetti & Levinthal (2000): “the wholesale shift 
in behavior driven by a new cognitive representation may result in a tremendous loss of experiential 
wisdom” (p. 134). Remember that the PDS strategy was formulated by corporate managers outside 
the device area and was partly met with skepticism from the device managers. The vision was not 




rooted in experiential learning, but in cognitive analysis. This might have undermined the successful 
execution of the strategy. One might interpret the tension as a ‘framing contest’ between different 
parts of the organization (Kaplan, 2008).  
2002, the financial shake weakened the risk willingness of the executive team, supported by negative 
market experiences from the first electronic device systems (Innovo® and InDuo®), which had been 
developed during the previous period. These events blocked the further investments in technology 
acquisition, for example with regards to continuous glucose monitoring. When the internal 
development project for continuous glucose monitoring then also was delayed and later stalled, the 
PDS strategy in reality fell apart in spring 2004. Still, no change in official strategy was announced 
until the summer of 2005. In this period, from spring 2004 to summer 2005, PDS represented an 
example of what Burgelman & Grove (1996) call strategic dissonance – meaning misalignment in 
between official strategic intent and strategic action. In their terminology, one could see the crisis in 
2002 as a ‘Strategic Inflection Point’, which called for reformulation of the strategy.  
The innovation strategy of PDS was withdrawn before PDS achieved to influence the corporate 
strategy. Consequently, PDS – from a corporate perspective – still represented strategy ‘in the 
making’, being part of the ecology of strategic variation. The implications of the strategy had not been 
fully understood before implementation; the theory was ‘crude’, as Nelson (2008) terms it. Also after 
the public launch of the strategy in 2001, the vision had the nature of a hypothesis, to be tested out in 
the external environment. Thus, the induced device innovation strategy underwent learning cycles 
after the implementation of the strategy, still being a part of the strategic experimentation at 
corporate level. The device innovation strategy served as a learning lab for corporate strategy, so to 
speak. Perhaps one can see this sort of strategic experiment as deliberate creation of temporary 
strategic dissonance; the vision of PDS was far ahead of the actual experiences and capabilities. 
Successful execution of the PDS strategy would have dissolved the strategic dissonance by bringing 
strategic action ‘up to’ the visionary level of the strategic intent. Oppositely, failure in the execution 
would require the strategy to be reformulated in order to bring the strategic intent ‘down to’ the 
actual level of action (which was what happened). In this understanding, ‘deliberate strategic 
dissonance’ is a way of creating induced strategic learning. 
 
The present case study is not about the corporate innovation strategy at Novo Nordisk, which is 
mainly centered on developing new pharmaceutical drugs. Even though the case study thus is about a 
local innovation strategy, it is clear from the analysis that this local strategy in general was not 
developed from beneath – the process did not resemble Burgelman’s analysis of strategic initiatives, 
which gradually gained resonance at yet higher hierarchical levels. Instead, the strategies were 
formed as part of the corporate induced strategy making process, from the top. In this strategy 
making, corporate management formulated a strategy for a local area, which served as strategic 
variation at corporate level; had PDS been successful in building up new product-markets, corporate 
strategy would have been reconfigured.  




From the current case study of the evolution of innovation strategy, one could therefore propose that 
the new ‘middle ground’ of strategic research (Gavetti & Levinthal, 2004) embraces a dynamic role of 
the corporate, induced strategy process. In some cases it might even be relevant to apply the concept 
of ‘perpetual disequilibrium’ as proposed by Meyer et al (2005): “as a theory of organizational action, 
“adaptation” is an unproductive concept in nonlinear settings. When discontinuous changes are 
rippling through an organizational field, there is no equilibrium to be sought, and the idea of 
organizational adaptation loses meaning” (p. 457 – my emphasis). However, in the context of the 
present research project, discontinuity seems less salient than continuity; industry-wise as well as at 
the case organization. Perhaps it is exactly in such condition of relatively stability that the induced 
strategy process takes over the entrepreneurial role, which else is often linked to the emergent or 
autonomous sphere. Compared to local experiments and bottom-up autonomous initiatives, the 
corporate induced strategy process logically always will be more deliberate, controlled and 
institutionalized. But if we include the ‘external ecology’ in the analysis, then the corporate induced 
strategy process is also hypothetical or experimental in its enactment of strategic renewal, and is 
subject to entrepreneurial learning, which might lead to a reformulated ‘theory’ (Nelson, 2008). 
Innovation strategies here can serve as tools for deliberate creation of induced strategic renewal; it 
just requires a longitudinal perspective at multiple levels of analysis to recognize this 
entrepreneurial and experimental role of induced strategy.  
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Introduction 
The present research project aims for understanding the evolution of innovation strategy, studied in 
the context of the medical devices activities of Novo Nordisk A/S; an incumbent pharmaceutical firm 
operating in a well-established industry.  
The overall research question is “How does innovation strategy evolve?” with special focus on the 
‘internal ecology’ model, stated in the research question “What is the role of induced and autonomous 
strategy processes for the evolution of innovation strategy?” 
As a basic theoretical frame, Burgelman’s evolutionary theory on strategy making has been applied 
(Burgelman 1991, 2002). Some expansions of this framework were needed. First, the present study 
puts greater emphasis on analyzing the external environment and its influence on the internal 
strategy processes. Second, it includes the role of management cognition in the analysis; hereunder 
the corporate dominant logic (Prahalad & Bettis, 1986; Bettis & Prahalad, 1995; Prahalad, 2004), 
understood as an enduring top management worldview or mindset, based on reinforcement of 
experiences from the past. Third, the present research project focuses on the evolution of innovation 
strategy, as opposed to the general business strategy, defined as such:  
 Innovation strategy is the strategy for the individual innovation activities with the objective to 
create product or business innovations (strategy understood as a plan for the future or a 
storyline of the past). 
 
The empirical case study has some specific traits: 
• It includes multiple levels of analysis: external dynamics; corporate events, top management 
cognition and corporate strategy; local events at the device area (cognition, strategy and 
structure); and concrete innovation activities (portfolio of innovation projects and product 
launches). 
• It maps long term patterns – across several lifecycles of strategy, covering the period 1980-
2008. 




• It analyzes the relationship between a classic core product of a firm (insulin) and 
complementary products (medical devices), which hold the potential to either enhance the 
value of the core product, or to become a distinct business of its own.  
 
Findings 
The pattern in the evolution of innovation strategy for medical devices at Novo Nordisk was: 
 The first entrepreneurial initiatives with medical devices (before 1988) were inspired by 
external events (competitor moves on the drug side and dialogue among diabetes experts). 
These first activities were highly successful. 
 The institutionalization of the innovation strategy in 1988 with the establishment of MSD 
was driven by top management cognition holding visions for an autonomous, device-based 
strategy, which led to an entrepreneurial period and profound investments in devices. 
However, the results were mixed.  
 The retreat from the MSD strategy in 1992 was driven by external events (crises and 
competition) and resulted in a drug-based innovation strategy. Within a confined scope, the 
device innovation activities bloomed for many years, successfully serving as means of market 
differentiation.  
 The next strategic transformation, implemented with PDS in 2001, was driven by top 
management cognition holding extremely ambitious visions for an autonomous, device-
based strategy, which led to substantial investments in device innovation. The high 
ambitions were never fulfilled.  
 The retreat from the PDS strategy, completed in 2005, was again driven by external events 
(crises and competition), and turned the strategy ‘back to basics’, i.e. drug-based. 
Hence, this case study provides evidence for an evolution of innovation strategy where top 
management visions drove the strategic renewal, and external events drove the strategic retreats. 
The evolution can be interpreted as strategic learning cycles, in which successful results 
substantiated the initiatives (positive reinforcement), whereas negative results undermined the 
initiatives (negative reinforcement). The reinforcement cycles compromised external market 
feedback as well as success or failure in the internal product development.  
The cycles unfolded a pattern of alternating modes of strategy, which content-wise could be 
characterized as either autonomous (device-based) or induced (drug-based). The autonomous cycles 
of device-based innovation strategy had the challenge to escape the gravity of the internal identity 
and the corporate dominant logic (Bettis & Prahalad, 1995), which was pharmaceutical and drug-
centered. Both autonomous waves of strategy represented alternative strategy frames, because 
medical devices were here seen as core assets for innovation in contrast to the ‘normal’ periods of 
induced strategy, where the devices were seen only as means of market differentiation, i.e. 
enhancement of the insulin sales. Neither of the two device-based strategic waves achieved 




momentum enough to escape the gravity of dominant logic for real – in each case, competition and 
crises made the strategy bend back to the safe ‘fetal position’, centered on the drug. Hence, the 
dominant logic showed itself as a more enduring component of management cognition than the more 
instrumental strategy formulation – like a deep structure (Gersick, 1991) of strategy making.  
Even though the two device-based strategy waves were surely autonomous in content, they were 
created out of top management reasoning, vision ‘ex ante’. In this sense, the strategy making followed 
the induced strategy process as analyzed in Burgelman (1991). As such, the two device-based strategy 
cycles can be seen as induced strategic experimentation; new innovation strategies were formulated 
as hypotheses, which were tried out for real, but still subject for learning. These strategic 
experiments could be seen as deliberate creation of strategic dissonance (Burgelman & Grove, 1996) 
in the sense that the strategic hypotheses were far ahead of the experiences and capabilities. The 
intent was to move the organization to follow the vision, thereby dissolving the dissonance between 
vision and reality over time. 
The above analysis suggests an induced strategy making process at incumbents, which experiments 
with alternating innovation strategies through several lifecycles of strategy, thereby creating 
strategic variation over extended time. This understanding identifies an underresearched, 
entrepreneurial role of the induced strategy making process and of top management cognition. In 
emergent views on strategy formation (e.g. Mintzberg, 1994, 2007; Burgelman, 1991, 2002) 
reasoning and strategy formulation marks the end of an explorative and action-driven learning 
process. In the case study at hand, strategy formulation also marks the beginning of a theory-driven, 
yet explorative learning process: from the external ecology, the induced strategy process intercepts 
novel opportunities or threats; integrates these in the strategy formulation as strategic hypotheses in 
the form of innovation strategy; initiates the structural context determination (Burgelman, 1991) for 
the new innovation strategy; and enacts the new strategic hypotheses into the external environment, 
for example in the form of new products. Based on the response in the market, the new strategic 
experiments are either reinforced or withdrawn. This theory-driven and entrepreneurial learning 
cycle takes place within the top management driven, induced strategy process. In the present case 
study, such learning cycles seem to have counteracted the forces of ‘co-evolutionary lock-in’ 
(Burgelman, 2002).  
 
Contribution 
The present research project analyzes an entrepreneurial aspect of the corporate, induced strategy 
process, in which strategic visions drive explorative learning via alternating innovation strategies, 
which serve as a ‘strategic laboratory’ at corporate level. Hence, for innovation strategy, strategic 
variation and trial-and-error learning is not restricted to the autonomous initiatives in the ‘internal 
ecology’. 
The induced strategy process displays adaptation and explorative learning in two dimensions: 




1. Towards the internal ecology via strategic context determination, which intercepts valuable 
autonomous initiatives (as analyzed by Burgelman 1991, 2002). This is primarily a process of 
experience-based, backward-looking strategic learning, which reformulates the strategic 
vision ‘ex post’.  
2. Towards the external ecology via cycles of interception of environmental change, reasoning 
(interpretation) and strategy formulation, structural context determination, enactment of 
new innovation strategies, interception of the response from the market and so forth. This 
strategic learning process is primarily forward-looking, vision ‘ex ante’; but experience-
based learning also occurs, via feedback loops from the market.  
Therefore, the induced strategy process can be seen as a dynamic ‘exchange market’, which mediates 
between internal and external ecologies in an iterative strategy creation process, by means of 
induced strategic experiments, i.e. enactment of alternating innovation strategies over time. This 
conception of the induced strategy process does not eliminate the ‘internal ecology’ model described 
by Burgelman (1991, 2002). Rather, it adds another layer of strategic entrepreneurship to the 
internal ecology model. See a model of my analysis in figure VI-1. 
 
 
Figure VI-1. A model of the induced strategy process as an ‘exchange market’, mediating between internal 
and external ‘ecologies’. The model shows an entrepreneurial role of the induced strategy process, displaying 
plasticity in two dimensions: Towards internal ecology by integrating successful autonomous initiatives, as 
described in Burgelman’s ‘internal ecology’ model of strategy making (1991); and towards external ecology 
by enactment of induced experiments with innovation strategy. If these experiments are successful, the 
strategic hypotheses are reinforced, and this may lead to renewal of the corporate induced strategy. If the 
strategic experiments fail or meet significant resistance in the environment, the existing strategy and its 
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This theoretical interpretation of the empirical case study leads exactly into the ‘middle ground’ 
between behavioral and rational-choice perspectives on strategy, which Gavetti & Levinthal (2004) 
propose as the future theoretical paradigm to be developed based on evolutionary theory: “Strategic 
action clearly involves greater degrees of intentionality, so fuller representations of cognition would 
need to be incorporated into such theoretical efforts” (p. 1310); and “Work in this middle ground treats 
actors as boundedly rational—limited both spatially and temporally in their ability to evaluate the 
consequences of their choices. It also grapples with the challenge of adaptation in the presence of rival 
firms and shifting bases of competitive advantage” (p. 1313). 
In such ‘middle ground’, deliberation and reasoning should not be seen in contrast to learning. The 
use of conceptual dichotomies such as deliberate vs. emergent (Mintzberg, 2007, p. 4), cognition vs. 
action (Gavetti & Rivkin, 2007, title), control vs. learning (Mintzberg, 2007, p. 5), rational vs. 
behavioral (Gavetti & Levinthal, 2004, p. 1310) tend to trap our understanding – the conceptual 
relationships become either-or, not interactive interdependencies. Conversely, Nelson (2008) 
analyzes ‘bounded rationality’ as a dualistic ability to reasoning and learning from trial-and-error; 
this understanding dissolves the dichotomy. Such dualistic understanding seems required for 
decoding the dynamics of the multifaceted strategy making at mature companies. In the present case 
study, the duality is represented at different time perspectives: the strategic transformations were 
result of deliberate reasoning – that is the rational aspect – but the long-term evolution displayed 
trial-and-error – that is the ‘bounded’ aspect. We are here back to Lucas’ (1986) notion that the 
underlying decision rules continuously are subject to ‘adaptation’ via trial-and-error. The 
longitudinal lens enables us to discover the experimental or adaptive dimension of the seemingly 
‘theory’-based strategy making.   
In the same dualistic understanding, the induced strategy process can be seen as unfolding both 
modes of organizational learning described by March (1991), exploitation and exploration, practiced 
in two directions: towards the internal and the external environment. One could label these two 
directions of strategic learning respectively ‘inbound’ and ‘outbound’ (inspired by Porter’s labels 
‘inbound and outbound logistics’ in the classic value chain analysis, e.g. Porter, 1991).  
Inbound, strategy holds a function of alignment and control (cf. Porter, 1991). The whole purpose of 
strategy is to establish enduring elements of corporate behavior, thus selection and retention is 
needed within the ‘internal ecology’. Without this function of strategic selection and retention, the 
activities of a firm would pursue countless autonomous directions, in effect dissolving the strategy 
and the business itself. The dominant logic facilitates this function as an enduring element of 
management cognition: “Interestingly, it provides a set of heuristics that simplify and speed decision 
making. This inherently results in ‘adaptive ability’, so long as changes in the underlying logic are not 
necessary” (Bettis & Prahalad, 1995, p. 11). This function of alignment establishes the exploitation 
mode of inbound strategic learning. However, the induced strategy process also has a dimension of 
inbound exploration, by opening up for interception of autonomous initiatives: “The capacity to 
activate and successfully complete such processes [autonomous initiatives and strategic context 
determination] can be viewed as a measure of the intelligence of the company’s internal selection 




environment and may be at the very heart of strategy making as an adaptive organizational capability” 
(Burgelman 2002, p. 355). 
Outbound, strategy has a similar function of alignment of the activities and exploitation of 
established positions and capabilities. However, the induced strategy process also holds an 
explorative function via anticipation of change in the environment. This function is established 
through experiments with alternative strategies in order to sustain the adaptability and viability of 
the firm. Hence, strategic variation is sought by testing alternating innovation strategies as ‘strategic 
hypotheses’ via extended learning cycles in the market. For this purpose, innovation strategy serves 
as a ‘strategy lab’ for the corporate induced strategy process. Here, the gravity of the dominant logic 
poses a permanent challenge: it may momentarily loosen up for new innovation strategies, but it 
pulls back to safe territories whenever encountering crises.  
 
 Inbound Outbound 
Exploitation Expanding existing strategy and 
capabilities 
Expanding existing strategy and 
established product-markets 
Exploration Strategic context determination of 
autonomous initiatives from the 
‘internal ecology’ (Burgelman, 
2002) 
Experimenting with alternative 
innovation strategies in the market 
(potentially creating new product-
markets) 
 
Table VI-1. The strategic learning modes of the induced strategy process. 
 
The above analysis (summarized in table VI-1) of the learning modes of the corporate induced 
strategy process builds on a longitudinal case study of the evolution of innovation strategy for a 
complementary product area within a mature company. More research is needed for generalization 
of such theory.   
 
Implications for research  
Burgelman (2002) sees an organization’s ability for strategic adaptation as depending on its ability to 
exploit the internal ecology of autonomous initiatives. This understanding builds on case studies of 
respectively internal corporate venturing units (Burgelman, 1988) and a young IT company in a 
young industry (Burgelman, 1991, 2002). The present research proposes that a firm’s ability for 
strategic adaptation might depend both on strategic context determination of autonomous initiatives 
(as in Burgelman, 2002) and on ability to exploit induced strategic experiments via enactment of 
alternating innovation strategies. However, this analysis of a more entrepreneurial role of the 
induced strategy process might be bound to the specific circumstances of the evolution of local 
innovation strategy or to the integration of complementary assets for innovation within the setting of 
a mature (incumbent) company in a stable industry.  The big unanswered question remains: is the 
analysis of the present research project context specific, or does it have validity for other mature 
companies in stable industries? In any case, the existence of induced strategic renewal should be 




examined further in research at the ‘middle ground’ of business strategy (Gavetti & Levinthal, 2004). 
The understanding of innovation strategies as hypotheses – serving as a laboratory for corporate 
strategic renewal – might here add to the theories on strategic search. Further, the idea of seeing 
induced strategic experiments as deliberate strategic dissonance might also be worth while exploring 
in theories about strategic entrepreneurship. 
 
Implications for management practice 
The first managerial learning from the case study could be respect to the positive power of internal 
identity and dominant logic. Surely, these forces may hinder strategic renewal, but they also ensure 
enduring qualities of the organizational behavior. In the case of Novo Nordisk, this conservatism has 
been fortunate. Imagine Novo having had an agile and entrepreneurial management style back in the 
1970’s, where the enzyme business had grown to become larger than the insulin business, and the 
enzyme managers even joked about selling off the insulin business, since it didn’t grow anyway. By 
yearend 2011, the drug business held 32,000 employees and had a turnover of 66 billion DKK. To 
compare, the enzyme business (since 2000 divested in Novozymes A/S) had a turnover of 10.5 
billion DKK and employed 5,800 people by yearend 2011. Top management of Novo in the 1970’s 
probably did not foresee the explosion of the Type 2 diabetes market, which is the main cause of this 
difference; but a strong internal identity and dominant logic, originating all the way back to the 
founders, made it unthinkable to divest the insulin business – apart from the jokes at the 
management corridors. Strategic inertia can indeed be a sound force, when your core market holds 
immense growth potential, and your industry is relatively stable, compared to for instance the IT 
industry.  
However, there is also reason to warn against ‘co-evolutionary lock-in’ (Burgelman 2002), implying 
that everything else than core business is seen as distraction. Strategic context determination of 
‘autonomous’ strategies seems to be almost non-existent at Novo Nordisk – which according to 
Burgelman (2002) can threaten the long-term viability of the firm. One can discuss whether the 
fortunate and stable market conditions of Novo Nordisk make the ‘internal ecology model’ of 
autonomous initiatives obsolete. Does a company in an external environment, characterized by 
immense growth potential and relative stability, need anything more than the strategic learning from 
the top-driven ‘induced’ process? For Novo Nordisk, it takes a very long time horizon to get a glimpse 
of severe threats. Further, the company historically has proven ability to act when confronted with 
‘Strategic Inflection Points’ (Burgelman & Grove, 1996) within the core industry. The introduction of 
NovoPen® partly as response to the threat of recombinant human insulin from Eli Lilly is one 
example. The establishment of the costly R&D project for inhalable insulin as response to the threat 
from Pfizer is another. In contrast, the very slow reorientation of the business towards serving the 
market of Type 2 diabetes is a negative example. Here, the internal identity and the dominant logic 
were barriers to the strategic reorientation, because of bonds to the diabetes experts and their 




sophisticated treatment of Type 1 diabetes patients. Thus, one cannot exclude that Novo Nordisk’s 
future strategic viability might depend on continuous experimentation with the innovation strategy. 
Currently, a so-called Innovation Culture project at Novo Nordisk comprises a handful of explorative 
projects. These activities, however, are financially prioritized very low. One could fear that more is 
needed for ensuring long-term strategic viability.   
The medical devices have indeed been very successful market differentiators for Novo Nordisk, ever 
since the introduction of the first NovoPen® in 1985. According to several informants, the initial 
exploration of the device opportunities ‘slipped through the filter’ because devices were perceived as 
complementary assets, not core. This leads me to an important implication for management practice: 
Explore and utilize the value of complementary assets! These are perfect guinea-pigs for 
experimenting with innovation strategies without risking the core business, yet holding potentials 
far beyond what can be foreseen without real-life strategic experiments. No theory does it in itself – a 
combination of vision (theory) and trial-and-error in the market is needed. Perhaps you even find a 
gold vein from such experiments.  
Another implication is that the successful integration of complementary assets is complex and 
dynamic – the balance between core and complementary will shift and be negotiated again and again. 
The integration of complementary assets for innovation in corporate strategy seems at least as 
challenging as the integration of different businesses. But the exploration of complementary assets 
for innovation offers a potential way to strategic renewal.   
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The purpose of this empirical investigation was to identify and analyze the ‘dominant logic’ (Prahalad 
& Bettis, 1986) of the device innovation area with regards to the management mindset on innovation 
– here termed ‘dominant innovation logic’.  
The following detailed description of the research method has some overlap to the description in 
Chapter 3 of the research method for the 2007 analysis. Besides adding more details, the present 
description covers both analyses (2007 and 2010), even though the findings from the 2010 analysis 
could not be used, because of business confidentiality issues.  
Sample and data 
The unit of analysis was the device innovation area of Novo Nordisk A/S, in the period from June 
2007 to September 2010. This unit existed within two different organizational structures at the time 
of the two investigations. A sample of 10 managers was selected as informants in 2007. These 10 
were chosen in order to represent the organizational functions as broadly as possible. First of all, the 
VPs of the three functional areas were chosen, plus a VP from a governance unit, who was a former 
VP from the device area. The other 6 were department managers. In 2010, 6 of the informants from 
2007 were still employed at the device area, including the VP from the governance unit, who now 
again had become a VP within the device area. These 6 informants were reused. 4 new informants 
were selected, again with emphasis on the broadest possible representation of the functions at the 
device area.  
The interviews were conducted as qualitative, semi-structured in-depth interviews throughout the 
summer of 2007 and again in August-September 2010. See total list of interviews in Chapter 3. The 
20 interviews lasted from 35 to 123 minutes each (mean 60 min.). All interviews were conducted in 
Danish. The 2007 interviews were broader in scope and therefore took longer time than the 2010 
interviews, since the 2007 interviews included insights into the history of the device innovation at 
Novo Nordisk. – All interviews were recorded and transcribed.  




The interviews were based on lists of questions, which included the themes a) industry 
identification; b) value proposition; c) core capabilities; d) product innovation portfolio;  
e) innovation barriers and enhancers.  
The use of semi-structured in-depth interviews has the advantage of active influence by the 
informant on the direction of the conversation and thus can provide a genuine impression of his or 
her thinking. The other side of the coin, however, is that you do not walk away with 100% 
comparable data sets across the interviews, since the topics discussed not always are the ones 
foreseen by the researcher. Therefore, I regret today that I did not supplement the interviews with 
short questionnaires, to have two supplementary identical data sets for comparison.  
 
Some disclaimers should be made concerning the effect of self-ethnography (M. Alveson, 2003): The 
researcher was well known by the informants, including standpoints and attitudes. This might have 
influenced the way the informants expressed their opinions. However, this potential influence was 
constant over time and across the interviews. A perhaps worse problem was that the interviews 
were based on a mutual pre-understanding of the device area; many basic questions were not 
uttered, and many statements were uttered ‘between the lines’ via implicit connotations. There are 
two dimensions of this problem: 
1. The cognitive; that I may have been blind to factors which would have fallen into the eyes of 
external observers 
2. The communicative; throughout the data analysis I was able to use very condensed 
wordings, since I (being the only researcher) was familiar with all connotations and 
presumptions behind the wordings.  
My way of working myself out of the second problem was to reformulate the aggregated condensed 
statements (called ‘constructs’) into full sentences, and to include explanations of the context when 
needed.  
For the purpose of longitudinal studies, the method of in-depth interviews implies another problem. 
With a time interval of 3 years, the context of the interviews had changed and therefore different 
topics appeared relevant in the conversations. In 2010, I deliberately tried to stick to a basic skeleton 
of questions similar to the 2007 interviews, but differences in topics were inevitable. The differences 
increased the difficulties of direct comparison between the 2007 and 2010 data sets. My way to deal 
with this problem was to apply an identical thematic structure for the data analysis of both data sets. 
Furthermore, in 2010 I went back to the 2007 data (transcriptions as well as maps / summaries) in 
order to reexamine some of the topics, which had been emphasized more loudly in 2010. This way, a 
more symmetrical structure of themes could be applied for the data analysis. Again, the dilemma 
goes back to the desired data richness and uniqueness from using qualitative methods such as semi-
structured in-depth interviews, weighted against the difficulties by cross-sample comparison and 
quantification of the results.  
 




Summaries of the interviews were made in a format resembling ‘cognitive maps’ (see next part), and 
short follow-up interviews were conducted to get approval from the informants of the summary. The 
follow-up interviews were not recorded, but the corrections by the informants were noted and 
approved at the interview. These follow-up interviews typically lasted 15-30 minutes. Thereafter, the 
data analysis was based on the summaries as data input.  




Figure A-1. A map of the research methodology, which is further explained in the following text. The numbers 
divided by plus (“680 + 436”) refer to the two years of investigation (2007 + 2010). (FIF structure: 
Foundation-Innovation-Future). 
 
The use of ‘cognitive maps’ 
The concept of ‘cognitive maps’ is understood very differently in various contexts – sometimes 
referring to models or schemes in the minds of people – which rather should be termed ‘mental 
models’17 – at other occasions referring to artifacts such as graphic representations of the mental 






17 For a discussion of the conceptual confusions in this area, see Swan (1997) and Eden (1992) 
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models. These graphic representations lay out a framework of constructs and relationships as a 
visual representation of how individuals perceive their environment (Fiol & Huff 1992). Many 
different techniques exist for making graphic cognitive maps, including software tools, and they can 
be made for many different purposes (Eden, 1988; Fiol & Huff, 1992; Barr, Stimpert & Huff, 1992; 
Bougon, 1992). The most prevailing form is causal maps, which outline the network of elements and 
cause-effect relationships found in individuals’ view on a particular domain (Langfield-Smith, 1992). 
Since Prahalad & Bettis (1986) themselves mention cognitive maps, it was obvious to use this 
approach as one of the methods for eliciting the dominant innovation logic. 
Based on the transcriptions of the interviews, the verbal statements were reformulated in slightly 
more general terms, so that each summarized or condensed statement could refer to more (typically 
2-3) original verbal sentences. These condensed statements were then clustered in cognitive maps, 
using explicit themes from the transcriptions as well as themes implied by the interview questions 
(e.g. “core capabilities”). The ‘cognitive maps’ served first for intermediary presentation of the 
condensed statements at the follow-up interviews. After the informants’ approval of the condensed 
statements, the maps served as data for the further analysis.  
The 2 x 10 cognitive maps contained respectively 680 and 436 condensed statements in total in 2007 
and 2010. This gives averages values of respectively 0.92 and 0.95 condensed statement per 
interview minute for 2007 and 2010.  
One common ‘landscape’ model 
The condensed statements were taken from the individual cognitive maps into a spreadsheet, 
reformulated in yet more generic terms, termed ‘constructs’, so that each reformulated construct 
could cover several informants’ condensed statements. At the same time, the language was changed 
from Danish to English. Exactly this part of the analysis is very sensitive to subjective bias from the 
researcher. You compare the condensed statements, two by two, and ask yourself the question: Do 
these two statements cover the same basic meaning, in spite of different wording? Or you compare a 
set of statements and ask: Could I extract a more generic meaning, i.e. could I reformulate these 
statements at a higher level of abstraction, so that the core of each statement is covered, even some 
details and nuances fall out? The answer to such questions can only be a matter of subjective 
interpretation – there is no right solution. This also implies that the number of constructs is not given 
from the data. If the statements are used directly as constructs, you have a 1:1 relation between the 
data and your constructs, but you also have not achieved the advantage of reducing complexity via 
models. If you are very rude in your interpretation, you achieve the advantage of a simple model, but 
you risk having damaged the validity towards the original statements. In my case, I think I had more 
respect for the data in 2010, implying a finer grid of constructs than in my first 2007 analysis. I 
managed this difference by going back to the data analysis for 2007 to loosen up the simplifications 
of the constructs and move closer to the data.  
For the analysis, the constructs were clustered in three main spheres, Foundation-Innovation-Future 
(FIF), which basically formed a timeline of past, present and future. The FIF structure emerged out of 




the data analysis in 2007 and was then reused in 2010. Within each sphere, the constructs were 
clustered in groups, resulting in a common structure of topics across the interviews for each sample. 
See table III-4 with the generic FIF structure.  
 
The FIF structure was applied for the data analysis in the spreadsheet of the total constructs. The 
spreadsheet was used as an instrument for quantification; each construct was correlated with the 
data to determine exactly which of the informants who supported the construct in question in their 
individual statements. This way I could quantify how widespread each of the constructs was amongst 
the 10 informants. For traceability, the exact timestamps from the interview transcriptions of the 
statements in support of each construct were also noted. 
The clusters of constructs from the spreadsheet were then transferred to a map, following the 
Foundation-Innovation-Future structure, comprising all constructs from the informants in 
respectively 2007 and 2010. In this total map, the constructs within each cluster were prioritized 
according to the number of managers behind each construct. In a traditional physical map of a 
landscape, the height compared to sea level is indicated with color codes from blue over green to 
yellow and more brownish nuances. This color-coding system was adopted for visualizing how 
widespread the constructs were amongst the sample of managers. The ‘landscape’ of management 
constructs formed three ‘continents’ (Foundation-Innovation-Future), and more clusters or 
‘countries’ within each continent. The color-coding used the brownish nuances to indicate the 
constructs, which were most widespread within the management team, and so forth. This graphical 
representation of the management statements provided an immediate overview of the level of 
consensus. The total map can be seen in the right side of figure A-1. 
The use of ‘creative questionnaires’ when interviewing 
As suggested by Prahalad & Bettis (1986), “creative questionnaires” were applied in the data capture 
process. Three such methods were applied: 1) Project portfolio puzzle; 2) actant modeling; and 3) car 
metaphor. These are explained in the following.  
In the project portfolio puzzle, the informants were asked to select a sample of development 
projects of their own choice and place them within a matrix, outlining four quadrants along two 
dimensions of innovativeness: Respectively as seen from a market perspective or from a technology 
perspective (see the generic matrix in figure A-2). Before the interview, the titles of all development 
projects were noted on small Post-It® notes, so that they could easily be placed manually on a print 
of the matrix. There was of course no ‘right answer’ to the task – the placement will always be a 
matter of assessment. This exercise was conducted to see if there was a common understanding of 
the distribution of the product innovation portfolio.  
The project portfolio puzzle was quite time consuming and was therefore only applied in 2007, and 
only in 6 of the 10 interviews.  






Figure A-2.The project portfolio matrix. The text describing the top score in the vertical axis is copied from 
the empirical definition of ‘radical innovation’ in Leifer et al (2000). 
 
The ‘actant modeling’ exercise uses a model displaying the roles and structure of a common folklore 
story. This model has been a common part of the Danish high school curriculum since the 1970’s, 
where the author was taught to analyze literature using this model. It was originally developed by 
the French philosopher A. J. Greimas. For further information, please see Wikipedia under “actantial 
model”18. At several earlier occasions, I have experienced this model as a very fruitful dialogue 
enhancer for describing phenomena such as a company or a product. The exercise was used to get 
alternative insights into the informants’ view on their business, especially the value offering. The 
roles in the model are: The subject (“the knight”) striving for the object (“the princess”), enabled by a 
provider (“the king”) and a supporter (“the wizard”), fighting an opponent (“the dragon”), in the end 
giving the object to a receiver (often the subject himself). In all cases, I had set the subject as “Device 
R&D” and let it be open for the informants to identify the actors of the remaining roles. The generic 
model can be seen in figure A-3. The actant modeling exercise was carried out in 6 of the interviews 






18 http://en.wikipedia.org/wiki/Actantial_model, accessed 2010-11-11, refers to the original source: 
Greimas, Algirdas Julien [1966] Structural Semantics: An Attempt at a Method  
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in 2007 and in all interviews in 2010. This tool was especially valuable for identifying the overall goal 
of the organization, the key stakeholders and the value proposition.  
 
Figure A-3. The generic actant model as applied in the research19. 
 
The car metaphor. A method often used in design is to encircle the identity of an organization, a 
product or a customer segment by using artifacts or images as metaphors for inner traits. It has 
shown to be easier for informants to express subtle, inner characteristics indirectly via such 
metaphors. The method of using metaphors is therefore often applied in product development 
activities, also at Novo Nordisk Device Research & Development. In my case study, I simply asked the 
informants: “If Device R&D was a car – which car would it be?” – And if the informants immediately 
named a car brand or car model, I asked “Why?” to get to the associations and characteristics, which 
led them to their choice. These considerations often gave very fine portraits of the culture or identity 
of the case organization.  
Identifying the dominant innovation logic 
The dominant logic is a worldview shared across the management team. Arguably, idiosyncratic 
individual viewpoints cannot belong to the ‘dominant’ logic. Therefore, to get a clearer picture of the 
management thinking, all constructs with less than 5 supporters (of 10 possible) were deleted from 
the total ‘landscape’ of constructs. As references for this criterion, Tyler & Gnyawali (2002) similarly 






19 See for instance http://www.signosemio.com/greimas/a_actantiel.asp (accessed 2010-11-11) 


















assess the concept of ‘shared cognition’ in a management team such that 50% must agree in a small 
group; 40% in a large group (where 30 managers make a large group).  
The relatively few constructs left (respectively 28 in 2007 and 22 in 2010) made a conclusive 
‘cognitive map’ of the shared management perceptions. These dominant constructs were ‘translated’ 
into full sentence narratives, which outlined the dominant worldview of the management team. 
[Again, see figure III-2 describing the methodology]. 
The weaknesses of the methodology 
There are several points in the data capturing and analysis, which are widely open for subjective 
influence by the researcher:  
1. The researcher selects the questions raised during the interviews. Thus, the researcher, not 
the informant, defines the default elements of the worldview of the informant. However, the 
semi-structured interviews allow high influence from the informant on the course of the 
conversation.  
2. After the informant has approved the summarized or condensed statements, the next level of 
abstraction is made solely by the researcher: namely the transformation from condensed 
statements to ‘constructs’. This is a process of interpretation and reformulation for which 
there obviously is not a 1:1 solution, so the choices made are subjective.  
3. The same disclaimers are valid for the last process step: the translation from dominant 
constructs into full sentence wording.  
Some researchers use inter-subjectivity to reduce possible biases of the researcher, letting more 
researchers analyze the same data (e.g. Barr, Stimpert & Huff 1992). Still, also such inter-subjectivity 
might be biased by cultural backgrounds, values and other traits common across the team of 
researchers, and therefore may reduce but not eliminate the problem of researchers’ subjectivity. In 
any case, being the sole researcher I did not have this possibility. On the other hand, there also is a 
strength in the sole researcher approach: all the way from conceptualization of the research 
questions, through data collection and data analysis there is only one subject to influence the results, 
so the researcher bias at least is consequent and coherent across the entire process.  
Besides the ‘sole researcher’ problem, I also struggled with the subjectivity issues from “self-
ethnography” (Alveson, 2003), see above. However, my belonging to the case organization had great 
advantages, such as unlimited access to data, easy access to informants and last, not least, the 
comprehensive background knowledge from which I could immediately understand the connotations 
of the statements, i.e. what was being said ‘between the lines’. This pre-understanding enhanced the 
analysis from interviews into constructs; but in a way that is not easily traceable for outside 
researchers, who do not posses the same vast background knowledge and therefore might not see 
the link between a verbal statement and a construct. The part of the analysis using the constructs 
(e.g. the landscape model) is the least transparent; whereas the steps before consists of verbal 
statements or condensed statements, which are recognized and approved by the informants; and the 




step after uses full sentence wording, which can be compared to the verbal statements in the 
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